Compounds and compositions for treating diseases associated with STING activity
By developing compounds that can directly bind or modify STING proteins, inhibit STING signaling, the problem of irrepressible diseases caused by excessive activation of STING signaling pathway is solved, and effective treatment of related diseases is achieved.
Patent Information
- Application Number
- CN201980057319.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-06-14
- Filing Date
- 2019-07-02
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2039-07-02
AI Technical Summary
Diseases caused by excessive activation of STING signaling pathways, such as cancer, type I interferon disease and inflammation-related diseases, are difficult to effectively inhibit the prior art.
Provide a compound or a pharmaceutically acceptable salt, hydrate or co-crystal thereof for direct binding or modifying STING protein, inhibiting its activity, interfering or blocking STING signaling, preparing the compound and its composition, and Apply to treatment by in vitro or in vivo methods.
Effectively inhibit STING signal transduction, relieve or eliminate symptoms of related diseases, delay or stop disease progression, and especially show therapeutic effects in cancer and inflammation-related diseases.
Smart Images

Figure FDA0004974682700000011 
Figure FDA0004974682700000021 
Figure FDA0004974682700000031
Abstract
Description
[0001] Priority Declaration
[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 693,768, filed on July 3, 2018, and U.S. Provisional Application No. 62 / 861,825, filed on June 14, 2019, which are incorporated herein by reference in their entireties. Technical Field
[0003] The present invention provides chemical entities (e.g., compounds or pharmaceutically acceptable salts and / or hydrates and / or co-crystals and / or drug combinations) that inhibit (e.g., antagonize) stimulator of interferon genes (STING). The chemical entity can be used, for example, to treat conditions, diseases, or disorders in which STING activation (e.g., STING signaling) is increased (e.g., excessive) leading to a morbid state and / or symptoms and / or progression of a condition, disease, or disorder (e.g., cancer) in a subject (e.g., a human). The present invention also provides compositions comprising the chemical entity and methods of using and preparing the composition. Background Art
[0004] STING, also known as transmembrane protein 173 (TMEM173) and MPYS / MITA / ERIS, is a protein encoded by the TMEM173 gene in humans. STING has been shown to play a role in innate immunity. When cells are infected with intracellular pathogens (such as viruses, mycobacteria, and intracellular parasites), STING induces the production of type I interferons. Type I interferons mediated by STING protect infected cells and nearby cells from local infection in both autocrine and paracrine manners.
[0005] The STING pathway is crucial in mediating the recognition of cytoplasmic DNA. In this context, STING, a transmembrane protein localized to the endoplasmic reticulum (ER), acts as a second messenger receptor for 2',3' cyclic GMP-AMP (hereafter referred to as cGAMP) produced by cGAS following dsDNA binding. Furthermore, STING serves as a primary pattern recognition receptor for bacterial cyclic dinucleotides (CDNs) and small molecule agonists. Recognition of endogenous or prokaryotic CDNs occurs via STING's carboxyl-terminal domain, which faces the cytoplasm and creates a V-shaped binding pocket formed by the STING homodimer. Ligand-induced STING activation triggers its relocalization to the Golgi apparatus, a process essential for facilitating STING's interaction with TBK1. This protein complex, in turn, signals through the transcription factor IRF-3, inducing type I interferons (IFNs) and other co-regulated antiviral factors. Furthermore, STING has been shown to trigger activation of NF-κB and MAP kinases. Following signaling initiation, STING is rapidly degraded, which is important in terminating inflammatory responses.
[0006] Excessive activation of STING is associated with a subset of monogenic autoinflammatory disorders, the so-called type I interferonopathies. Examples of these diseases include the clinical syndrome known as STING-associated vasculopathy of infancy (SAVI), which is caused by gain-of-function mutations in TMEM173 (the gene for STING). Furthermore, STING is implicated in the pathogenesis of Aicardi-Gutières syndrome (AGS) and hereditary forms of lupus. Unlike SAVI, in AGS, dysregulation of nucleic acid metabolism underlies continuous innate immune activation. Beyond these genetic disorders, emerging evidence suggests a more general pathogenic role for STING in a range of inflammation-related diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and cancer. Therefore, small-molecule-based pharmacological interventions in the STING signaling pathway hold great potential for treating a wide range of diseases. SUMMARY OF THE INVENTION
[0008] The present invention provides chemical entities (e.g., compounds or pharmaceutically acceptable salts and / or hydrates and / or co-crystals and / or drug combinations) that inhibit (e.g., antagonize) stimulator of interferon genes (STING). The chemical entity can be used, for example, to treat conditions, diseases, or disorders in which STING activation (e.g., STING signaling) is increased (e.g., excessive) leading to a morbid state and / or symptoms and / or progression of a condition, disease, or disorder (e.g., cancer) in a subject (e.g., a human). The present invention also provides compositions comprising the chemical entity and methods of using and preparing the composition.
[0009] "STING antagonists" include compounds that directly bind to or modify STING at the protein level, resulting in a decrease in STING activity, such as by inhibiting, blocking, or attenuating agonist-mediated responses, altering distribution, or otherwise. STING antagonists include chemical entities that interfere with or inhibit STING signaling.
[0010] In one aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof:
[0011]
[0012] Among them, X 1 、X 2 、Y 1 、Y 2 、Y 3 、Y 4 , Z, W, Q and A are as defined anywhere herein.
[0013] In one aspect, the invention provides pharmaceutical compositions comprising a chemical entity described herein (eg, a compound as generally or specifically described herein, or a pharmaceutically acceptable salt thereof, or a composition comprising the same) and one or more pharmaceutically acceptable excipients.
[0014] In one aspect, the present invention provides a method of inhibiting (e.g., antagonizing) STING activity, comprising contacting STING with a chemical entity as described herein (e.g., a compound generally or specifically described herein, or a pharmaceutically acceptable salt thereof, or a composition comprising the same). The method includes in vitro methods, such as contacting a sample comprising one or more cells comprising STING (e.g., innate immune cells, such as mast cells, macrophages, dendritic cells (DCs), and natural killer cells) with the chemical entity. The method may also include in vivo methods; for example, administering the chemical entity to a subject (e.g., a human) having a disease in which STING signaling is increased (e.g., excessive) thereby leading to the pathology and / or symptoms and / or progression of the disease.
[0015] In one aspect, the present invention provides a method for treating a condition, disease, or disorder that is ameliorated by antagonizing STING, wherein increased (e.g., excessive) STING activation (e.g., STING signaling) results in pathology and / or symptoms and / or progression of the condition, disease, or disorder (e.g., cancer) in a subject (e.g., a human). The method comprises administering to a subject in need of such treatment an effective amount of a chemical entity described herein (e.g., a compound generally or specifically described herein, or a pharmaceutically acceptable salt thereof, or a composition comprising the same).
[0016] In another aspect, the present invention provides a method of treating cancer comprising administering to a subject in need of such treatment an effective amount of a chemical entity described herein (e.g., a compound generally or specifically described herein, or a pharmaceutically acceptable salt thereof, or a composition comprising the same).
[0017] In another aspect, the present invention provides methods for treating other STING-related diseases, such as type I interferonopathies (e.g., STING-associated vasculopathy of infancy (SAVI)), Aicardi-Goutières Syndrome (AGS), hereditary forms of lupus, and inflammation-related diseases such as systemic lupus erythematosus and rheumatoid arthritis. The method comprises administering to a subject in need of such treatment an effective amount of a chemical entity described herein (e.g., a compound generally or specifically described herein, or a pharmaceutically acceptable salt thereof, or a composition comprising the same).
[0018] In another aspect, the present invention provides a method of inhibiting STING-dependent type I interferon production in a subject in need thereof, comprising administering to the subject an effective amount of a chemical entity described herein (e.g., a compound generally or specifically described herein, or a pharmaceutically acceptable salt thereof, or a composition comprising the same).
[0019] In another aspect, the present invention provides a method for treating a disease in which increased (e.g., excessive) STING activation (e.g., STING signaling) leads to pathology and / or symptoms and / or progression of the disease. The method comprises administering to a subject in need of such treatment an effective amount of a chemical entity described herein (e.g., a compound generally or specifically described herein, or a pharmaceutically acceptable salt thereof, or a composition comprising the same).
[0020] In another aspect, the present invention provides a method of treatment comprising administering to a subject an effective amount of a chemical entity described herein (e.g., a compound generally or specifically described herein, or a pharmaceutically acceptable salt thereof, or a composition comprising the same); wherein the subject has (or is susceptible to) a disease in which increased (e.g., excessive) STING activation (e.g., STING signaling) leads to pathology and / or symptoms and / or progression of the disease.
[0021] In another aspect, the present invention provides methods of treatment comprising administering to a subject a chemical entity described herein (e.g., a compound generally or specifically described herein, or a pharmaceutically acceptable salt thereof, or a composition comprising the same), wherein the chemical entity is administered in an amount effective to treat a disease in which increased (e.g., excessive) STING activation (e.g., STING signaling) leads to pathology and / or symptoms and / or progression of the disease, thereby treating the disease.
[0022] Implementations may include one or more of the following features.
[0023] The chemical entity can be given in combination with one or more additional therapeutic agents and / or treatment regimens.For example, the method can further include giving one or more (e.g., two, three, four, five, six or more) additional agents.
[0024] The chemical entity can be administered in combination with one or more additional therapeutic agents and / or treatment regimens useful for treating other STING-associated diseases, for example, type I interferonopathies (e.g., STING-associated vasculopathy of infancy (SAVI)), Aicardi-Goutières Syndrome (AGS), hereditary forms of lupus, and inflammation-related diseases, such as systemic lupus erythematosus and rheumatoid arthritis.
[0025] The chemical entity can be administered in combination with one or more additional cancer therapies (e.g., surgery, radiation therapy, chemotherapy, toxin therapy, immunotherapy, cryotherapy, or gene therapy, or a combination thereof); for example, chemotherapy comprising the administration of one or more (e.g., two, three, four, five, six, or more) additional chemotherapeutic agents. Non-limiting examples of additional chemotherapeutic agents are selected from the group consisting of: alkylating agents (e.g., cisplatin, carboplatin, mechlorethamine, cyclophosphamide, chlorambucil, ifosfamide, and / or oxaliplatin); antimetabolites (e.g., azathioprine and / or mercaptopurine); terpenoids (e.g., vinca alkaloids); alkaloid and / or taxane; for example, vincristine, vinblastine, vinorelbine and / or vindesine, taxol, paclitaxel and / or docetaxel); topoisomerase (for example, type I topoisomerase and / or type 2 topoisomerase; for example, camptothecin, for example, irinotecan and / or topotecan; amsacrine, etoposide, etoposide phosphate and / or teniposide); )); cytotoxic antibiotics (e.g., actinomycin, anthracycline, doxorubicin, daunorubicin, valrubicin, idarubicin, epirubicin, bleomycin, plicamycin and / or mitomycin); hormones (e.g., luteinizing hormone-releasing hormone agonists; for example, leuprolidine, goserelin, triptorelin, histrelin, bicalutamide, flutamide and / or nilutamide);Antibodies (e.g., Abciximab, Adalimumab, Alemtuzumab, Atlizumab, Basiliximab, Belimumab, Bevacizumab, Brentuximab Vedotin, Canakinumab, Cetuximab, Certolizumab pegol pegol, Daclizumab, Denosumab, Eculizumab, Efalizumab, Gemtuzumab, Golimumab, Ibritumomabtiuxetan, Infliximab, Ipilimumab, Muromonab-CD3, Natalizumab lizumab, ofatumumab, omalizumab, palivizumab, panitumuab, ranibizumab, rituximab, tocilizumab, tositumomab, and / or trastuzumab); antiangiogenic agents; cytokines; thrombotic agents; growth inhibitors; anthelmintics;and immune checkpoint inhibitors targeting immune checkpoint receptors selected from the group consisting of CTLA-4, PD-1, PD-L1, PD-1–PD-L1, PD-1–PD-L2, interleukin-2 (IL-2), indoleamine 2,3-dioxygenase (IDO), IL-10, transforming growth factor-β (TGFβ), T cell immunoglobulin and mucin 3 (TIM3 or HAVCR2), galectin 9-TIM3, phosphatidylserine-TIM3, lymphocyte activation gene 3 protein (LAG3), MHC Class II–LAG3, 4-1BB–4-1BB ligand, OX40–OX40 ligand, GITR, GITR ligand–GITR, CD27, CD70-CD27, TNFRSF25, TNFRSF25–TL1A, CD40L, CD40–CD40 ligand, HVEM–LIGHT–LTA, HVEM, HVEM–BTLA, HVEM–CD160, HVEM–LIGHT, HVEM–BTLA–CD160, CD80, CD80–PDL-1, PDL2–CD80, CD244, CD48–CD244, CD244, ICOS, ICOS–ICOS ligand, B7-H3, B7-H4, VISTA, TMI GD2, HHLA2–TMIGD2, butyrophilin, including BTNL2, Siglec family, TIGIT and PVR family members, KIRs, ILTs and LIRs, NKG2D and NKG2A, MICA and MICB, CD244, CD28, CD86–CD28, CD86–CTLA, CD80–CD28, CD39, CD73 adenosine–CD39–CD73, CXCR4–CXCL12, phosphatidylserine, TIM3, phosphatidylserine–TIM3, SIRPA–CD47, VEGF, neuropilin, CD160, CD30, and CD155 (e.g., CTLA-4 or PD1 or PD-L1).
[0026] The subject may have cancer; for example, the subject has undergone and / or is currently undergoing and / or will undergo one or more cancer treatments.
[0027] Non-limiting examples of cancer include melanoma, cervical cancer, breast cancer, ovarian cancer, prostate cancer, testicular cancer, urothelial carcinoma, bladder cancer, non-small cell lung cancer, small cell lung cancer, sarcoma, colorectal adenocarcinoma, gastrointestinal stromal tumor, gastroesophageal cancer, colorectal cancer, pancreatic cancer, renal cancer, hepatocellular carcinoma, malignant mesothelioma, leukemia, lymphoma, myelodysplastic syndrome, multiple myeloma, transitional cell carcinoma, neuroblastoma, plasmacytoma, Wilms' tumor or hepatocellular carcinoma. In certain embodiments, the cancer can be a refractory cancer.
[0028] The chemical entity can be administered intratumorally.
[0029] The method may further include identifying the object.
[0030] Other embodiments include those described in the detailed description and / or claims.
[0031] Additional definition
[0032] In order to promote the understanding of the disclosure set forth herein, a plurality of other terms are defined below. Generally, the nomenclature used herein and the laboratory procedures of organic chemistry, medicinal chemistry and pharmacology described herein are well-known and commonly used in the art. Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art. Each patent, application, disclosed application and other publications mentioned throughout the specification, as well as the appendix attached, are incorporated herein by reference in their entirety.
[0033] As used herein, the term "STING" is intended to include, but is not limited to, nucleic acids, polynucleotides, oligonucleotides, sense and antisense polynucleotide chains, complementary sequences, peptides, polypeptides, proteins, homologous and / or orthologous STING molecules, isoforms, precursors, mutants, variants, derivatives, splice variants, alleles, different species, and active fragments thereof.
[0034] As used herein, the term "acceptable" with respect to a formulation, composition or ingredient means having no persistent detrimental effect on the general health of the subject being treated.
[0035] “API” means active pharmaceutical ingredient.
[0036] As used herein, the term "effective amount" or "therapeutically effective amount" refers to a sufficient amount of a chemical entity (e.g., a compound that exhibits activity as a mitochondrial uncoupler, or a pharmaceutically acceptable salt and / or hydrate and / or cocrystal thereof; for example, a compound such as niclosamide, or a pharmaceutically acceptable salt and / or hydrate and / or cocrystal thereof; for example, a compound such as a niclosamide analog, or a pharmaceutically acceptable salt and / or hydrate and / or cocrystal thereof) administered to relieve to some extent one or more of the symptoms of the disease or condition being treated. Results include reduction and / or alleviation of the signs, symptoms, or causes of the disease, or any other desired alteration in a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising a compound disclosed herein required to achieve a clinically significant alleviation of the symptoms of the disease. In any case, an appropriate "effective" amount can be determined using any appropriate technique (e.g., a dose escalation study).
[0037] The term "excipient" or "pharmaceutically acceptable excipient" refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, carrier, solvent, or encapsulating material. In one embodiment, each component is "pharmaceutically acceptable" in the sense of being compatible with the other ingredients of the pharmaceutical formulation and suitable for contact with human and animal tissues or organs without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit / risk ratio. See, e.g., Remington: The Science and Practice of Pharmacy, 21st ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients, 6th ed.; Rowe et al., eds., The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd ed.; Ash and Ash, eds., Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd ed., Gibson, ed., CRC Press LLC: Boca Raton, FL, 2009).
[0038] The term "pharmaceutically acceptable salt" refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound. In some cases, pharmaceutically acceptable salts are obtained by reacting a compound described herein with an acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. In some cases, a pharmaceutically acceptable salt is obtained by reacting a compound described herein having an acidic group with a base, such as an ammonium salt, an alkali metal salt, such as a sodium or potassium salt, an alkaline earth metal salt, such as a calcium salt or a magnesium salt, a salt of an organic base, such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, and a salt formed with an amino acid, such as arginine, lysine, and the like, or by other methods previously determined. There is no particular limitation on the pharmaceutically acceptable salt, as long as it can be used in medicine. Examples of salts formed with bases of the compounds described herein include the following: salts with inorganic bases such as sodium, potassium, magnesium, calcium, and aluminum; salts with organic bases such as methylamine, ethylamine, and ethanolamine; salts with basic amino acids such as lysine and ornithine; and ammonium salts. The salts may be acid addition salts, specifically exemplified by addition salts formed with the following acids: inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, and ethanesulfonic acid; and acidic amino acids such as aspartic acid and glutamic acid.
[0039] The term "pharmaceutical composition" refers to a mixture of a compound described herein with other chemical components (collectively referred to herein as "excipients"), such as carriers, stabilizers, diluents, dispersants, suspending agents, and / or thickening agents. Pharmaceutical compositions facilitate administration of a compound to an organism. Various techniques for administering a compound exist in the art, including, but not limited to, rectal, oral, intravenous, aerosol, parenteral, ocular, pulmonary, and topical administration.
[0040] The term "subject" can refer to an animal, including but not limited to a primate (e.g., a human), monkey, cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. The terms "subject" and "patient" are used interchangeably herein, e.g., to refer to a mammalian subject, e.g., a human subject.
[0041] In the context of treating a disease or disorder, the term "treating" is intended to include alleviating or eliminating the disease, disorder or condition or one or more symptoms associated with the disease, disorder or condition; or slowing the progression, spread or worsening of the disease, disorder or condition or one or more symptoms thereof. "Cancer treatment" refers to one or more of the following effects: (1) inhibiting tumor growth to some extent, including (i) slowing and (ii) complete arrest of growth; (2) reducing the number of tumor cells; (3) maintaining tumor size; (4) reducing tumor size; (5) inhibiting, including (i) reducing, (ii) slowing or (iii) completely preventing tumor cell infiltration into peripheral organs; (6) inhibiting, including (i) reducing, (ii) slowing or (iii) completely preventing cancer metastasis; (7) enhancing anti-tumor immune responses, which can (i) maintain tumor size, (ii) reduce tumor size, (iii) slow tumor growth, (iv) reduce, slow or prevent invasion and / or (8) reducing to some extent the severity or number of one or more symptoms associated with the disease.
[0042] The term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I).
[0043] The term "alkyl" refers to a hydrocarbon chain which may be straight or branched, containing the indicated number of carbon atoms. For example, C 1-10 Indicates that the group may have from 1 to 10 (inclusive) carbon atoms. Non-limiting examples include methyl, ethyl, iso-propyl, tert-butyl, n-hexyl.
[0044] The term "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by independently selected halogens.
[0045] The term "alkoxy" refers to an -O-alkyl group (eg, -OCH3).
[0046] The term "alkylene" refers to a divalent alkyl group (eg, -CH2-).
[0047] The term "alkenyl" refers to a hydrocarbon chain that may be straight or branched and has one or more carbon-carbon double bonds. The alkenyl moiety contains the specified number of carbon atoms. For example, C 2-6 It means that the group may have 2 to 6 (inclusive) carbon atoms.
[0048] The term "alkynyl" refers to a hydrocarbon chain that may be straight or branched and has one or more carbon-carbon triple bonds. The alkynyl moiety contains the indicated number of carbon atoms. For example, C 2-6 It means that the group may have 2 to 6 (inclusive) carbon atoms.
[0049] The term "aryl" refers to a monocyclic, bicyclic, tricyclic or polycyclic group of 6 to 20 carbon atoms, wherein at least one ring in the system is aromatic (e.g., a 6-carbon monocyclic, 10-carbon bicyclic or 14-carbon tricyclic aromatic ring system); and wherein 0, 1, 2, 3 or 4 atoms of each ring may be substituted with substituents. Examples of aryl groups include phenyl, naphthyl, tetrahydronaphthyl, and the like.
[0050] The term "cycloalkyl" as used herein includes cycloalkyl groups having 3 to 20 ring carbons, preferably 3 to 16 ring carbons, and more preferably 3 to 12 ring carbons or 3-10 ring carbons or 3-6 ring carbons, wherein the cycloalkyl group may be optionally substituted. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Cycloalkyl groups may include multiple fused rings and / or bridged rings. Non-limiting examples of fused / bridged cycloalkyls include: bicyclo[1.1.0]butane, bicyclo[2.1.0]pentane, bicyclo[1.1.1]pentane, bicyclo[3.1.0]hexane, bicyclo[2.1.1]hexane, bicyclo[3.2.0]heptane, bicyclo[4.1.0]heptane, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane, bicyclo[4.2.0]octane, bicyclo[3.2.1]octane, bicyclo[2.2.2]octane, etc. Cycloalkyls also include spirocycles (e.g., spirobicycles in which the two rings are connected by only one atom). Non-limiting examples of spirocyclic cycloalkyls include: spiro[2.2]pentane, spiro[2.5]octane, spiro[3.5]nonane, spiro[3.5]nonane, spiro[3.5]nonane, spiro[4.4]nonane, spiro[2.6]nonane, spiro[4.5]decane, spiro[3.6]decane, spiro[5.5]undecane, and the like.
[0051] The term "cycloalkenyl" as used herein includes partially unsaturated cyclic hydrocarbon groups having 3 to 20 ring carbons, preferably 3 to 16 ring carbons, and more preferably 3 to 12 ring carbons or 3-10 ring carbons or 3-6 ring carbons, wherein the cycloalkenyl group may be optionally substituted. Examples of cycloalkenyl groups include, but are not limited to, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. The cycloalkenyl group may have any degree of saturation, provided that all rings in the ring system are not aromatic; and the cycloalkenyl group is generally not fully saturated. The cycloalkenyl group may include multiple fused rings and / or bridged rings and / or spirocycles.
[0052] As used herein, the term "heteroaryl" refers to a monocyclic, bicyclic, tricyclic or polycyclic group having 5 to 20 ring atoms, or 5, 6, 9, 10 or 14 ring atoms; and sharing 6, 10 or 14 pi electrons in the cyclic array; wherein at least one ring in the system is aromatic (but not necessarily a ring containing a heteroatom, such as tetrahydroisoquinolinyl, such as tetrahydroquinolinyl), and at least one ring in the system contains one or more heteroatoms independently selected from N, O and S. Heteroaryl groups can be unsubstituted or substituted with one or more substituents. Examples of heteroaryl groups include thienyl, pyridyl, furyl, oxazolyl, oxadiazolyl, pyrrolyl, imidazolyl, triazolyl, thiadiazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thiazolylbenzothiophenyl, benzoxadiazolyl, benzofuranyl, benzimidazolyl, benzotriazolyl, cinnolinyl, indazolyl, indolyl, isoquinolyl, isothiazolyl, naphthyridinyl, purinyl, thienopyridinyl, pyrido[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyridinyl, quinolyl, oxazolinyl, quinolinyl, thieno[2,3-c]pyridinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-c]pyridinyl, pyrazolo[4,3-c]pyridine, pyrazolo[4,3-b]pyridinyl, tetrazolyl, chromane, 2,3-dihydrobenzo[b][1,4]dioxine, benzo[d][1,3]dioxole, 2,3-dihydrobenzofuran, tetrahydroquinoline, 2,3-dihydrobenzo[b][1,4]oxathiine, isoindole, etc. In some embodiments, heteroaryl is selected from thienyl, pyridinyl, furanyl, pyrazolyl, imidazolyl, isoindole, pyranyl, pyrazinyl and pyrimidinyl.
[0053] The term "heterocyclyl" refers to a monocyclic, bicyclic, tricyclic or polycyclic non-aromatic ring system having 3-16 ring atoms (e.g., a 5-8 membered monocyclic, 8-12 membered bicyclic or 11-14 membered tricyclic ring system), having 1-3 heteroatoms (if monocyclic), 1-6 heteroatoms (if bicyclic) or 1-9 heteroatoms (if tricyclic or polycyclic), wherein the heteroatoms are selected from O, N or S (e.g., if monocyclic, bicyclic or tricyclic, respectively, having carbon atoms and 1-3, 1-6 or 1-9 heteroatoms selected from N, O or S), wherein 0, 1, 2 or 3 atoms of each ring may be substituted with a substituent. Examples of heterocyclyl groups include piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl and the like. Heterocyclyl groups may include multiple fused and / or bridged rings. Non-limiting examples of fused / bridged heterocyclic groups include: 2-azabicyclo[1.1.0]butane, 2-azabicyclo[2.1.0]pentane, 2-azabicyclo[1.1.1]pentane, 3-azabicyclo[3.1.0]hexane, 5-azabicyclo[2.1.1]hexane, 3-azabicyclo[3.2.0]heptane, octahydrocyclopenta[c]pyrrole, 3-azabicyclo[4.1.0]heptane, 7-azabicyclo[2.2.1]heptane, 6-azabicyclo[3.1.1]heptane, 7-azabicyclo[4.2.0]octane, 2-azabicyclo[2.2.2]octane, 3-azabicyclo[3.1.0]hexane, 5-azabicyclo[2.1.1]hexane, 3-azabicyclo[3.2.0]heptane, octahydrocyclopenta[c]pyrrole, 3-azabicyclo[4.1.0]heptane, 7-azabicyclo[2.2.1]heptane, 6-azabicyclo[3.1.1]heptane, 7-azabicyclo[4.2.0]octane, 2-azabicyclo[2.2.2]octane, 3- Azabicyclo[3.2.1]octane, 2-oxabicyclo[1.1.0]butane, 2-oxabicyclo[2.1.0]pentane, 2-oxabicyclo[1.1.1]pentane, 3-oxabicyclo[3.1.0]hexane, 5-oxabicyclo[2.1.1]hexane, 3-oxabicyclo[3.2.0]heptane, 3-oxabicyclo[4.1.0]heptane, 7-oxabicyclo[2.2.1]heptane, 6-oxabicyclo[3.1.1]heptane, 7-oxabicyclo[4.2.0]octane, 2-oxabicyclo[2.2.2]octane, 3-oxabicyclo[3.2.1]octane, etc. Heterocyclyl also includes spirocycles (e.g., spirobicycles in which the two rings are connected by only one atom).Non-limiting examples of spirocyclic heterocyclyls include: 2-azaspiro[2.2]pentane, 4-azaspiro[2.5]octane, 1-azaspiro[3.5]nonane, 2-azaspiro[3.5]nonane, 7-azaspiro[3.5]nonane, 2-azaspiro[4.4]nonane, 6-azaspiro[2.6]nonane, 1,7-diazaspiro[4.5]decane, 7-azaspiro[4.5]decane, 2,5-diazaspiro[3.6]decane, 3-azaspiro[5.5]undecane, 2-oxo[4.5]decane, 4-azaspiro[3.5]octane, 1-azaspiro[3.5]nonane, 2-azaspiro[3.5]nonane, 7-azaspiro[3.5]nonane, 2-azaspiro[4.4]nonane, 6-azaspiro[2.6]nonane, 1,7-diazaspiro[4.5]decane, 7-azaspiro[4.5]decane, 2,5-diazaspiro[3.6]decane, 3-azaspiro[5.5]undecane, 2-oxo[4.5] ... 1-oxaspiro[2.2]pentane, 4-oxaspiro[2.5]octane, 1-oxaspiro[3.5]nonane, 2-oxaspiro[3.5]nonane, 7-oxaspiro[3.5]nonane, 2-oxaspiro[4.4]nonane, 6-oxaspiro[2.6]nonane, 1,7-dioxaspiro[4.5]decane, 2,5-dioxaspiro[3.6]decane, 1-oxaspiro[5.5]undecane, 3-oxaspiro[5.5]undecane, 3-oxa-9-azaspiro[5.5]undecane, etc.
[0054] As used herein, "including Z, Y 1 、Y 2 、Y 3 and Y 4 The term "partially unsaturated ring" means that the ring may have any degree of unsaturation, as long as the ring is not aromatic and is not fully saturated as a whole. Examples of such rings include:
[0055] In addition, the atoms comprising the compounds of the present embodiments are intended to include all isotopic forms of such atoms. As used herein, isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and not limitation, isotopes of hydrogen include tritium and deuterium, while isotopes of carbon include 13 C and 14 C.
[0056] In addition, compounds generally or specifically disclosed herein are intended to include all tautomeric forms. Thus, for example, a compound containing the portion The compounds include those containing part Similarly, a pyridinyl or pyrimidinyl moiety described as optionally substituted with hydroxy includes pyridone or pyrimidone tautomeric forms.
[0057] The following description further details one or more embodiments of the present invention. Other features, objectives and advantages of the present invention are apparent from the description and claims. DETAILED DESCRIPTION
[0058] The present invention provides chemical entities (e.g., compounds or pharmaceutically acceptable salts and / or hydrates and / or co-crystals and / or drug combinations) that inhibit (e.g., antagonize) stimulator of interferon genes (STING). The chemical entity can be used, for example, to treat conditions, diseases, or disorders in which STING activation (e.g., STING signaling) is increased (e.g., excessive) leading to a morbid state and / or symptoms and / or progression of a condition, disease, or disorder (e.g., cancer) in a subject (e.g., a human). The present invention also provides compositions comprising the chemical entity and methods of using and preparing the composition.
[0059] Compounds of formula I
[0060] In one aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof:
[0061]
[0062] or a pharmaceutically acceptable salt or N-oxide thereof,
[0063] in:
[0064] Z is selected from: key, CR 1 、C(R 3 2. N and NR 2 ;
[0065] Y 1 、Y 2 and Y 3 Independently selected from: O, S, CR 1 、C(R 3 2. N and NR 2 ;
[0066] Y 4 is C or N;
[0067] X 1 Selected from: O, S, N, NR 2 and CR 1 ;
[0068] X 2 Selected from: O, S, N, NR 4 and CR 5 ;
[0069] Each are independently single bonds or double bonds, provided that Y 4 、X 1 and X 2 The five-membered ring is a heteroaryl group;
[0070] W is selected from:
[0071] (i) C(=O);
[0072] (ii) C(=S);
[0073] (iii)S(O) 1-2 ;
[0074] (iv) C(=NR d );
[0075] (v) C(=NH);
[0076] (vi) C (=C-NO2);
[0077] (vii)S(O)N(R d );and
[0078] (viii) S(O)NH;
[0079] QA is defined as follows:
[0080] (A)
[0081] Q is NH or N(C 1-6 alkyl), wherein C 1-6 The alkyl group is optionally replaced by 1-2 independently selected R a Replace, and
[0082] A is:
[0083] (i)-(Y A1 ) n -Y A2 ,in:
[0084] n is 0 or 1;
[0085] ·Y A1 It is C 1-6 Alkylene, which is optionally substituted by 1-6 R a replace; and
[0086] ·Y A2 yes:
[0087] (a)C 3-20 Cycloalkyl, which is optionally substituted by 1-4 R b replace,
[0088] (b)C 6-20 Aryl, which is optionally substituted by 1-4 R c replace;
[0089] (c) a heteroaryl group containing 5 to 20 ring atoms, wherein 1 to 4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R c Replace, or
[0090] (d) a heterocyclic group containing 3 to 16 ring atoms, wherein 1 to 3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace,
[0091] or
[0092] (ii)-Z 1 -Z 2 -Z 3 ,in:
[0093] ·Z 1 It is C 1-3 Alkylene, which is optionally substituted by 1-4 R a replace;
[0094] ·Z 2 It is –N(H)-, -N(R d )-, -O-, or –S-; and
[0095] ·Z 3 It is C 2-7 Alkyl, which is optionally replaced by 1-4 R a replace;
[0096] or
[0097] (iii)C 1-10 Alkyl, optionally substituted with 1-6 independently selected R a Replace; or
[0098] (B)
[0099] Q and A together form:
[0100] in represents the point of connection to W; and
[0101] E is a heterocyclic group comprising 3 to 16 ring atoms, wherein, in addition to the nitrogen atom present, 0 to 3 other ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace,
[0102] Each occurrence of R 1Independently selected from: H, halogen, cyano, optionally substituted by 1-2 R a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, optionally substituted by 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl, optionally substituted by 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 6-10 Aryl, optionally substituted by 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-5-10 membered heteroaryl, -S(O) 1-2 (C 1-4 alkyl), -NR e R f , –OH, oxo, -S(O) 1-2 (NR'R"), -C 1-4 Thioalkoxy, -NO2, -C(=O)(C 1-4 alkyl), -C(=O)O(C 1-4 alkyl), -C(=O)OH and -C(=O)N(R')(R");
[0103] Each occurrence of R 2 Independently selected from:
[0104] (i)C 1-6 Alkyl, which is optionally substituted by 1-2 independently selected R a replace;
[0105] (ii)C 3-6 Cycloalkyl;
[0106] (iii) a heterocyclic group comprising 3 to 10 ring atoms, wherein 1 to 3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O;
[0107] (iv)-C(O)(C 1-4 alkyl);
[0108] (v)-C(O)O(C 1-4 alkyl);
[0109] (vi)-CON(R')(R");
[0110] (vii)-S(O) 1-2 (NR’R”);
[0111] (viii)-S(O) 1-2 (C 1-4 alkyl);
[0112] (ix)-OH;
[0113] (x)C 1-4 alkoxy; and
[0114] (xi)H;
[0115] Each occurrence of R 3 Independently selected from: H, optionally 1-6 independently selected R a Substituted C 1-6 Alkyl; C 1-4 Haloalkyl; –OH; -F; -Cl; -Br; –NR e R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; -C(=O)N(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl; or two R on the same carbon 3 Combine to form oxo;
[0116] R 4 Selected from: H and C 1-6 alkyl;
[0117] R 5 Selected from: H, halogen, C 1-4 Alkoxy, OH, oxo, and C 1-6 alkyl;
[0118] Each occurrence of R a Independently selected from: -OH; -F; -Cl; -Br; -NR e R f ; C 1-4 Alkoxy; C 1-4 Halogenated alkoxy; -C(=O)O(C 1-4 alkyl); -C(=O)(C 1-4alkyl); -C(=O)OH; -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl;
[0119] Each occurrence of R b Independently selected from: optionally 1-6 independently selected R a Substituted C 1-10 Alkyl; C 1-4 Haloalkyl; –OH; oxo; -F; -Cl; -Br; –NR e R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; -C(=O)N(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; optionally 1-4 independently selected C 1-4 Alkyl substituted C 6-10 Aryl; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl;
[0120] Each occurrence of R c Independently selected from:
[0121] (i) halogen;
[0122] (ii) cyano;
[0123] (iii) optionally 1-6 independently selected R a Substituted C 1-10 alkyl;
[0124] (iv)C 2-6 alkenyl;
[0125] (v)C 2-6 Alkynyl;
[0126] (vi)C 1-4 alkyl halide;
[0127] (vii)C 1-4 alkoxy;
[0128] (viii)C 1-4 haloalkoxy;
[0129] (ix) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl;
[0130] (x)-(C 0-3 Alkylene)-heterocyclyl, wherein the heterocyclyl comprises 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from: N, N(H), N(R d ) and O;
[0131] (xi)-S(O) 1-2 (C 1-4 alkyl);
[0132] (xii)-NR e R f ;
[0133] (xiii)–OH;
[0134] (xiv)-S(O) 1-2 (NR’R”);
[0135] (xv)-C 1-4 Thioalkoxy;
[0136] (xvi)-NO2;
[0137] (xvii)-C(=O)(C 1-4 alkyl);
[0138] (xviii)-C(=O)O(C 1-4 alkyl);
[0139] (xix)-C(=O)OH; and
[0140] (xx)-C(=O)N(R′)(R”);
[0141] R d Selected from: C 1-6 Alkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; and C 1-4 alkoxy;
[0142] Each occurrence of R e and R f Independently selected from: H; C 1-6 Alkyl; C 1-6 Haloalkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; and C 1-4 Alkoxy; or R e and R f Together with the nitrogen atom to which they are attached, they form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each carbon atom being replaced by 1-2 carbon atoms independently selected from H and C 1-3 (b) 0-3 ring heteroatoms (excluding the nitrogen atom connected to R' and R"), each of which is independently selected from N(R d ), O and S; and
[0143] Each occurrence of R' and R" is independently selected from: H and C 1-4 or R' and R" together with the nitrogen atom to which they are attached form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each carbon atom being replaced by 1-2 independently selected from H and C 1-3 (b) 0-3 ring heteroatoms (excluding the nitrogen atom connected to R' and R"), each of which is independently selected from N(R d ), O and S.
[0144] In one aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof:
[0145]
[0146] or a pharmaceutically acceptable salt or N-oxide thereof,
[0147] in:
[0148] Z is selected from: key, CR 1 、C(R 3 2. N and NR 2 ;
[0149] Y 1 、Y 2 and Y 3 Independently selected from: O, S, CR 1 、C(R3 2. N and NR 2 ;
[0150] Y 4 is C or N;
[0151] X 1 Selected from: O, S, N, NR 2 and CR 1 ;
[0152] X 2 Selected from: O, S, N, NR 4 and CR 5 ;
[0153] Each are independently single bonds or double bonds, provided that Y 4 、X 1 and X 2 The five-membered ring is a heteroaryl group;
[0154] W is selected from:
[0155] (i) C(=O);
[0156] (ii) C(=S);
[0157] (iii)S(O) 1-2 ;
[0158] (iv) C(=NR d );
[0159] (v) C(=NH);
[0160] (vi) C (=C-NO2);
[0161] (vii)S(O)N(R d );and
[0162] (viii) S(O)NH;
[0163] QA is defined as follows:
[0164] (A)
[0165] Q is NH or N(C 1-6 alkyl), wherein C 1-6 The alkyl group is optionally replaced by 1-2 independently selected R a Replace, and
[0166] A is:
[0167] (i)-(Y A1 ) n -YA2 ,in:
[0168] n is 0 or 1;
[0169] ·Y A1 It is C 1-6 Alkylene, which is optionally substituted by 1-6 R a replace; and
[0170] ·Y A2 yes:
[0171] (a)C 3-20 Cycloalkyl, which is optionally substituted by 1-4 R b replace,
[0172] (b)C 6-20 Aryl, which is optionally substituted by 1-4 R c replace;
[0173] (c) a heteroaryl group containing 5 to 20 ring atoms, wherein 1 to 4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R c Replace, or
[0174] (d) a heterocyclic group containing 3 to 16 ring atoms, wherein 1 to 3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace,
[0175] or
[0176] (ii)-Z 1 -Z 2 -Z 3 ,in:
[0177] ·Z 1 It is C 1-3 Alkylene, which is optionally substituted by 1-4 R a replace;
[0178] ·Z 2 It is –N(H)-, -N(R d )-, -O-, or –S-; and
[0179] ·Z 3 It is C 2-7 Alkyl, which is optionally replaced by 1-4 R a replace;
[0180] or
[0181] (iii)C 1-10 Alkyl, which is optionally substituted by 1-6 independently selected R a Replace; or
[0182] (B)
[0183] Q and A together form:
[0184] in represents the point of connection to W; and
[0185] E is a heterocyclic group comprising 3 to 16 ring atoms, wherein, in addition to the nitrogen atom present, 0 to 3 other ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace,
[0186] Each occurrence of R 1 Independently selected from: H, halogen, cyano, optionally substituted by 1-2 R a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, optionally substituted by 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl, -S(O) 1-2 (C 1-4 alkyl), -NR e R f , –OH, oxo, -S(O) 1-2 (NR'R"), -C 1-4 Thioalkoxy, -NO2, -C(=O)(C 1-4 alkyl), -C(=O)O(C 1-4 alkyl), -C(=O)OH, and -C(=O)N(R')(R");
[0187] Each occurrence of R 2 Independently selected from:
[0188] (i)C 1-6 Alkyl, which is optionally substituted by 1-2 independently selected R a replace;
[0189] (ii)C 3-6 Cycloalkyl;
[0190] (iii) a heterocyclic group comprising 3 to 10 ring atoms, wherein 1 to 3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O;
[0191] (iv)-C(O)(C 1-4 alkyl);
[0192] (v)-C(O)O(C 1-4 alkyl);
[0193] (vi)-CON(R')(R");
[0194] (vii)-S(O) 1-2 (NR’R”);
[0195] (viii)-S(O) 1-2 (C 1-4 alkyl);
[0196] (ix)-OH;
[0197] (x)C 1-4 alkoxy; and
[0198] (xi)H;
[0199] Each occurrence of R 3 Independently selected from: H, optionally 1-6 independently selected R a Substituted C 1-6 Alkyl; C 1-4 Haloalkyl; –OH; -F; -Cl; -Br; –NR e R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; -C(=O)N(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl; or two R on the same carbon 3 Combine to form oxo;
[0200] R 4 Selected from: H and C 1--6 alkyl;
[0201] R5 Selected from: H, halogen, C 1-4 Alkoxy, OH, oxo, and C 1-6 alkyl;
[0202] Each occurrence of R a Independently selected from: -OH; -F; -Cl; -Br; -NR e R f ; C 1-4 Alkoxy; C 1-4 Halogenated alkoxy; -C(=O)O(C 1-4 alkyl); -C(=O)(C 1-4 alkyl); -C(=O)OH; -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl;
[0203] Each occurrence of R b Independently selected from: optionally 1-6 independently selected R a Substituted C 1-10 Alkyl; C 1-4 Haloalkyl; –OH; oxo; -F; -Cl; -Br; –NR e R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; -C(=O)N(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; optionally 1-4 independently selected C 1-4 Alkyl substituted C 6-10 Aryl; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl;
[0204] Each occurrence of R c Independently selected from:
[0205] (i) halogen;
[0206] (ii) cyano;
[0207] (iii) optionally 1-6 independently selected Ra Substituted C 1-10 alkyl;
[0208] (iv)C 2-6 alkenyl;
[0209] (v)C 2-6 Alkynyl;
[0210] (vi)C 1-4 alkyl halide;
[0211] (vii)C 1-4 alkoxy;
[0212] (viii)C 1-4 haloalkoxy;
[0213] (ix) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl;
[0214] (x)-(C 0-3 Alkylene)-heterocyclyl, wherein the heterocyclyl comprises 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from: N, N(H), N(R d ) and O;
[0215] (xi)-S(O) 1-2 (C 1-4 alkyl);
[0216] (xii)-NR e R f ;
[0217] (xiii)–OH;
[0218] (xiv)-S(O) 1-2 (NR’R”);
[0219] (xv)-C 1-4 Thioalkoxy;
[0220] (xvi)-NO2;
[0221] (xvii)-C(=O)(C 1-4 alkyl);
[0222] (xviii)-C(=O)O(C 1-4 alkyl);
[0223] (xix)-C(=O)OH; and
[0224] (xx)-C(=O)N(R′)(R”);
[0225] R d Selected from: C 1-6 Alkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; and C 1-4 alkoxy;
[0226] Each occurrence of R e and R f Independently selected from: H; C 1-6 Alkyl; C 1-6 Haloalkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; and C 1-4 Alkoxy; or R e and R f Together with the nitrogen atom to which they are attached, they form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each carbon atom being replaced by 1-2 carbon atoms independently selected from H and C 1-3 (b) 0-3 ring heteroatoms (excluding the nitrogen atom connected to R' and R"), each independently selected from N(R d ), O and S; and
[0227] Each occurrence of R' and R" is independently selected from: H and C 1-4 or R' and R" together with the nitrogen atom to which they are attached form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each carbon atom being replaced by 1-2 independently selected from H and C 1-3 (b) 0-3 ring heteroatoms (excluding the nitrogen atom connected to R' and R"), each independently selected from N(R d ), O and S.
[0228] In one aspect, the present invention provides compounds of formula (I):
[0229]
[0230] or a pharmaceutically acceptable salt or N-oxide thereof,
[0231] in:
[0232] Z is selected from: key, CR 1 、C(R 3 2. N and NR 2 ;
[0233] Y 1 、Y 2 and Y 3 Independently selected from: O, S, CR 1 、C(R 3 2. N and NR 2 ;
[0234] Y 4 is C or N;
[0235] X 1 Selected from: O, S, N, NR 2 and CR 1 ;
[0236] X 2 Selected from: O, S, N, NR 4 and CR 5 ;
[0237] Each are independently single bonds or double bonds, provided that Y 4 、X 1 and X 2 The five-membered ring is a heteroaryl group;
[0238] W is selected from:
[0239] (i) C(=O);
[0240] (ii) C(=S);
[0241] (iii)S(O) 1-2 ;
[0242] (iv) C(=NR d );
[0243] (v) C(=NH);
[0244] (vi) C (=C-NO2);
[0245] (vii)S(O)N(R d );and
[0246] (viii) S(O)NH;
[0247] QA is defined as follows:
[0248] (A)
[0249] Q is NH or N(C 1-6 alkyl), wherein C 1-6 The alkyl group is optionally replaced by 1-2 independently selected R a Replace, and
[0250] A is:
[0251] (i)-(Y A1 ) n -Y A2 ,in:
[0252] n is 0 or 1;
[0253] ·Y A1 It is C 1-6 Alkylene, which is optionally substituted by 1-6 R a replace; and
[0254] ·Y A2 yes:
[0255] (a)C 3-20 Cycloalkyl, which is optionally substituted by 1-4 R b replace,
[0256] (b)C 6-20 Aryl, which is optionally substituted by 1-4 R c replace;
[0257] (c) a heteroaryl group containing 5 to 20 ring atoms, wherein 1 to 4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R c Replace, or
[0258] (d) a heterocyclic group containing 3 to 16 ring atoms, wherein 1 to 3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R b )、N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace,
[0259] or
[0260] (ii)-Z 1 -Z 2 -Z 3 ,in:
[0261] ·Z 1 It is C 1-3 Alkylene, which is optionally substituted by 1-4 R a replace;
[0262] ·Z 2 It is -N(H)-, -N(R d )-, -O-, or –S-; and
[0263] ·Z 3 It is C 2-7 Alkyl, which is optionally replaced by 1-4 R a replace;
[0264] or
[0265] (iii)C 1-10 Alkyl, which is optionally substituted by 1-6 independently selected R a Replace; or
[0266] (B)
[0267] Q and A together form:
[0268] in represents the point of connection to W; and
[0269] E is a ring comprising 3-16 ring atoms, wherein, in addition to the nitrogen atom, 0-3 other ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace,
[0270] Each occurrence of R 1 independently selected from: H; halogen; cyano; optionally substituted by 1-2 R a Substituted C 1-6 Alkyl; C 2-6 Alkenyl; C 2-6 Alkynyl; C 1-4 Haloalkyl; C 1-4 Alkoxy; C 1-4 haloalkoxy; optionally substituted by 1-4 independently selected R g Substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl; optionally substituted by 1-4 independently selected R g Substituted-(C 0-3 Alkylene)-C 6-10 Aryl; -(C 0-3alkylene)-5-10 membered heteroaryl, wherein 1-3 ring atoms of the heteroaryl are independently selected from N, NH, NR d , O and S heteroatoms, wherein the heteroaryl group is optionally substituted by 1-4 independently selected R g Replacement; -(C 0-3 alkylene)-5-10 membered heterocyclic group, wherein 1-3 ring atoms of the heterocyclic group are independently selected from N, NH, NR d , O and S heteroatoms, wherein the heterocyclic group is optionally substituted by 1-4 independently selected R g Substitution; -S(O) 1-2 (C 1-4 alkyl); -NR e R f ;–OH; oxo; -S(O) 1-2 (NR'R");-C 1-4 Thioalkoxy; -NO2; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; and -C(=O)N(R')(R");
[0271] Each occurrence of R 2 Independently selected from:
[0272] (i)C 1-6 Alkyl, which is optionally substituted by 1-2 independently selected R a replace;
[0273] (ii)C 3-6 Cycloalkyl;
[0274] (iii) a heterocyclic group comprising 3 to 10 ring atoms, wherein 1 to 3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O;
[0275] (iv)-C(O)(C 1-4 alkyl);
[0276] (v)-C(O)O(C 1-4 alkyl);
[0277] (vi)-CON(R')(R");
[0278] (vii)-S(O) 1-2 (NR’R”);
[0279] (viii)-S(O) 1-2 (C 1-4 alkyl);
[0280] (ix)-OH;
[0281] (x)C 1-4 alkoxy; and
[0282] (xi)H;
[0283] Each occurrence of R 3 Independently selected from: H, optionally 1-6 independently selected R a Substituted C 1-6 Alkyl; C 1-4 Haloalkyl; –OH; -F; -Cl; -Br; –NR e R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; -C(=O)N(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl; or two R on the same carbon 3 Combine to form oxo;
[0284] R 4 Selected from: H and C 1-6 alkyl;
[0285] R 5 Selected from: H, halogen, C 1-4 Alkoxy, OH, oxo, and C 1-6 alkoxy;
[0286] Each occurrence of R a Independently selected from: -OH; -F; -Cl; -Br; -NR e R f ; C 1-4 Alkoxy; C 1-4 Halogenated alkoxy; -C(=O)O(C 1-4 alkyl); -C(=O)(C 1-4 alkyl); -C(=O)OH; -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl;
[0287] Each occurrence of R b Independently selected from: optionally 1-6 independently selected R a Substituted C 1-10 Alkyl; C 1-4 Haloalkyl; –OH; oxo; -F; -Cl; -Br; –NR e R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; -C(=O)N(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; optionally 1-4 independently selected C 1-4 Alkyl substituted (C 0-3 Alkylene)-C 6-10 Aryl; and optionally 1-4 independently selected C 1-4 Alkyl substituted (C 0-3 Alkylene)-C 3-6 Cycloalkyl;
[0288] Each occurrence of R c Independently selected from:
[0289] (i) halogen;
[0290] (ii) cyano;
[0291] (iii) optionally 1-6 independently selected R a Substituted C 1-10 alkyl;
[0292] (iv)C 2-6 alkenyl;
[0293] (v)C 2-6 Alkynyl;
[0294] (vi)C 1-4 alkyl halide;
[0295] (vii)C 1-4 alkoxy;
[0296] (viii)C 1-4 haloalkoxy;
[0297] (ix) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C3-6 Cycloalkyl;
[0298] (x)-(C 0-3 Alkylene)-heterocyclyl, wherein the heterocyclyl comprises 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from: N, N(H), N(R d ) and O;
[0299] (xi)-S(O) 1-2 (C 1-4 alkyl);
[0300] (xii)-NR e R f ;
[0301] (xiii)–OH;
[0302] (xiv)-S(O) 1-2 (NR’R”);
[0303] (xv)-C 1-4 Thioalkoxy;
[0304] (xvi)-NO2;
[0305] (xvii)-C(=O)(C 1-4 alkyl);
[0306] (xviii)-C(=O)O(C 1-4 alkyl);
[0307] (xix)-C(=O)OH; and
[0308] (xx)-C(=O)N(R′)(R”);
[0309] (xxi) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 6-10 aryl; and
[0310] (xxii)-(C 0-3 alkylene)-5-10 membered heteroaryl, wherein 1-3 ring atoms of the heteroaryl are heteroatoms, each independently selected from: N, NH, NR d , O and S, wherein heteroaryl is optionally replaced by 1-4 independently selected C 1-4 Alkyl substitution;
[0311] R d Selected from: C 1-6 Alkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -CN; -OH; and C 1-4 alkoxy;
[0312] Each occurrence of R e and R f Independently selected from: H; C 1-6 Alkyl; C 1-6 Haloalkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; and C 1-4 Alkoxy; or R e and R f Together with the nitrogen atom to which they are attached, they form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each carbon atom being replaced by 1-2 carbon atoms independently selected from H and C 1-3 Alkyl substituents; (b) 0-3 ring heteroatoms (except R e and R f connected nitrogen atoms), each of which is independently selected from N(R d ), O and S;
[0313] Each occurrence of R g independently selected from: halogen; cyano; optionally 1-2 independently selected R a Substituted C 1-6 Alkyl; C 1-4 haloalkyl; optionally substituted by 1-2 independently selected R a Substituted C 1-6 Alkoxy; C 1-4 Haloalkoxy; S(O) 1-2 (C 1-4 alkyl); -NR e R f ;–OH; oxo; -S(O) 1-2 (NR'R");-C 1-4 Thioalkoxy; -NO2; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; and -C(=O)N(R')(R");
[0314] as well as
[0315] Each occurrence of R' and R" is independently selected from: H and C 1-4 or R' and R" together with the nitrogen atom to which they are attached form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each carbon atom being replaced by 1-2 independently selected from H and C 1-3 (b) 0-3 ring heteroatoms (excluding the nitrogen atom connected to R' and R"), each independently selected from N(R d ), O and S;
[0316] Provided that one or more of the following a), b) and c) apply:
[0317] a) Z and Y in the lower ring 1 、Y 2 、Y 3 and Y 4 One or more of are independently selected heteroatoms:
[0318]
[0319] b) Including Z, Y 1 、Y 2 、Y 3 and Y 4 The ring is partially unsaturated; or
[0320] c) Z is a bond;
[0321] The conditions also include: if QA is defined according to (A); A is in the opposite position to C 1-10 Alkyl (e.g., C 2-6 Alkyl (e.g., C 3-5 Alkyl (eg, C4 alkyl (eg, n-butyl)))) monosubstituted C6 aryl; and including Z, Y 1 、Y 2 、Y 3 and Y 4 The ring is aromatic, including Z, Y 1 、Y 2 、Y 3 and Y 4 The ring must be surrounded by one or more R 1 Replacement; and
[0322] The proviso also includes that the compound is not selected from the group consisting of:
[0323]
[0324] In some embodiments, the proviso includes: if QA is according to the definition of (A); A is a C6 aryl group monosubstituted in the para position by a C4 alkyl group (eg, n-butyl); and includes Z, Y 1 、Y 2 、Y 3 and Y 4 The ring is aromatic, including Z, Y 1 、Y 2 、Y 3 and Y 4 The ring must be surrounded by one or more R 1 replace.
[0325] In another aspect, the present invention provides compounds of formula (I):
[0326]
[0327] or a pharmaceutically acceptable salt or N-oxide thereof,
[0328] in:
[0329] Z, Y in the lower ring 1 、Y 2 、Y 3 and Y 4 One or more of are independently selected heteroatoms:
[0330] Z is selected from: CR 1 and N;
[0331] Y 1 、Y 2 and Y 3 Each independently selected from: CR 1 and N;
[0332] The conditions are Z, Y 1 、Y 2 and Y 3 One or more of the CRs are independently selected 1 ;
[0333] Y 4 It is C;
[0334] X 1 It is NH;
[0335] X 2 It is CH;
[0336] Each are independently single bonds or double bonds, provided that Y 4 、X 1 and X 2 The five-membered ring of is heteroaryl; and
[0337] Including Z, Y 1 、Y 2 、Y 3 and Y 4 The ring is aromatic;
[0338] W is selected from:
[0339] (i) C(=O);
[0340] (ii) C(=S);
[0341] (iv) C(=NR d );and
[0342] (v) C(=NH);
[0343] QA is defined as follows:
[0344] (A)
[0345] Q is NH or N(C 1-6 alkyl), wherein C 1-6 The alkyl group is optionally replaced by 1-2 independently selected R a Replace, and
[0346] A is:
[0347] (i)-(Y A1 ) n -Y A2 ,in:
[0348] n is 0 or 1;
[0349] ·Y A1 It is C 1-6 Alkylene, which is optionally substituted by 1-6 R a replace; and
[0350] ·Y A2 yes:
[0351] (a)C 3-20 Cycloalkyl, which is optionally substituted by 1-4 R b replace,
[0352] (b)C 6-20 Aryl, which is optionally substituted by 1-4 R c replace;
[0353] (c) a heteroaryl group containing 5 to 20 ring atoms, wherein 1 to 4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected Rc Replace, or
[0354] (d) a heterocyclic group containing 3 to 16 ring atoms, wherein 1 to 3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R b )、N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace,
[0355] or
[0356] (ii)-Z 1 -Z 2 -Z 3 ,in:
[0357] ·Z 1 It is C 1-3 Alkylene, which is optionally substituted by 1-4 R a replace;
[0358] ·Z 2 It is -N(H)-, -N(R d )-, -O-, or –S-; and
[0359] ·Z 3 It is C 2-7 Alkyl, which is optionally replaced by 1-4 R a replace;
[0360] or
[0361] (iii)C 1-10 Alkyl, which is optionally substituted by 1-6 independently selected R a replace;
[0362] or
[0363] (B)
[0364] Q and A together form:
[0365] in represents the point of connection to W; and
[0366] E is a ring comprising 3-16 ring atoms, wherein, in addition to the nitrogen atom, 0-3 other ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace,
[0367] Each occurrence of R 1independently selected from: H; halogen; cyano; optionally substituted by 1-2 R a Substituted C 1-6 Alkyl; C 2-6 Alkenyl; C 2-6 Alkynyl; C 1-4 Haloalkyl; C 1-4 Alkoxy; C 1-4 haloalkoxy; optionally substituted by 1-4 independently selected R g Substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl; optionally substituted by 1-4 independently selected R g Substituted-(C 0-3 Alkylene)-C 6-10 Aryl; -(C 0-3 alkylene)-5-10 membered heteroaryl, wherein 1-3 ring atoms of the heteroaryl are independently selected from N, NH, NR d , O and S heteroatoms, wherein the heteroaryl group is optionally substituted by 1-4 independently selected R g Replacement; -(C 0-3 alkylene)-5-10 membered heterocyclic group, wherein 1-3 ring atoms of the heterocyclic group are independently selected from N, NH, NR d , O and S heteroatoms, wherein the heterocyclic group is optionally substituted by 1-4 independently selected R g Substitution; -S(O) 1-2 (C 1-4 alkyl); -NR e R f ;–OH; oxo; -S(O) 1-2 (NR'R");-C 1-4 Thioalkoxy; -NO2; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; and -C(=O)N(R')(R");
[0368] Each occurrence of R a Independently selected from: -OH; -F; -Cl; -Br; -NR e R f ; C 1-4 Alkoxy; C 1-4 Halogenated alkoxy; -C(=O)O(C 1-4 alkyl); -C(=O)(C 1-4 alkyl); -C(=O)OH; -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4alkyl); cyano; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl;
[0369] Each occurrence of R b Independently selected from: optionally 1-6 independently selected R a Substituted C 1-10 Alkyl; C 1-4 Haloalkyl; –OH; oxo; -F; -Cl; -Br; –NR e R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; -C(=O)N(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; optionally 1-4 independently selected C 1-4 Alkyl substituted (C 0-3 Alkylene)-C 6-10 Aryl; and optionally 1-4 independently selected C 1-4 Alkyl substituted (C 0-3 Alkylene)-C 3-6 Cycloalkyl;
[0370] Each occurrence of R c Independently selected from:
[0371] (i) halogen;
[0372] (ii) cyano;
[0373] (iii) optionally 1-6 independently selected R a Substituted C 1-10 alkyl;
[0374] (iv)C 2-6 alkenyl;
[0375] (v)C 2-6 Alkynyl;
[0376] (vi)C 1-4 alkyl halide;
[0377] (vii)C 1-4 alkoxy;
[0378] (viii)C 1-4 haloalkoxy;
[0379] (ix) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl;
[0380] (x)-(C 0-3 Alkylene)-heterocyclyl, wherein the heterocyclyl comprises 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from: N, N(H), N(R d ) and O;
[0381] (xi)-S(O) 1-2 (C 1-4 alkyl);
[0382] (xii)-NR e R f ;
[0383] (xiii)–OH;
[0384] (xiv)-S(O) 1-2 (NR’R”);
[0385] (xv)-C 1-4 Thioalkoxy;
[0386] (xvi)-NO2;
[0387] (xvii)-C(=O)(C 1-4 alkyl);
[0388] (xviii)-C(=O)O(C 1-4 alkyl);
[0389] (xix)-C(=O)OH;
[0390] (xx)-C(=O)N(R′)(R”);
[0391] (xxi) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 6-10 aryl; and
[0392] (xxii)-(C 0-3 alkylene)-5-10 membered heteroaryl, wherein 1-3 ring atoms of the heteroaryl are heteroatoms, each independently selected from: N, NH, NR d , O and S, wherein heteroaryl is optionally replaced by 1-4 independently selected C 1-4 Alkyl substitution;
[0393] Rd Select from the following group: C 1-6 Alkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; -CN; and C 1-4 alkoxy;
[0394] Each occurrence of R e and R f Independently selected from: H; C 1-6 Alkyl; C 1-6 Haloalkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; and C 1-4 Alkoxy; or R e and R f Together with the nitrogen atom to which they are attached, they form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each carbon atom being replaced by 1-2 carbon atoms independently selected from H and C 1-3 Alkyl substituents; (b) 0-3 ring heteroatoms (except R e and R f connected nitrogen atoms), each of which is independently selected from N(R d ), O and S;
[0395] Each occurrence of R g Independently selected from: halogen; cyano; optionally 1-2 R a Substituted C 1-6 Alkyl; C 1-4 Halogenated alkyl; optionally substituted by 1-2 R a Substituted C 1-6 Alkoxy; C 1-4 Haloalkoxy; S(O) 1-2 (C 1-4 -NR e R f ;–OH; oxo; -S(O) 1-2 (NR'R");-C 1-4 Thioalkoxy; -NO2; -C(=O)(C 1-4alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; and -C(=O)N(R')(R");
[0396] as well as
[0397] Each occurrence of R' and R" is independently selected from: H and C 1-4 or R' and R" together with the nitrogen atom to which they are attached form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each carbon atom being replaced by 1-2 independently selected from H and C 1-3 (b) 0-3 ring heteroatoms (excluding the nitrogen atom connected to R' and R"), each independently selected from N(R d ), O and S;
[0398] Provided that: if QA is defined according to (A); A is a C6 aryl group monosubstituted in the para position by a C4 alkyl group (e.g., n-butyl), then Z, Y 1 、Y 2 、Y 3 and Y 4 The ring must be surrounded by one or more R 1 Replacement; and
[0399] The condition also includes that the compound is not one or more of the following compounds:
[0400]
[0401]
[0402] In another aspect, provided herein are compounds of formula (I),
[0403]
[0404] or a pharmaceutically acceptable salt or N-oxide thereof,
[0405] in:
[0406] Z, Y in the lower ring 1 、Y 2 、Y 3 and Y 4 One or more of are independently selected heteroatoms:
[0407] Z is selected from: CR 1 and N;
[0408] Y 1 、Y 2 and Y 3 Each independently selected from: CR1 and N;
[0409] The conditions are Z, Y 1 、Y 2 and Y 3 One or more of the CRs are independently selected 1 ;
[0410] Y 4 It is C;
[0411] X 1 It is NH;
[0412] X 2 It is CH;
[0413] Each are independently single bonds or double bonds, provided that Y 4 、X 1 and X 2 The five-membered ring of is heteroaryl; and
[0414] Including Z, Y 1 、Y 2 、Y 3 and Y 4 The ring is aromatic;
[0415] W is selected from:
[0416] (i) C(=O);
[0417] (ii) C(=S);
[0418] (iv) C(=NR d );as well as
[0419] (v) C(=NH);
[0420] QA is defined as follows:
[0421] (A)
[0422] Q is NH or N(C 1-6 alkyl), wherein C 1-6 The alkyl group is optionally replaced by 1-2 independently selected R a Replace, and
[0423] A is:
[0424] (i)-(Y A1 ) n -Y A2 ,in:
[0425] n is 0 or 1;
[0426] ·YA1 It is C 1-6 Alkylene, which is optionally substituted by 1-6 R a replace; and
[0427] ·Y A2 yes:
[0428] (a)C 3-20 Cycloalkyl, which is optionally substituted by 1-4 R b replace,
[0429] (b)C 6-20 Aryl, which is optionally substituted by 1-4 R c replace;
[0430] (c) a heteroaryl group containing 5 to 20 ring atoms, wherein 1 to 4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R c Replace, or
[0431] (d) a heterocyclic group containing 3 to 16 ring atoms, wherein 1 to 3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R b )、N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace,
[0432] or
[0433] (ii)-Z 1 -Z 2 -Z 3 ,in:
[0434] ·Z 1 It is C 1-3 Alkylene, which is optionally substituted by 1-4 R a replace;
[0435] ·Z 2 It is -N(H)-, -N(R d )-, -O-, or –S-; and
[0436] ·Z 3 It is C 2-7 Alkyl, which is optionally replaced by 1-4 R a replace;
[0437] or
[0438] (iii)C 1-10 Alkyl, optionally substituted with 1-6 independently selected Ra Replace; or
[0439] (B)
[0440] Q and A together form:
[0441] in represents the point of connection to W; and
[0442] E is a ring comprising 3-16 ring atoms, wherein, in addition to the nitrogen atom, 0-3 other ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace,
[0443] Each occurrence of R 1 independently selected from: H; halogen; cyano; optionally substituted by 1-2 R a Substituted C 1-6 Alkyl; C 2-6 Alkenyl; C 2-6 Alkynyl; C 1-4 Haloalkyl; C 1-4 Alkoxy; C 1-4 haloalkoxy; optionally substituted by 1-4 independently selected R g Substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl; optionally substituted by 1-4 independently selected R g Substituted-(C 0-3 Alkylene)-C 6-10 Aryl; -(C 0-3 alkylene)-5-10 membered heteroaryl, wherein 1-3 ring atoms of the heteroaryl are independently selected from N, NH, NR d , O and S heteroatoms, wherein the heteroaryl group is optionally substituted by 1-4 independently selected R g Replacement; -(C 0-3 alkylene)-5-10 membered heterocyclic group, wherein 1-3 ring atoms of the heterocyclic group are independently selected from N, NH, NR d , O and S heteroatoms, wherein the heterocyclic group is optionally substituted by 1-4 independently selected R g Substitution; -S(O) 1-2 (C 1-4 alkyl); -NR e R f ;–OH; oxo; -S(O) 1-2 (NR'R");-C 1-4 Thioalkoxy; -NO2; -C(=O)(C1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; and -C(=O)N(R')(R");
[0444] Each occurrence of R a Independently selected from: -OH; -F; -Cl; -Br; -NR e R f ; C 1-4 Alkoxy; C 1-4 Halogenated alkoxy; -C(=O)O(C 1-4 alkyl); -C(=O)(C 1-4 alkyl); -C(=O)OH; -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl;
[0445] Each occurrence of R b Independently selected from: optionally 1-6 independently selected R a Substituted C 1-10 Alkyl; C 1-4 Haloalkyl; –OH; oxo; -F; -Cl; -Br; –NR e R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; -C(=O)N(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; optionally 1-4 independently selected C 1-4 Alkyl substituted (C 0-3 Alkylene)-C 6-10 Aryl; and optionally 1-4 independently selected C 1-4 Alkyl substituted (C 0-3 Alkylene)-C 3-6 Cycloalkyl;
[0446] Each occurrence of R c Independently selected from:
[0447] (i) halogen;
[0448] (ii) cyano;
[0449] (iii) optionally 1-6 independently selected R a Substituted C 1-10 alkyl;
[0450] (iv)C 2-6 alkenyl;
[0451] (v)C 2-6 Alkynyl;
[0452] (vi)C 1-4 alkyl halide;
[0453] (vii)C 1-4 alkoxy;
[0454] (viii)C 1-4 haloalkoxy;
[0455] (ix) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl;
[0456] (x)-(C 0-3 Alkylene)-heterocyclyl, wherein the heterocyclyl comprises 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from: N, N(H), N(R d ) and O;
[0457] (xi)-S(O) 1-2 (C 1-4 alkyl);
[0458] (xii)-NR e R f ;
[0459] (xiii)–OH;
[0460] (xiv)-S(O) 1-2 (NR’R”);
[0461] (xv)-C 1-4 Thioalkoxy;
[0462] (xvi)-NO2;
[0463] (xvii)-C(=O)(C 1-4 alkyl);
[0464] (xviii)-C(=O)O(C 1-4 alkyl);
[0465] (xix)-C(=O)OH;
[0466] (xx)-C(=O)N(R′)(R”);
[0467] (xxi) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 6-10 aryl; and
[0468] (xxii)-(C 0-3 alkylene)-5-10 membered heteroaryl, wherein 1-3 ring atoms of the heteroaryl are heteroatoms, each independently selected from: N, NH, NR d , O and S, wherein heteroaryl is optionally replaced by 1-4 independently selected C 1-4 Alkyl substitution;
[0469] R d Select from the following group: C 1-6 Alkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; -CN; and C 1-4 alkoxy;
[0470] Each occurrence of R e and R f Independently selected from: H; C 1-6 Alkyl; C 1-6 Haloalkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; and C 1-4 Alkoxy; or R e and R f Together with the nitrogen atom to which they are attached, they form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each carbon atom being replaced by 1-2 carbon atoms independently selected from H and C 1-3 Alkyl substituents; (b) 0-3 ring heteroatoms (except R e and R f connected nitrogen atoms), each of which is independently selected from N(Rd ), O and S;
[0471] Each occurrence of R g Independently selected from: halogen; cyano; optionally 1-2 R a Substituted C 1-6 Alkyl; C 1-4 Halogenated alkyl; optionally substituted by 1-2 R a Substituted C 1-6 Alkoxy; C 1-4 Haloalkoxy; S(O) 1-2 (C 1-4 -NR e R f ;–OH; oxo; -S(O) 1-2 (NR'R");-C 1-4 Thioalkoxy; -NO2; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; and -C(=O)N(R')(R");
[0472] as well as
[0473] Each occurrence of R' and R" is independently selected from: H and C 1-4 or R' and R" together with the nitrogen atom to which they are attached form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each carbon atom being replaced by 1-2 independently selected from H and C 1-3 (b) 0-3 ring heteroatoms (excluding the nitrogen atom connected to R' and R"), each independently selected from N(R d ), O and S;
[0474] The conditions are:
[0475] (1) If W is C(=O), A is not unsubstituted ethyl or unsubstituted phenyl;
[0476] (2) If W is C(=S), R 1 is not morpholin-4-yl; and
[0477] (3) If Y 2 It is N; Z, Y 1 and Y 3 Each is CH, then A is not replaced by C(O)2(C 1-3 alkyl) (e.g., C(O)2Et) monosubstituted C6 aryl;
[0478] Provided that: if QA is defined according to (A); A is a C6 aryl group monosubstituted in the para position by a C4 alkyl group (e.g., n-butyl), then Z, Y 1 、Y 2 、Y 3 and Y 4 The ring must be surrounded by one or more R 1 replace.
[0479] In another aspect, provided herein are compounds of formula (I),
[0480]
[0481] or a pharmaceutically acceptable salt or N-oxide thereof,
[0482] in:
[0483] Z, Y in the lower ring 1 、Y 2 、Y 3 and Y 4 One or more of are independently selected heteroatoms:
[0484]
[0485] Z is selected from: CR 1 and N;
[0486] Y 1 、Y 2 and Y 3 Each independently selected from: CR 1 and N;
[0487] The conditions are Z, Y 1 、Y 2 and Y 3 One or more of the CRs are independently selected 1 ;
[0488] Y 4 It is C;
[0489] X 1 It is NH;
[0490] X 2 It is CH;
[0491] Each are independently single bonds or double bonds, provided that Y 4 、X 1 and X 2 The five-membered ring of is heteroaryl; and
[0492] Including Z, Y 1 、Y 2 、Y3 and Y 4 The ring is aromatic;
[0493] W is selected from:
[0494] (i) C(=O);
[0495] (ii) C(=S);
[0496] (iv) C(=NR d );and
[0497] (v) C(=NH);
[0498] QA is defined as follows:
[0499] (A)
[0500] Q is NH or N(C 1-6 alkyl), wherein C 1-6 The alkyl group is optionally replaced by 1-2 independently selected R a Replace, and
[0501] A is:
[0502] (i)-(Y A1 ) n -Y A2 ,in:
[0503] n is 0 or 1;
[0504] ·Y A1 It is C 1-6 Alkylene, which is optionally substituted by 1-6 R a replace; and
[0505] ·Y A2 yes:
[0506] (a)C 3-20 Cycloalkyl, which is optionally substituted by 1-4 R b replace,
[0507] (b) C6 aryl, which is optionally substituted by 1 to 4 R c Replace one occurrence of R c It is R c’ ;
[0508] (c)C 7-20 Aryl, which is optionally substituted by 1-4 R c replace;
[0509] (d) a heteroaryl group containing 5-6 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(Rd ), O and S, and wherein one or more heteroaryl ring carbon atoms are replaced by 1-4 independently selected R c replace,
[0510] (e) heteroaryl containing 7-20 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R c Replace, or
[0511] (f) a heterocyclic group containing 3 to 16 ring atoms, wherein 1 to 3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R b )、N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace,
[0512] or
[0513] (ii)-Z 1 -Z 2 -Z 3 ,in:
[0514] ·Z 1 It is C 1-3 Alkylene, which is optionally substituted by 1-4 R a replace;
[0515] ·Z 2 It is -N(H)-, -N(R d )-, -O-, or –S-; and
[0516] ·Z 3 It is C 2-7 Alkyl, which is optionally replaced by 1-4 R a replace;
[0517] or
[0518] (iii)C 3-10 Alkyl (e.g., C 5-10 ,C 6-10 or C 7-10 alkyl), which is optionally replaced by 1-6 independently selected R a Replace; or
[0519] (B)
[0520] Q and A together form:
[0521] in represents the point of connection to W; and
[0522] E is a ring comprising 3-16 ring atoms, wherein, in addition to the nitrogen atom, 0-3 other ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace,
[0523] Each occurrence of R 1 independently selected from: H; halogen; cyano; optionally substituted by 1-2 R a Substituted C 1-6 Alkyl; C 2-6 Alkenyl; C 2-6 Alkynyl; C 1-4 Haloalkyl; C 1-4 Alkoxy; C 1-4 haloalkoxy; optionally substituted by 1-4 independently selected R g Substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl; optionally substituted by 1-4 independently selected R g Substituted-(C 0-3 Alkylene)-C 6-10 Aryl; -(C 0-3 alkylene)-5-10 membered heteroaryl, wherein 1-3 ring atoms of the heteroaryl are independently selected from N, NH, NR d , O and S heteroatoms, wherein the heteroaryl group is optionally substituted by 1-4 independently selected R g Replacement; -(C 0-3 alkylene)-5-10 membered heterocyclic group, wherein 1-3 ring atoms of the heterocyclic group are independently selected from N, NH, NR d , O and S heteroatoms, wherein the heterocyclic group is optionally substituted by 1-4 independently selected R g Substitution; -S(O) 1-2 (C 1-4 alkyl); -NR e R f ;–OH; oxo; -S(O) 1-2 (NR'R");-C 1-4 Thioalkoxy; -NO2; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; and -C(=O)N(R')(R");
[0524] Each occurrence of R a Independently selected from: -OH; -F; -Cl; -Br; -NR eR f ; C 1-4 Alkoxy; C 1-4 Halogenated alkoxy; -C(=O)O(C 1-4 alkyl); -C(=O)(C 1-4 alkyl); -C(=O)OH; -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl;
[0525] Each occurrence of R b Independently selected from: optionally 1-6 independently selected R a Substituted C 1-10 Alkyl; C 1-4 Haloalkyl; –OH; oxo; -F; -Cl; -Br; –NR e R f ; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; -C(=O)N(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); cyano; optionally 1-4 independently selected C 1-4 Alkyl substituted (C 0-3 Alkylene)-C 6-10 Aryl; and optionally 1-4 independently selected C 1-4 Alkyl substituted (C 0-3 Alkylene)-C 3-6 Cycloalkyl;
[0526] Each occurrence of R c Independently selected from:
[0527] (i) halogen;
[0528] (ii) cyano;
[0529] (iii) optionally 1-6 independently selected R a Substituted C 1-10 alkyl;
[0530] (iv)C 2-6 alkenyl;
[0531] (v)C2-6 Alkynyl;
[0532] (vi)C 1-4 alkyl halide;
[0533] (vii)C 1-4 alkoxy;
[0534] (viii)C 1-4 haloalkoxy;
[0535] (ix) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl;
[0536] (x)-(C 0-3 Alkylene)-heterocyclyl, wherein the heterocyclyl comprises 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from: N, N(H), N(R d ) and O;
[0537] (xi)-S(O) 1-2 (C 1-4 alkyl);
[0538] (xii)-NR e R f ;
[0539] (xiii)–OH;
[0540] (xiv)-S(O) 1-2 (NR’R”);
[0541] (xv)-C 1-4 Thioalkoxy;
[0542] (xvi)-NO2;
[0543] (xvii)-C(=O)(C 1-4 alkyl);
[0544] (xviii)-C(=O)O(C 1-4 alkyl);
[0545] (xix) -C(=O)OH;
[0546] (xx)-C(=O)N(R')(R"); and
[0547] (xxi) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 6-10 aryl; and
[0548] (xxii)-(C 0-3 alkylene)-5-10 membered heteroaryl, wherein 1-3 ring atoms of the heteroaryl are heteroatoms, each independently selected from: N, NH, NR d , O and S, wherein heteroaryl is optionally replaced by 1-4 independently selected C 1-4 Alkyl substitution;
[0549] R c’ Independently selected from:
[0550] (i) halogen;
[0551] (ii) cyano;
[0552] (iii) optionally 1-6 independently selected R a Substituted C 1-10 alkyl;
[0553] (iv)C 2-6 alkenyl;
[0554] (v)C 2-6 Alkynyl;
[0555] (vi)C 1-4 alkyl halide;
[0556] (vii)C 1-4 alkoxy;
[0557] (viii)C 1-4 haloalkoxy;
[0558] (ix) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl;
[0559] (x)-(C 0-3 Alkylene)-heterocyclyl, wherein the heterocyclyl comprises 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from: N, N(H), N(R d ) and O;
[0560] (xi)-S(O) 1-2 (C 1-4 alkyl);
[0561] (xii)-NR e R f ;
[0562] (xiii)–OH;
[0563] (xiv)-S(O) 1-2 (NR’R”);
[0564] (xv)-C 1-4 Thioalkoxy;
[0565] (xvi)-NO2;
[0566] (xvii)-C(=O)(C 1-4 alkyl);
[0567] (xviii) –C(=O)OMe or -C(=O)O(C 3-4 alkyl);
[0568] (xix) -C(=O)OH;
[0569] (xx)-C(=O)N(R')(R"); and
[0570] (xxi) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 6-10 aryl; and
[0571] (xxii)-(C 0-3 alkylene)-5-10 membered heteroaryl, wherein 1-3 ring atoms of the heteroaryl are heteroatoms, each independently selected from: N, NH, NR d , O and S, wherein heteroaryl is optionally replaced by 1-4 independently selected C 1-4 Alkyl substitution;
[0572] R d Select from the following group: C 1-6 Alkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4 alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; -CN; and C 1-4 alkoxy;
[0573] Each occurrence of R e and R f Independently selected from: H; C 1-6 Alkyl; C 1-6 Haloalkyl; C 3-6 Cycloalkyl; -C(O)(C 1-4 alkyl); -C(O)O(C 1-4alkyl); -CON(R')(R"); -S(O) 1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); -OH; and C 1-4 Alkoxy; or R e and R f Together with the nitrogen atom to which they are attached, they form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each carbon atom being replaced by 1-2 carbon atoms independently selected from H and C 1-3 Alkyl substituents; (b) 0-3 ring heteroatoms (except R e and R f connected nitrogen atoms), each of which is independently selected from N(R d ), O and S;
[0574] Each occurrence of R g Independently selected from: halogen; cyano; optionally 1-2 R a Substituted C 1-6 Alkyl; C 1-4 Halogenated alkyl; optionally substituted by 1-2 R a Substituted C 1-6 Alkoxy; C 1-4 Haloalkoxy; S(O) 1-2 (C 1-4 -NR e R f ;–OH; oxo; -S(O) 1-2 (NR'R");-C 1-4 Thioalkoxy; -NO2; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; and -C(=O)N(R')(R");
[0575] as well as
[0576] Each occurrence of R' and R" is independently selected from: H and C 1-4 or R' and R" together with the nitrogen atom to which they are attached form a ring containing 3-8 ring atoms, wherein the ring contains: (a) 1-7 ring carbon atoms, each carbon atom being replaced by 1-2 independently selected from H and C 1-3 (b) 0-3 ring heteroatoms (excluding the nitrogen atom connected to R' and R"), each independently selected from N(R d ), O and S,
[0577] Provided that: if QA is defined according to (A); A is a C6 aryl group monosubstituted in the para position by a C4 alkyl group (e.g., n-butyl), then Z, Y 1 、Y 2 、Y 3 and Y 4 The ring must be surrounded by one or more R 1 replace.
[0578] Implementations may include any one or more of the features described below and / or in the claims.
[0579] In some embodiments, Z, Y 1 、Y 2 、Y 3 and Y 4 One or more of are independently selected heteroatoms:
[0580]
[0581] In some embodiments, including Z, Y 1 、Y 2 、Y 3 and Y 4 Ring
[0582] It is aromatic.
[0583] In some embodiments, Z is not a bond.
[0584] In some of these embodiments, Z, Y 1 、Y 2 、Y 3 and Y 4 1-2 of them are independently N. For example, including Z, Y 1 、Y 2 、Y 3 and Y 4 The ring is selected from:
[0585] Each of these Indicates and includes X 1 and X 2 The connection point of the ring, and the bottom Indicates that X 1 connection point.
[0586] For example, including Z, Y 1 、Y 2 、Y 3 and Y 4 The ring is selected from:
[0587]
[0588] Each of these Indicates and includes X 1 and X 2 The connection point of the ring, and the bottom Indicates that X 1 connection point.
[0589] In other embodiments, Z is a bond.
[0590] In some of these embodiments, Y 2 It's CR 1 .
[0591] In some of these embodiments, Y 1 and Y 3 1-2 of them are not CR 1 .
[0592] In some of these embodiments, Y 1 and Y 3 1-2 of which are independently selected from: N, CR 1 and S.
[0593] For example, including Z, Y 1 、Y 2 、Y 3 and Y 4 The ring is selected from:
[0594] Each of these Indicates and includes X 1 and X 2 The connection point of the ring, and the bottom Indicates that X 1 connection point.
[0595] In some embodiments, including Z, Y 1 、Y 2 、Y 3 and Y 4 The ring is partially unsaturated.
[0596] In some of these embodiments, including Z, Y 1 、Y 2 、Y 3 and Y 4 The ring is:
[0597] Each of these Indicates and includes X 1 and X 2 The connection point of the ring, and the bottom Indicates that X 1 connection point.
[0598] In others of these embodiments, Z is not a single bond.
[0599] In some embodiments, Y 4 It’s C.
[0600] In some embodiments, Z, Y 1 、Y 2 and Y 3 One of them is not C(R 3 )2.
[0601] For example, including Z, Y 1 、Y 2 、Y 3 and Y 4 The ring is:
[0602] Each of these Indicates and includes X 1 and X 2 The connection point of the ring, and the bottom Indicates that X 1 connection point.
[0603] In some embodiments, X 2 Is N or CR 5 (For example, X 2 It's CR 5 ).
[0604] In some embodiments, X 1 Selected from: N and NR 2 (For example, R 2 Yes H).
[0605] In some embodiments, the compound has the formula:
[0606]
[0607] For example, the compound has the formula:
[0608]
[0609] In some embodiments, the compound has formula (I-a1); or the compound has formula (I-b1); or the compound has formula (I-c1); or the compound has formula (I-d1); or the compound has formula (I-e1); or the compound has formula (I-f1); or the compound has formula (I-g1); or the compound has formula (I-h1).
[0610] In some embodiments, the compound has the formula:
[0611]
[0612] In some embodiments, the compound has the formula:
[0613] (For example,
[0614] In some embodiments, the compound has formula (I-a2): (For example ).
[0615] In some embodiments, the compound has formula (I-d2): (For example, ).
[0616] In some embodiments, the compound has formula (I-e2): (For example, ).
[0617] In some embodiments, the compound has formula (I-f2): (For example, (For example )).
[0618] In some embodiments, the compound has formula (I-c2) or (I-i2):
[0619] In some embodiments, R 1 Independently selected from: H, halogen, cyano, optionally substituted by 1-2 R a Substituted C 1-6 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, OH, -S(O) 1-2 (C 1-4 alkyl), -S(O) 1-2 (NR'R"), -C 1-4 Thioalkoxy, -NO2, -C(=O)(C 1-4 alkyl), -C(=O)O(C 1-4 alkyl), -C(=O)OH, and -C(=O)N(R')(R").
[0620] In some embodiments, one or more occurrences of R 1 is independently H.
[0621] In some embodiments, the remaining occurrences of R 1 Each as defined in claim 32 (e.g., not H). For example, the remaining occurrences of R 1 Each selected from: methyl, C(O)NHMe, CF3, hydroxy-C 1-6 alkyl (e.g., 1-hydroxy-eth-1-yl), and methoxy.
[0622] In some embodiments, each R 1 independently selected from: H; halogen; cyano; optionally substituted by 1-2 R a Substituted C 1-6 Alkyl; C 1-4 Haloalkyl; C 2-6 Alkenyl (eg vinyl); C 2-6 Alkynyl (e.g. ethynyl); C 1-4 Alkoxy; C 1-4 Haloalkoxy; OH; -S(O) 1-2 (C 1-4 alkyl); -S(O) 1-2 (NR'R");-C 1-4 Thioalkoxy; -NO2; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; -C(=O)N(R')(R"); optionally 1-4 independently selected R g Substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl; optionally substituted by 1-4 independently selected R g Substituted-(C 0-3 Alkylene)-C 6-10 Aryl; -(C 0-3 alkylene)-5-10 membered heteroaryl, wherein 1-3 ring atoms of the heteroaryl are independently selected from N, NH, NR d , O and S heteroatoms, wherein the heteroaryl group is optionally substituted by 1-4 independently selected R g Replacement; and -(C 0-3 alkylene)-5-10 membered heterocyclic group, wherein 1-3 ring atoms of the heterocyclic group are independently selected from N, NH, NR d , O and S heteroatoms, wherein the heterocyclic group is optionally substituted by 1-4 independently selected R g replace.
[0623] In some embodiments, R 1 1-2 times (for example, 1 time) of the occurrence is not H.
[0624] In some embodiments, R1 1-2 (eg 1) occurrences of are independently selected from: halogen (eg F), cyano, C 1-3 Alkyl (such as methyl), C 1-3 Haloalkyl, -C(=O)N(R')(R"), hydroxy-C 1-6 Alkyl (e.g., 1-hydroxy-eth-1-yl), and methoxy (e.g., R 1 is independently halogen).
[0625] In some embodiments, R 1 1-2 (eg 1) occurrences of are independently halogen (eg F).
[0626] In some embodiments, R 1 1 occurrence is optionally replaced by 1-2 R a Substituted C 1-6 In some embodiments, R 1 1 occurrence of C 1-6 Alkyl groups (e.g., methyl or ethyl.
[0627] In some embodiments, R 1 1 occurrence of C 2-6 Alkenyl (eg, vinyl).
[0628] In some embodiments, R 1 1 occurrence of C 2-6 Alkynyl (eg, ethynyl).
[0629] In some embodiments, R 1 1 occurrence of C 1-4 Alkoxy (eg, methoxy).
[0630] In some embodiments, R 1 The 1 occurrence is cyano.
[0631] In some embodiments, R 1 1 occurrence of selected from:
[0632] Optionally 1-4 independently selected R g Substituted C 3-6 Cycloalkyl;
[0633] Optionally 1-4 independently selected R g Substituted C 6-10 Aryl (eg, optionally substituted with 1-4 independently selected R g substituted phenyl);
[0634] 5- to 10-membered heteroaryl (e.g., 5- or 6-membered heteroaryl), wherein 1-3 ring atoms of the heteroaryl are each independently selected from N, NH, NR d , O and S heteroatoms, wherein the heteroaryl group is optionally substituted by 1-4 independently selected R g substituted (e.g., pyrimidinyl, pyridinyl, pyrazolyl and thienyl (e.g., pyrazolyl), each of which is optionally substituted with 1-3 independently selected R g replaced); and
[0635] ·5-10 membered heterocyclic group, wherein 1-3 ring atoms of the heterocyclic group are independently selected from N, NH, NR d , O and S heteroatoms, wherein the heterocyclic group is optionally substituted by 1-4 independently selected R g substituted (e.g., tetrahydropyridinyl or tetrahydropyranyl, each of which is optionally substituted with 1-4 independently selected R g replace).
[0636] In some of these embodiments, R 1 Each occurrence of is independently optionally replaced by 1-4 independently selected R g Substituted C 6-10 Aryl.
[0637] In some embodiments, R 1 Each occurrence of is independently optionally 1-4 (eg, 1-3) independently selected R g Substituted phenyl.
[0638] In some embodiments, R 1 is independently a 5-10 membered heteroaryl, wherein 1-3 ring atoms of the heteroaryl are heteroatoms, each independently selected from: N, NH, NR d , O and S, wherein heteroaryl is optionally replaced by 1-4 independently selected R g replace.
[0639] In some of these embodiments, R 1 is independently a 5-membered heteroaryl, wherein 1-3 (e.g., 1 or 2-3) ring atoms of the heteroaryl are heteroatoms, each independently selected from: N, NH, NR d , O and S, wherein heteroaryl is optionally replaced by 1-4 independently selected R g replace.
[0640] As non-limiting examples of these embodiments, R 1 is optionally 1-3 independently selected R g Substituted pyrazolyl (e.g., ).
[0641] As another non-limiting example, R 1 is optionally 1-2 independently selected R g Substituted thiazolyl.
[0642] As another non-limiting example, R 1 is optionally 1-2 independently selected R g Substituted thienyl.
[0643] In some embodiments, R 1 is independently a 6-membered heteroaryl, wherein 1-2 ring atoms of the heteroaryl are ring nitrogen atoms, wherein the heteroaryl is optionally substituted by 1-4 independently selected R g replace.
[0644] In some of these embodiments, R 1 is pyridinyl or pyrimidinyl, each of which is optionally replaced by 1-4 independently selected R g Substituted (e.g., 3-pyridyl (e.g. (For example )).
[0645] In some embodiments, R 1 is a 5-10 membered heterocyclyl, wherein 1-3 ring atoms in the heterocyclyl are independently selected from N, NH, NR d , O and S heteroatoms, wherein the heterocyclic group is optionally substituted by 1-4 independently selected R g Substituted (e.g., tetrahydropyridyl or tetrahydropyranyl (e.g. ), each of which is optionally replaced by 1-4 independently selected R g replace)).
[0646] In some embodiments, R 1 An occurrence of is optionally replaced by 1-4 independently selected R g Substituted C 3-6 Cycloalkyl (e.g., optionally substituted with 1-2 independently selected R g substituted C6 cycloalkyl (e.g., cyclohexyl or cyclohexenyl)).
[0647] In one or more of the foregoing embodiments, each R g Independently selected from: NR e R f (e.g. NH2, 4-methylpiperazin-1-yl, morpholin-4-yl), C 1-4 Alkyl (such as methyl, ethyl or isopropyl), C 1-4 Haloalkyl (e.g. CF3), R a Substituted C 1-4Alkyl (e.g. OH, NR e R f or C(O)OC 1-4 Alkyl substituted C 1-4 alkyl), optionally replaced by R a Substituted C 1-4 Alkoxy (e.g., methoxy or -OCH2-cyclopropyl), -S(O) 1-2 (NR'R") (e.g., S(O)2NMe2 or S(O)2NH2), and -S(O) 1-2 (C 1-4 alkyl) (e.g. S(O)2Me).
[0648] In some embodiments, each R 2 Independently selected from:
[0649] (i)C 1-6 Alkyl, which is optionally substituted by 1-2 independently selected R a replace;
[0650] (ii)C 3-6 Cycloalkyl;
[0651] (iii) a heterocyclic group comprising 3 to 10 ring atoms, wherein 1 to 3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O; and
[0652] (xi)H.
[0653] In some embodiments, each R 2 Independently selected from:
[0654] (i)C 1-6 Alkyl, which is optionally substituted by 1-2 independently selected R a Replacement; and
[0655] (xi) H (e.g., each R 2 are independently H).
[0656] In some embodiments, each R 3 Independently selected from: H, optionally 1-6 independently selected R a Substituted C 1-6 Alkyl; C 1-4 Haloalkyl; –OH; -F; -Cl; -Br; C 1-4 Alkoxy; C 1-4 Haloalkoxy; -C(=O)(C 1-4 alkyl); -C(=O)O(C 1-4 alkyl); -C(=O)OH; -C(=O)N(R')(R"); -S(O)1-2 (NR'R");-S(O) 1-2 (C 1-4 alkyl); and cyano; or two R 3 Combine to form oxo;
[0657] In some embodiments, each R 3 Independently selected from: H, optionally 1-6 independently selected R a Substituted C 1-6 Alkyl; and C 1-4 Haloalkyl; or two R on the same carbon 3 Combine to form an oxo group.
[0658] In some embodiments, each R 3 Independently selected from: H, optionally 1-6 independently selected R a Substituted C 1-6 Alkyl; and C 1-4 Halogenated alkyl.
[0659] In some embodiments, each R 3 It’s H.
[0660] In some embodiments, each R 5 Independently selected from: H, oxo and hydroxy.
[0661] In some embodiments, each R 5 Is H or C 1-3 Alkyl (e.g., R 5 Yes H).
[0662] In some embodiments, W is selected from the group consisting of:
[0663] (i) C(=O);
[0664] (ii) C(=S);
[0665] (iii)S(O) 1-2 ;
[0666] (iv) C(=NR d );
[0667] (v) C(=NH); and
[0668] (vi) C (=C-NO2).
[0669] In some embodiments, W is C(=O).
[0670] In some embodiments, W is S(O)2.
[0671] In some embodiments, W is C(=NRd ). In some of these embodiments, W is C(=N-CN).
[0672] In some embodiments, Q and A are defined according to (A).
[0673] In some embodiments, Q is NH.
[0674] In some embodiments, Q is N(C 1-3 alkyl).
[0675] In some embodiments, A is -(Y A1 ) n -Y A2 .
[0676] In some embodiments, n is 0.
[0677] In some embodiments, n is 1. In some of these embodiments, Y A1 It is C 1-3 In some other embodiments, Y is A1 Is R a Substituted C 1-3 Alkylene (e.g., CHR a CH2 (e.g., CH(C(=O)NHMe)CH2)).
[0678] In some of the foregoing embodiments, Y A2 It is C 6-20 Aryl, which is optionally substituted by 1-4R c replace.
[0679] For example, Y A2 Can be C 6-10 Aryl, which is optionally substituted by 1-3 R c Replace; for example, Y A2 It may be a phenyl group, which is optionally substituted by 1-3 R c In some embodiments, Y A2 is optionally replaced by 1 R c Substituted phenyl (eg, in the para position).
[0680] As another example, Y A2 It may be naphthyl, which is optionally substituted by 1 to 3 R c replace.
[0681] As another example, Y A2 It may be a tetrahydronaphthyl group, which is optionally substituted by 1 to 3 R c replace.
[0682] In some embodiments, YA2 is a C6 aryl group, which is independently substituted by 1-4 R c replace.
[0683] In some of these embodiments, Y A2 is a C6 aryl group, which is independently substituted by 1-3 R c Substituted, where R c One occurrence of R c’ .
[0684] In some embodiments, Y A2 is selected by 1-3 independent R c Substituted phenyl (e.g., by an R c substituted phenyl; or substituted by an R c’ substituted phenyl), wherein R c The first appearance is in the opposite position of R c’ .
[0685] In some embodiments, Y A2 is selected by 1-3 independent R c Substituted phenyl (e.g., by an R c substituted phenyl; or substituted by an R c’ substituted phenyl), wherein R c The first occurrence of R is in the meta position c’ .
[0686] In some embodiments, Y A2 It is C 7-20 Aryl, which is optionally substituted by 1-4 R c replace.
[0687] As a non-limiting example of the foregoing embodiment, Y A2 Selected from: naphthyl, tetrahydronaphthyl (e.g. ), and dihydroindanyl (e.g. ).
[0688] In other cases of the foregoing embodiments, Y A2 is a heteroaryl group containing 5 to 20 ring atoms, wherein 1 to 4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 independently selected R c replace.
[0689] For example, Y A2 is a heteroaryl group containing 5-10 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-4 (e.g., 1-3) independently selected R c replace.
[0690] In certain embodiments, Y A2 is a heteroaryl group containing 5-10 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from N, N(H) and N(R d ), and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-3 independently selected R c replace.
[0691] In certain embodiments, Y A2 is a heteroaryl group containing 5-10 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from N, N(H) and N(R d ), and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c replace.
[0692] In certain embodiments, Y A2 is a heteroaryl group containing 6-10 ring atoms, wherein 1-2 ring atoms are heteroatoms, each independently selected from N, N(H) and N(R d ), and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-2 independently selected R c replace.
[0693] For example, Y A2 is quinolinyl or tetrahydroquinolinyl, which is optionally substituted by 1-2 independently selected R c substituted (eg, unsubstituted quinolinyl or tetrahydroquinolinyl).
[0694] In certain embodiments, Y A2 is a heteroaryl group containing 5-6 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are replaced by 1-3 independently selected R c replace.
[0695] In some of these embodiments, Y A2 is a heteroaryl group containing 5 ring atoms, wherein 1-3 (e.g. 1-2) ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are replaced by 1-2 independently selected R c replace.
[0696] As a non-limiting example of the foregoing embodiment, YA2 is selected by 1-2 independent R c Substituted thiazolyl or pyrazolyl (e.g., thiazolyl, e.g. ).
[0697] In certain embodiments, Y A2 is a heteroaryl group containing 6 ring atoms (e.g., pyridinyl or pyrimidinyl), wherein 1-2 ring atoms are ring nitrogen atoms, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-3 independently selected R c replace.
[0698] In some of these embodiments, R c One occurrence is relative to Y A1 The alignment of the connection points.
[0699] In certain embodiments, (if Y A2 is a heteroaryl group containing 6 ring atoms (e.g., pyridinyl or pyrimidinyl), wherein 1-2 ring atoms are ring nitrogen atoms, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-3 independently selected R c Replace), R c One occurrence is relative to Y A1 The inter-position of the connection point.
[0700] In certain other embodiments, Y A2 is a heteroaryl group containing 7-12 (e.g., 8-10) ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S, and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-3 independently selected R c replace.
[0701] As a non-limiting example, Y A2 is optionally 1-2 independently selected R c Substituted isoquinolinyl, quinolinyl, tetrahydroquinolinyl or tetrahydroisoquinolinyl (eg, unsubstituted quinolinyl or tetrahydroquinolinyl).
[0702] As another non-limiting example, Y A2 is optionally 1-2 independently selected R c Substituted benzothiazolyl (e.g. ).
[0703] In some of the foregoing embodiments, each occurrence of R c Independently selected from:
[0704] (iii) optionally 1-6 independently selected R a Substituted C1-10 alkyl;
[0705] (ix) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 3-6 cycloalkyl; and
[0706] (x)-(C 0-3 Alkylene)-heterocyclyl, wherein the heterocyclyl comprises 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from: N, N(H), N(R d ) and O.
[0707] In some embodiments, each occurrence of R c is independently optionally 1-6 independently selected R a Substituted C 1-6 alkyl.
[0708] In some embodiments, R c are independently selected from: optionally halogen (eg, F), C 1-4 Alkoxy and / or NR e R f Substituted C 1-6 alkyl.
[0709] For example, R c may independently be unsubstituted C 1-6 Alkyl (e.g., n-butyl), ethoxymethyl, CH2NHCH2CF3 and CH2CF2CH2CH3.
[0710] Non-limiting examples of A can be selected from:
[0711]
[0712] In some embodiments, each occurrence of R c Independently selected from:
[0713] (ix) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 3-6 cycloalkyl; and
[0714] (x)-(C 0-3 Alkylene)-heterocyclyl, wherein the heterocyclyl comprises 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from: N, N(H), N(R d ) and O.
[0715] In some embodiments, each occurrence of R cIndependently selected from:
[0716] (ix) optionally 1 independently selected C 1-4 Alkyl-substituted-(C1 alkylene)-C 3-6 cycloalkyl; and
[0717] (x)-heterocyclyl, wherein the heterocyclyl comprises 6 ring atoms, one of which is a heteroatom, each independently selected from: N, N(H), N(R d ) and O.
[0718] For example, each occurrence of R c Independently selected from:
[0719]
[0720] In some of the foregoing embodiments, R c or R c’ Each occurrence of is independently optionally replaced by 1-6 independently selected R a Substituted C 1-10 (For example, C 1-2 ,C3,C4,C5,C6 or C 7-10 )alkyl.
[0721] In some of these embodiments, R c or R c’ One occurrence is unsubstituted C 1-10 (For example, C 1-2 ,C3,C4,C5,C6 or C 7-10 )alkyl (e.g., butyl).
[0722] In some other embodiments, R c or R c’ An occurrence of is independently selected by 1-6 independent R a Substituted C 1-10 (e.g. C3, C4, C5, C6 or C 7-10 )alkyl.
[0723] In some of these embodiments, R a is independently selected from: halogen (eg, F), C 1-4 Alkoxy (such as methoxy or ethoxy) and NR e R f .
[0724] As a non-limiting example of the foregoing embodiment, R c or R c’ One occurrence is selected from the group consisting of: CF3, ethoxymethyl, CH2NHCH2CF3 and CH2CF2CH2CH3 (e.g., Rc or R c’ One occurrence is CF3).
[0725] In some embodiments, R c or R c’ An occurrence of C is independently 1-4 Halogenated alkyl.
[0726] As a non-limiting example, R c or R c’ One of the first occurrences is CF3.
[0727] In some embodiments, R c or R c’ One occurrence of is independently selected from:
[0728] (ix) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl;
[0729] (x)-(C 0-3 Alkylene)-heterocyclyl, wherein the heterocyclyl comprises 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from: N, N(H), N(R d ) and O;
[0730] (xxi) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 6-10 aryl; and
[0731] (xxii)-(C 0-3 alkylene)-5-10 membered heteroaryl, wherein 1-3 ring atoms of the heteroaryl are heteroatoms, each independently selected from: N, NH, NR d , O and S, wherein heteroaryl is optionally replaced by 1-4 independently selected C 1-4 Alkyl substitution.
[0732] In some embodiments, R c or R c’ One occurrence of is independently selected from: optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 1-3 Alkylene)-C 3-6 Cycloalkyl. For example, R c or R c’ One occurrence of is cyclohexyl. For example, R c or R c’ As another example, Rc or R c’ One appearance is
[0733] In some embodiments, R c or R c’ One occurrence of -(C 0-3 alkylene)-heterocyclyl, wherein the heterocyclyl comprises 3-16 ring atoms, of which 1-3 ring atoms are heteroatoms, each independently selected from: N, N(H), N(R d ) and O.
[0734] In some of these embodiments, R c or R c’ One occurrence of -(C 0-3 alkylene)-heterocyclyl, wherein the heterocyclyl comprises 3-10 ring atoms, of which 1-3 ring atoms are heteroatoms, each independently selected from: N, N(H), N(R d ) and O.
[0735] In some embodiments, R c or R c’ One occurrence of -(C 0-3 alkylene)-heterocyclyl, wherein the heterocyclyl comprises 5-6 ring atoms, of which 1-3 ring atoms are heteroatoms, each independently selected from: N, N(H), N(R d ) and O.
[0736] In some embodiments, R c or R c’ One occurrence of is selected from:
[0737] (xxi) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 6-10 Aryl (e.g. C 6-10 aryl, such as phenyl); and
[0738] (xxii)-(C 0-3 alkylene)-5-10 membered heteroaryl, wherein 1-3 ring atoms of the heteroaryl are heteroatoms, each independently selected from: N, NH, NR d , O and S, wherein heteroaryl is optionally replaced by 1-4 independently selected C 1-4 Alkyl substitution.
[0739] In some embodiments, R c or R c’ One occurrence is C 2-6 Alkenyl (e.g., vinyl) or C 2-6 Alkynyl (e.g., ethynyl).
[0740] As a non-limiting example, R c or R c’ One occurrence is C 2-6 Alkynyl (e.g., ethynyl).
[0741] Non-limiting examples of A can be selected from:
[0742]
[0743] In other cases of the foregoing embodiments, Y A2 It is C 3-10 Cycloalkyl, which is optionally substituted by 1-4 R b replace.
[0744] In some embodiments, Y A2 It is C 3-8 Monocyclic cycloalkyl (eg, cyclobutyl and cyclohexyl), optionally substituted with 1-4 R b replace.
[0745] As a non-limiting example of the foregoing embodiment, Y A2 is a C6 cycloalkyl group (eg, cyclohexyl), which is optionally substituted by 1-3 R b Substituted, where R b The first time it appeared was in the opposite position.
[0746] As another non-limiting example, Y A2 is a C5 cycloalkyl group (e.g., cyclopentyl group (e.g., )).
[0747] As another non-limiting example, Y A2 is a C4 cycloalkyl group (e.g., ).
[0748] In certain other embodiments, Y A2 It is C 7-13 Bicyclic cycloalkyl, optionally substituted by 1-4 independently selected R b Replace, for example
[0749] In some embodiments, Y A2 It is C 7-13 Bicyclic (eg, spirobicyclic) cycloalkyl, optionally substituted by 1-4 independently selected R b Replace, for example
[0750] As a non-limiting example of the foregoing embodiment, Y A2 yes
[0751] In another aspect of the foregoing embodiment, Y A2 is a heterocyclic group containing 3 to 12 ring atoms, wherein 1 to 3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace.
[0752] In some embodiments, R b Each occurrence of is selected from: optionally 1-4 independently selected R a Substituted C 1-10 Alkyl; C 1-4 Haloalkyl; –OH; oxo; -F; -Cl; -Br; C 1-4 Alkoxy; C 1-4 Haloalkoxy; optionally substituted by 1-4 independently selected C 1-4 Alkyl substituted C 6-10 Aryl; and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl.
[0753] In some of these embodiments, R b Each occurrence of is selected from: optionally 1-6 independently selected R a Substituted C 1-10 Alkyl; C 1-4 Haloalkyl; -OH; oxo; -F; -Cl; -Br; C 1-4 Alkoxy; C 1-4 and optionally 1-4 independently selected C 1-4 Alkyl substituted C 3-6 Cycloalkyl.
[0754] In some of these embodiments, R b Each occurrence of is selected from: optionally 1-6 independently selected R a Substituted C 1-10 Alkyl and C 1-4 Halogenated alkyl.
[0755] In some of these embodiments, R b Each occurrence of is selected from: optionally 1-2 independently selected R a Substituted C 1-6 alkyl.
[0756] For example, R b Each occurrence of is selected from: unsubstituted C 1-6 Alkyl (eg, butyl, eg, n-butyl).
[0757] In some embodiments, R b Each occurrence of is independently optionally replaced by 1-6 independently selected R a Substituted C 1-10 (For example, C 1-2 ,C3,C4,C5,C6 or C 7-10 )alkyl.
[0758] In some of these embodiments, R b One occurrence is unsubstituted C 1-10 (For example, C 1-2 ,C3,C4,C5,C6 or C 7-10 )alkyl (e.g., butyl).
[0759] In some other embodiments, R b An occurrence of is independently selected by 1-6 independent R a Substituted C 1-10 (e.g. C3, C4, C5, C6 or C 7-10 )alkyl.
[0760] In some of these embodiments, R a is independently selected from: halogen (eg, F), C 1-4 Alkoxy and NR e R f .
[0761] In some other embodiments, R b One occurrence of is selected from: optionally 1-4 independently selected C 1-4 Alkyl substituted (C 0-1 Alkylene)-C 6-10 Aryl; and optionally 1-4 independently selected C 1-4 Alkyl substituted (C 0-1 Alkylene)-C 3-6 Cycloalkyl (eg, unsubstituted phenyl).
[0762] In the non-limiting examples of the foregoing embodiments, R b is unsubstituted phenyl or unsubstituted benzyl.
[0763] In some embodiments, Y A2 yes n1 is 0, 1, or 2; R cA R is independently selected c or R c’ ; and R cB R is independently selected c .
[0764] In some embodiments, Y A2 yes n1 is 0, 1, or 2; R cA R is independently selected c or R c’ ; and R cB R is independently selected c .
[0765] In some embodiments, Y A2 yes Q 1 ,Q 2 ,Q 3 and Q 4 1-2 of them are N; the rest are Q 1 ,Q 2 ,Q 3 and Q 4 are each CH; n1 is 0, 1 or 2; and R cA and R cB Each is independently selected R c .
[0766] In some embodiments, Y A2 yes Q 1 ,Q 2 ,Q 3 and Q 4 1-2 of them are N; the rest are Q 1 ,Q 2 ,Q 3 and Q 4 are each CH; n1 is 0, 1 or 2; and R cA and R cB Each is independently selected R c .
[0767] In some embodiments (if Y A2 yes ), R cA R according to any one of claims 174 to 178 c or R c’ Definition of .
[0768] In some embodiments (if Y A2 yes ), R cA R according to any one of claims 179 to 185 c or R c’ Definition of .
[0769] In some embodiments (if Y A2 yes ), n1 is 0.
[0770] In some other embodiments, n1 is 1 or 2. In some of these embodiments, each R cB are independently halogen, C 1-3 Alkyl or C 1-3 Halogenated alkyl.
[0771] In some embodiments, Y A2 yes n2 is 0, 1 or 2; and R bA and R bB Each is independently selected R b .
[0772] In some embodiments, Y A2 yes n2 is 0, 1 or 2; and R bA and R bB Each is independently selected R b .
[0773] In some embodiments (if Y A2 yes ), R bA R according to any one of claims 192 to 196 b Definition of .
[0774] In some embodiments (if Y A2 yes ), R bA R according to any one of claim 197 b Definition of .
[0775] In some embodiments (if Y A2 yes ), R bA R according to any one of claim 191 b Definition of .
[0776] In some embodiments (if Y A2 yes ), n2 is 0.
[0777] In some other embodiments, n2 is 1 or 2. In some of these embodiments, each R bB are independently halogen, C 1-3 Alkyl or C 1-3 Halogenated alkyl.
[0778] Other non-limiting examples of A can be selected from:
[0779] For example
[0780]
[0781] Other non-limiting examples of A may include:
[0782]
[0783] In some embodiments, Q and A are defined according to (B).
[0784] In some embodiments, E is a heterocyclyl group comprising 3-12 ring atoms, wherein, in addition to the nitrogen atom present, 0-3 additional ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-2 independently selected R b replace,
[0785] In some embodiments, E is a heterocyclyl group comprising 6-12 ring atoms, wherein, in addition to the nitrogen atom present, 0-3 additional ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-2 independently selected R b replace,
[0786] In some embodiments, E is a heterocyclyl group (e.g., a spirocyclic heterocyclyl group) comprising 6-12 ring atoms, wherein, in addition to the nitrogen atom present, 0-2 additional ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by one or more independently selected R b replace.
[0787] Non-limiting examples of E may be selected from:
[0788] (For example, R b is unsubstituted C 1-6 alkyl groups, such as n-butyl and ethyl); for example:
[0789] (For example, R b is unsubstituted C 1-6 alkyl, such as ethyl).
[0790] In some embodiments (if QA is defined according to (B)), Q and A together form:
[0791] in represents the connection point with W; and
[0792] E is a ring (e.g., monocyclic or bicyclic) comprising 5-12 ring atoms, wherein, in addition to the nitrogen atom, 0-3 of the other ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-4 independently selected R b replace.
[0793] In some embodiments, E is a heterocyclyl group comprising 5-10 (e.g., 5-6) ring atoms, wherein, in addition to the nitrogen atom present, 0-1 additional ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ) and O, and wherein one or more heterocyclyl ring carbon atoms are optionally replaced by 1-2 independently selected R b replace,
[0794] As a non-limiting example, E is piperidinyl (e.g., )or
[0795] In some embodiments, R of E b One occurrence of a substituent is independently selected from: C 1-4 Alkoxy (eg, propoxy); C 1-4 haloalkoxy; optionally substituted by 1-6 independently selected R a Substituted C 1-10 Alkyl (e.g., butyl); and C 1-4 Halogenated alkyl.
[0796] Other non-limiting examples of E may include:
[0797] Non-restricted combinations
[0798] In some embodiments, Q is NH; W is C(═O); and A is Y A2 , where Y A2 It is defined according to claims 51-55 and 62-65.
[0799] In some embodiments, Q is NH; W is C(═O); and A is Y A2 , where Y A2 It is defined according to claims 51-55 and 67-70.
[0800] In some embodiments, Q is NH; W is C(═O); and A is Y A2 , where Y A2 It is defined according to claims 56-61 and 62-65.
[0801] In some embodiments, Q is NH; W is C(═O); and A is Y A2 , where Y A2 It is defined according to claims 56-61 and 67-70.
[0802] In some embodiments, Q is NH; W is C(═O); and A is Y A2 , where Y A2 is defined according to claims 71 and 73-78.
[0803] In some embodiments, Q is NH; W is C(═O); and A is Y A2 , where Y A2 As defined in claims 72, 73-76 and 79.
[0804] In some embodiments, Q is NH; W is C(=S); and A is Y A2 , where Y A2 It is defined according to claims 51-55 and 62-65.
[0805] In some embodiments, Q is NH; W is C(=S); and A is Y A2 , where Y A2 It is defined according to claims 51-55 and 67-70.
[0806] In some embodiments, Q is NH; W is C(=S); and A is Y A2 , where Y A2 It is defined according to claims 56-61 and 62-65.
[0807] In some embodiments, Q is NH; W is C(=S); and A is Y A2 , where Y A2 It is defined according to claims 56-61 and 67-70.
[0808] In some embodiments, Q is NH; W is C(=S); and A is Y A2 , where Y A2 is defined according to claims 71 and 73-78.
[0809] In some embodiments, Q is NH; W is C(=S); and A is Y A2 , where Y A2 As defined in claims 72, 73-76 and 79.
[0810] In some embodiments, Q is NH; W is C(=NR d)(e.g., C(=N(Boc)); and A is Y A2 , where Y A2 It is defined according to claims 51-55 and 62-65.
[0811] In some embodiments, Q is NH; W is C(=NR d )(e.g., C(=N(Boc)); and A is Y A2 , where Y A2 It is defined according to claims 51-55 and 67-70.
[0812] In some embodiments, Q is NH; W is C(=NR d )(e.g., C(=N(Boc)); and A is Y A2 , where Y A2 It is defined according to claims 56-61 and 62-65.
[0813] In some embodiments, Q is NH; W is C(=NR d )(e.g., C(=N(Boc)); and A is Y A2 , where Y A2 It is defined according to claims 56-61 and 67-70.
[0814] In some embodiments, Q is NH; W is C(=NR d )(e.g., C(=N(Boc)); and A is Y A2 , where Y A2 is defined according to claims 71 and 73-78.
[0815] In some embodiments, Q is NH; W is C(=NR d )(e.g., C(=N(Boc)); and A is Y A2 , where Y A2 As defined in claims 72, 73-76 and 79.
[0816] In some embodiments, Q is NH; W is C(=NH); and A is Y A2 , where Y A2 It is defined according to claims 51-55 and 62-65.
[0817] In some embodiments, Q is NH; W is C(=NH); and A is Y A2 , where Y A2 It is defined according to claims 51-55 and 67-70.
[0818] In some embodiments, Q is NH; W is C(=NH); and A is YA2 , where Y A2 It is defined according to claims 56-61 and 62-65.
[0819] In some embodiments, Q is NH; W is C(=NH); and A is Y A2 , where Y A2 It is defined according to claims 56-61 and 67-70.
[0820] In some embodiments, Q is NH; W is C(=NH); and A is Y A2 , where Y A2 is defined according to claims 71 and 73-78.
[0821] In some embodiments, Q is NH; W is C(=NH); and A is Y A2 , where Y A2 As defined in claims 72, 73-76 and 79.
[0822] Any of the foregoing non-limiting combinations may include one or more of the following features.
[0823] W may be C(=O); and QA is as defined in claims 80-85.
[0824] W may be C(=S); and QA is as defined in claims 80-85.
[0825] W can be C(=NR d )(e.g., C(=NBoc)); and QA is defined according to claims 80-85.
[0826] W may be C(=NH); and QA is as defined in claims 80-85.
[0827] The compound may have formula (I-a1) or the compound may have formula (I-b1); or the compound may have (I-c1); or the compound may have (I-d1); or the compound may have (I-e1); or the compound may have (I-f1); or the compound may have (I-g1); or the compound may have (I-h1); or the compound may have (I-i1); or the compound may have (I-j1); or the compound may have (I-k1); or the compound may have (I-l1); or the compound may have (I-m1).
[0828] R 1 It can be defined according to claims 32-35.
[0829] R 2 It can be defined according to claims 36-37.
[0830] R 3 It can be defined according to claims 38-41.
[0831] R 5 It can be defined according to claim 43.
[0832] In some embodiments, the compound has the formula:
[0833] Among them, Z, Y 1 ,Y 2 and Y 3 Each independently is N or CR 1 , the condition is Z,Y 1 ,Y 2 and Y 3 One or more of them is N; R 7 Is H or C 1-3 Alkyl; n1 is 0, 1 or 2; R cA R is independently selected c or R c’ ; and each R cB R is independently selected c .
[0834] In some embodiments, the compound has the formula:
[0835] Among them, Z, Y 1 ,Y 2 and Y 3 Each independently is N or CR 1 , the condition is Z,Y 1 ,Y 2 and Y 3 One or more of them is N; R 7 Is H or C 1-3 Alkyl; n1 is 0, 1 or 2; R cA R is independently selected c or R c’ ; and each R cB R is independently selected c .
[0836] In some embodiments, the compound has the formula:
[0837] Among them, Z, Y 1 ,Y 2 and Y 3 Each independently is N or CR 1, the condition is Z,Y 1 ,Y 2 and Y 3 One or more of them is N; R 7 Is H or C 1-3 Alkyl; Q 1 ,Q 2 ,Q 3 and Q 4 1-2 of them are N; the rest are Q 1 ,Q 2 ,Q 3 and Q 4 are each CH; n1 is 0, 1 or 2; and R cA and R cB Each is independently selected R c .
[0838] In some embodiments, the compound has the formula:
[0839] Among them, Z, Y 1 ,Y 2 and Y 3 Each independently is N or CR 1 , the condition is Z,Y 1 ,Y 2 and Y 3 One or more of them is N; R 7 Is H or C 1-3 Alkyl; Q 1 ,Q 2 ,Q 3 and Q 4 1-2 of them are N; the rest are Q 1 ,Q 2 ,Q 3 and Q 4 are each CH; n1 is 0, 1 or 2; and R cA and R cB Each is independently selected R c .
[0840] In some embodiments of Formula (II), (III), (IV) and / or (V), R cA R according to any one of claims 174 to 178 c or R c’ Definition of .
[0841] In some embodiments of Formula (II), (III), (IV) and / or (V), R cA R according to any one of claims 179 to 185 c or R c’ Definition of .
[0842] In some embodiments of Formula (II), (III), (IV) and / or (V), n1 is 0.
[0843] In some other embodiments of Formula (II), (III), (IV) and / or (V), n1 is 1 or 2. In some of these embodiments, each R cB is a halogen, C 1-3 Alkyl or C 1-3 Halogenated alkyl.
[0844] In some embodiments, the compound has the formula: Among them, Z, Y 1 ,Y 2 and Y 3 Each independently is N or CR 1 , the condition is Z,Y 1 ,Y 2 and Y 3 One or more of them is N; R 7 Is H or C 1-3 alkyl; n2 is 0, 1 or 2; and R bA and R bB Each is independently selected R b .
[0845] In some embodiments, the compound has the formula: Among them, Z, Y 1 ,Y 2 and Y 3 Each independently is N or CR 1 , the condition is Z,Y 1 ,Y 2 and Y 3 One or more of them is N; R 7 Is H or C 1-3 alkyl; n2 is 0, 1 or 2; and R bA and R bB Each is independently selected R b .
[0846] In some embodiments of Formula (VI) and / or (VII), R bA R according to any one of claims 192 to 196 b Definition of .
[0847] In some embodiments of Formula (VI) and / or (VII), R bA R in claim 197 b Definition of .
[0848] In some embodiments of Formula (VI) and / or (VII), n2 is 0.
[0849] In some other embodiments, n2 is 1 or 2. In some of these embodiments, each R bB are independently halogen, C 1-3 Alkyl or C 1-3 Halogenated alkyl.
[0850] In some embodiments, the compound has the formula:
[0851]
[0852] Among them, Z, Y 1 ,Y 2 and Y 3 Each independently is N or CR 1 , the condition is Z,Y 1 ,Y 2 and Y 3 One or more of them is N;
[0853] R 7 Is H or C 1-3 alkyl; and
[0854] AA2 is selected from the group consisting of:
[0855] (a) a heteroaryl group comprising 9-10 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S (e.g., quinolinyl, isoquinolinyl, tetrahydroquinolinyl and benzothiazolyl (e.g. )), and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-3 independently selected R c Replacement; and
[0856] (b)C 7-11 Aryl (e.g. naphthyl, tetrahydronaphthyl (e.g. )), which is optionally replaced by 1-4 R c replace.
[0857] In some embodiments, AA2 is a heteroaryl group comprising 9-10 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S (e.g., quinolinyl, isoquinolinyl, tetrahydroquinolinyl and benzothiazolyl (e.g. )), and wherein one or more heteroaryl ring carbon atoms are optionally replaced by 1-3 independently selected R c replace.
[0858] In some embodiments, AA2 is (b) C 7-11 Aryl (e.g. naphthyl, tetrahydronaphthyl (e.g. )), which is optionally replaced by 1-4 R c replace.
[0859] As a non-limiting example, AA2 is
[0860] In some embodiments, the compound has the formula:
[0861]
[0862] Among them, Z, Y 1 ,Y 2 and Y 3 Each independently is N or CR 1 , the condition is Z,Y 1 ,Y 2 and Y 3 One or more of them is N;
[0863] R 7 Is H or C 1-3 alkyl; and
[0864] AA3 is a heteroaryl group comprising 5 ring atoms, wherein 1-3 (e.g. 1-2) ring atoms are heteroatoms, each independently selected from N, N(H), N(R d ), O and S (e.g., thiazolyl (e.g., )), and wherein one or more heteroaryl ring carbon atoms are replaced by 1-2 independently selected R c replace.
[0865] In some of these embodiments, AA3 is thiazolyl (e.g. ), which is optionally replaced by 1-2 independently selected R c replace.
[0866] In some of these embodiments, R c Selected from:
[0867] (xxi) optionally 1-4 independently selected C 1-4 Alkyl-substituted-(C 0-3 Alkylene)-C 6-10 aryl; and
[0868] (xxii)-(C 0-3 alkylene)-5-10 membered heteroaryl, wherein 1-3 ring atoms of the heteroaryl are heteroatoms, each independently selected from: N, NH, NR d, O and S, wherein heteroaryl is optionally replaced by 1-4 independently selected C 1-4 Alkyl substitution.
[0869] In some of these embodiments, R c Selected from:
[0870] (xxi) optionally 1-4 independently selected C 1-4 Alkyl-substituted-C 6-10 aryl; and
[0871] (xxii) 5-10 membered heteroaryl, wherein 1-3 ring atoms of the heteroaryl are heteroatoms, each independently selected from: N, NH, NR d , O and S, wherein heteroaryl is optionally replaced by 1-4 independently selected C 1-4 Alkyl substitution.
[0872] As a non-limiting example of the above embodiment, R c It is an unsubstituted phenyl group.
[0873] In some embodiments, the compound has the formula:
[0874]
[0875] Among them, Z, Y 1 ,Y 2 and Y 3 Each independently is N or CR 1 , the condition is Z,Y 1 ,Y 2 and Y 3 One or more of them is N;
[0876] R 7 Is H or C 1-3 alkyl; and
[0877] AA4 is C 7-13 Bicyclic cycloalkyl groups (e.g., Among them L ab is key or C 1-3 alkylene), which is optionally substituted by 1-4 independently selected R b replace.
[0878] In some of these embodiments, AA4 is
[0879] In some embodiments of Formula (II)-(X), -(Y A1 ) n where n is 0.
[0880] In some embodiments, the compound has the formula:
[0881] Among them, Z, Y 1 ,Y 2 and Y 3 Each independently is N or CR 1 , the condition is Z,Y 1 ,Y 2 and Y 3 One or more of n is N; n3 is 1 or 2; and each R b’ R is independently selected b ; or a pair of R attached to the same carbon atom or different carbon atoms b’ Together with the atoms to which they are attached, they form a ring comprising 3 to 8 ring atoms.
[0882] In some of these embodiments, n3 is 1. In some of these embodiments, R b’ Selected from: C 1-4 Alkoxy (eg, propoxy); C 1-4 haloalkoxy; optionally substituted by 1-6 independently selected R a Substituted C 1-10 Alkyl (e.g., butyl); and C 1-4 Halogenated alkyl.
[0883] In some other embodiments, n3 is 2; and a pair of R attached to the same carbon atom or to different carbon atoms b’ Together with the atoms to which they are attached, they form a ring comprising 3-8 ring atoms (e.g. ).
[0884] In some embodiments of Formulas (II)-(XI), Z is N; and Y 1 ,Y 2 and Y 3 Each is independently CR 1 For example, Z is N; Y 1 It's CR 1 ; and Y 2 and Y 3 Each is CH; or Z is N; Y 2 It's CR 1 ; and Y 1 and Y 3 Each is CH; or Z is N; Y 3 It's CR 1 ; and Y 2 and Y 1 Each is CH.
[0885] In some embodiments of Formulas (II)-(XI), Y 1 is N; and Z, Y 2 and Y3 Each is independently CR 1 For example, Y 1 is N; Z is CR 1 ; and Y 2 and Y 3 Each is CH; or Y 1 It is N; Y 2 It's CR 1 ; and Z and Y 3 Each is CH; or Y 1 It is N; Y 3 It's CR 1 ; and Z and Y 2 Each is CH.
[0886] In some embodiments of Formulas (II)-(XI), Y 2 is N; and Z, Y 1 and Y 3 Each is independently CR 1 For example, Y 2 is N; Z is CR 1 ; and Y 1 and Y 3 Each is CH; or Y 2 It is N; Y 1 It's CR 1 ; and Z and Y 3 Each is CH; or Y 2 It is N; Y 3 It's CR 1 ; and Z and Y 1 Each is CH;
[0887] In some embodiments of Formulas (II)-(XI), Y 3 is N; and Z, Y 1 and Y 2 Each is independently CR 1 For example, Y 3 is N; Z is CR 1 ; and Y 1 and Y 2 Each is CH; or Y 3 It is N; Y 1 It's CR 1 ; and Z and Y 2 Each is CH; or Y 3 It is N; Y 2 It's CR 1 ; and Z and Y 1 Each is CH.
[0888] In some embodiments of Formulas (II)-(XI), R 1One occurrence of R 1 One occurrence of is selected from:
[0889] Optionally 1-4 independently selected R g Substituted-(C 0-3 Alkylene)-C 3-6 Cycloalkyl;
[0890] Optionally 1-4 independently selected R g Substituted-(C 0-3 Alkylene)-C 6-10 Aryl; -(C 0-3 alkylene)-5-10 membered heteroaryl, wherein 1-3 ring atoms of the heteroaryl are heteroaryl, each independently selected from N, NH, NR d , O and S, and wherein heteroaryl is optionally replaced by 1-4 independently selected R g Replacement; and
[0891] ·-(C 0-3 Alkylene)-5-10 membered heterocyclic group, wherein 1-3 ring atoms of the heterocyclic group are heteroatoms, each independently selected from: N, NH, NR d , O and S, wherein the heterocyclyl is optionally replaced by 1-4 independently selected C 1-4 Alkyl substitution.
[0892] In some of these embodiments, R 1 One occurrence of is selected from:
[0893] Optionally 1-4 independently selected R g Substituted C 3-6 Cycloalkyl;
[0894] Optionally 1-4 independently selected R g Substituted C 6-10 Aryl (eg, optionally substituted with 1-4 independently selected R g substituted phenyl);
[0895] 5- to 10-membered heteroaryl (e.g., 5- or 6-membered heteroaryl), wherein 1-3 heteroatoms are independently selected from N, NH, NR d , O and S heteroatoms, wherein the heteroaryl group is optionally substituted by 1-4 independently selected R g substituted (e.g., pyrimidinyl, pyridinyl, pyrazolyl and thienyl (e.g., pyrazolyl), each of which is optionally substituted with 1-3 independently selected R g replaced); and
[0896] ·5-10 membered heterocyclic group, wherein 1-3 ring atoms in the heterocyclic group are independently selected from N, NH, NR d, O and S heteroatoms, wherein the heterocyclic group is optionally substituted by 1-4 independently selected R g substituted (e.g., tetrahydropyridinyl or tetrahydropyranyl, each of which is optionally substituted with 1-4 independently selected R g replace).
[0897] In some embodiments of Formulas (II)-(XI), R 1 One occurrence of is selected from:
[0898] Optionally 1-4 independently selected R g Substituted C 3-6 Cycloalkyl;
[0899] Optionally 1-4 independently selected R g Substituted C 6-10 Aryl (eg, optionally substituted with 1-4 independently selected R g substituted phenyl);
[0900] 5- or 6-membered heteroaryl, wherein 1-3 heteroatoms are independently selected from N, NH, NR d , O and S heteroatoms, wherein the heteroaryl group is optionally substituted by 1-4 independently selected R g substituted (e.g., pyrimidinyl, pyridinyl, pyrazolyl and thienyl (e.g., pyrazolyl), each of which is optionally substituted with 1-3 independently selected R g replaced); and
[0901] ·5-6 membered heterocyclic group, wherein 1-3 ring atoms in the heterocyclic group are independently selected from N, NH, NR d , O and S heteroatoms, wherein the heterocyclic group is optionally substituted by 1-4 independently selected R g substituted (e.g., tetrahydropyridinyl or tetrahydropyranyl, each of which is optionally substituted with 1-4 independently selected R g replace).
[0902] In some embodiments of Formulas (II)-(XI), R 1 One occurrence is according to the definition of claims 144-145.
[0903] In some embodiments of Formulas (II)-(XI), R 1 One occurrence is according to the definition of claims 146-148.
[0904] In some embodiments of Formulas (II)-(XI), R 1 One occurrence is according to the definition of claims 149-150.
[0905] In some embodiments of Formulas (II)-(XI), R 1 One occurrence is according to the definition in claim 151.
[0906] In some embodiments of Formulas (II)-(XI), R 1 One occurrence is according to the definition in claims 141-142.
[0907] In one or more instances of the foregoing embodiments, R g Each independently selected from: NR e R f (e.g. NH2, 4-methylpiperazin-1-yl, morpholin-4-yl), C 1-4 Alkyl (such as methyl, ethyl or isopropyl), C 1-4 Haloalkyl (e.g. CF3), R a Substituted C 1-4 Alkyl (e.g. OH, NR e R f or C(O)OC 1-4 Alkyl substituted C 1-4 alkyl), optionally replaced by R a Substituted C 1-4 Alkoxy (e.g., methoxy or -OCH2-cyclopropyl), -S(O) 1-2 (NR'R") (e.g., S(O)2NMe2 or S(O)2NH2), and -S(O) 1-2 (C 1-4 alkyl) (e.g. S(O)2Me).
[0908] In some embodiments of Formulas (II)-(XI), R 1 One occurrence of is a halogen (eg, F, Cl, or Br).
[0909] In some embodiments of Formulas (II)-(XI), R 1 The 1 occurrence is cyano.
[0910] In some embodiments of Formulas (II)-(XI), R 1 1 occurrence of C 1-6 Alkyl (eg, ethyl).
[0911] In some embodiments of Formulas (II)-(XI), R 1 One occurrence is C 2-6 Alkenyl (eg, vinyl).
[0912] In some embodiments of Formulas (II)-(XI), R 1 One occurrence is C 2-6 Alkynyl (e.g., ethynyl).
[0913] In some of the foregoing embodiments of Formulas (II)-(XI), the remaining occurrences of R 1 Each is H.
[0914] In some embodiments of Formulas (II)-(XI), W is C(═O).
[0915] In some embodiments of Formulas (II)-(XI), R 7 It’s H.
[0916] In some embodiments, the compound is selected from:
[0917]
[0918]
[0919]
[0920]
[0921]
[0922]
[0923]
[0924]
[0925]
[0926]
[0927]
[0928]
[0929]
[0930]
[0931]
[0932]
[0933]
[0934]
[0935]
[0936]
[0937]
[0938]
[0939]
[0940]
[0941]
[0942]
[0943]
[0944]
[0945]
[0946]
[0947]
[0948]
[0949]
[0950]
[0951]
[0952]
[0953]
[0954]
[0955]
[0956]
[0957]
[0958]
[0959]
[0960]
[0961]
[0962]
[0963]
[0964]
[0965]
[0966]
[0967]
[0968]
[0969]
[0970]
[0971]
[0972]
[0973]
[0974]
[0975] and pharmaceutically acceptable salts thereof.
[0976] Pharmaceutical compositions and administration
[0977] Overview
[0978] In some embodiments, a chemical entity (e.g., a compound that inhibits (e.g., antagonizes) STING, or a pharmaceutically acceptable salt, and / or hydrate, and / or cocrystal, and / or pharmaceutical combination thereof) is administered as a pharmaceutical composition comprising the chemical entity and one or more pharmaceutically acceptable excipients, and optionally one or more additional therapeutic agents described herein.
[0979] In some embodiments, the chemical entity can be administered in combination with one or more conventional pharmaceutical excipients. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS), such as d-α-tocopheryl polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms, such as Tweens, poloxamers or other similar polymer delivery matrices, serum proteins, such as human serum albumin, buffer substances, such as phosphates, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, and lanolin. Cyclodextrins such as α-, β- and γ-cyclodextrins, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-β-cyclodextrins, or other solubilized derivatives can also be used to provide delivery of the compounds described herein. Dosage forms or compositions comprising chemical entities described herein in the range of 0.005%-100% can be prepared, with the remainder being made up by non-toxic excipients. The compositions contemplated may comprise 0.001%-100% of the chemical entities provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, and in yet another embodiment 20-80%. The actual methods for preparing such dosage forms are known or understood by those skilled in the art; for example, see Remington: The Science and Practice of Pharmacy, 22nd edition (Pharmaceutical Press, London, England, 2012).
[0980] Routes of administration and composition components
[0981] In some embodiments, the chemical entities described herein or pharmaceutical compositions thereof can be administered to a subject in need thereof by any acceptable route of administration. Acceptable routes of administration include, but are not limited to, buccal, transdermal, intracervical, intrasinus, intratracheal, enteral, epidural, interstitial, intraperitoneal, intraarterial, intrabronchial, intrabursal, intracerebral, intracisternal, intracoronary, intradermal, intraductal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intragingival, intraileal, intralymphatic, intramedullary, intrameningeal, intramuscular, intraovarian, intraperitoneal, intraprostatic, intrapulmonary, intrasinus, intraspinal, intrasynovial, intratesticular, intrathecal, intratubular, intratumoral, intrauterine, intravascular, intravenous, nasal, nasogastric, oral, parenteral, transdermal, peridural, rectal, respiratory (inhalation), subcutaneous, sublingual, submucosal, topical, transdermal, transmucosal, transtracheal, ureteral, urethral, and vaginal. In some embodiments, the preferred route of administration is parenteral (eg, intratumoral).
[0982] The compositions can be formulated for parenteral administration, for example, for injection via intravenous, intramuscular, subcutaneous, or even intraperitoneal routes. Generally, such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for adding liquids prior to injection to prepare solutions or suspensions can also be prepared; and formulations can also be emulsified. The preparation of such formulations is known to those skilled in the art in light of the present disclosure.
[0983] Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil, or propylene glycol in water; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and fluid enough to allow easy syringability. It should also be stable under the conditions of manufacture and storage and must resist the contaminating action of microorganisms such as bacteria and fungi during storage.
[0984] The carrier can also be a solvent or dispersion medium comprising, for example, water, ethanol, a polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.), and suitable mixtures thereof, and vegetable oils. Suitable fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the desired particle size in the case of a dispersion, and by using a surfactant. The effects of microorganisms can be prevented by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc. In many cases, isotonic agents such as sugars or sodium chloride are preferably included. The absorption of the injectable composition can be prolonged by using agents that delay absorption, such as aluminum monostearate and gelatin in the composition.
[0985] Sterile injectable solutions are prepared by incorporating the desired amount of the active compound in a suitable solvent into the various other components described above, followed by filtration sterilization as needed. Typically, dispersions are prepared by incorporating the various sterile active ingredients into a sterile vehicle containing a basic dispersion medium and the other required ingredients described above. When preparing sterile powders for sterile injectable solutions, vacuum drying and freeze-drying techniques are preferred to obtain a powder of the active ingredient and any other required ingredients from a previously sterile-filtered solution.
[0986] For intratumoral injection, see, for example, Lammers et al., “Effect of Intratumoral Injection on the Biodistribution and the Therapeutic Potential of HPMA Copolymer-Based Drug Delivery Systems” Neoplasia. 2006, 10, 788-795.
[0987] Pharmaceutically acceptable excipients that can be used in rectal compositions as gels, creams, enemas, or rectal suppositories include, but are not limited to, one or more of the following: cocoa butter glycerides, synthetic polymers such as polyvinyl pyrrolidone, PEG (e.g., PEG ointment), glycerin, glycerinated gelatin, hydrogenated vegetable oils, poloxamers, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol, petrolatum, anhydrous lanolin, shark liver oil, sodium saccharin, menthol, sweet almond oil, sorbitol, sodium benzoate, Anoxidase, SBN, vanilla essential oil, parabens in aerosol, phenoxyethanol, sodium methylparaben, sodium propylparaben, diethylamine, carbomer, carbopol, methyl methoxybenzoate, polyethylene glycol cetearyl ether, decyl cocoate, isopropyl alcohol, propylene glycol, liquid paraffin, xanthan gum, carboxy-dimethylbenzyl metabisulfite, sodium EDTA, sodium benzoate, potassium metabisulfite, grapefruit seed extract, methylsulfonylmethane (MSM), lactic acid, glycine, vitamins (such as vitamins A and E), and potassium acetate.
[0988] In certain embodiments, suppositories can be prepared by mixing the chemical entities described herein with suitable non-irritating excipients or carriers, such as cocoa butter, polyethylene glycol, or suppository wax, which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum and release the active compound. In other embodiments, compositions for rectal administration are in the form of enemas.
[0989] In other embodiments, the compounds described herein, or pharmaceutical compositions thereof, are suitable for local delivery to the digestive or gastrointestinal tract by oral administration (eg, solid or liquid dosage forms).
[0990] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the chemical entity is mixed with one or more pharmaceutically acceptable excipients, such as sodium citrate or dicalcium phosphate and / or: a) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants, such as glycerol, d) disintegrants, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solubilizers, such as paraffin, f) absorption enhancers, such as quaternary ammonium compounds, g) wetting agents, such as cetyl alcohol and glyceryl monostearate, h) absorbents, such as kaolin and bentonite, and i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also contain buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or lactose fractions as well as high molecular weight polyethylene glycols.
[0991] In one embodiment, the composition can take the form of a unit dosage form such as a pill or tablet, and thus the composition may comprise, in addition to the chemical entities provided herein: a diluent such as lactose, sucrose, dicalcium phosphate, etc.; a lubricant such as magnesium stearate, etc.; a binder such as starch, gum arabic, polyvinyl pyrrolidone, gelatin, cellulose, cellulose derivatives, etc. In another solid dosage form, a powder, pill, solution or suspension (e.g., in propylene carbonate, vegetable oil, PEG's, poloxamer 124 or triglycerides) is encapsulated in a capsule (gelatin or cellulose-based capsule). Unit dosage forms in which one or more chemical entities or other active agents provided herein are physically separated are also contemplated, such as capsules containing individual drug particles (or tablets in capsules); double-layer tablets; double-chamber gel capsules, etc. Enteric-coated or delayed-release oral dosage forms are also contemplated.
[0992] Other physiologically acceptable compounds include wetting agents, emulsifiers, dispersants or preservatives, which are especially useful for preventing the growth or action of microorganisms. Various preservatives are well known and include, for example, phenol and ascorbic acid.
[0993] In certain embodiments, the excipient is sterile and generally free of undesirable substances. The composition can be sterilized by conventional, well-known sterilization techniques. For various oral dosage form excipients, such as tablets and capsules, sterility is not required. USP / NF standards are generally sufficient.
[0994] In certain embodiments, the solid oral dosage form may further include one or more components that chemically and / or structurally facilitate delivery of the composition to the stomach or lower GI; for example, the ascending colon and / or transverse colon and / or distal colon and / or small intestine. Exemplary formulation techniques are described, for example, in Filipski, KJ et al., Current Topics in Medicinal Chemistry, 2013, 13, 776-802, which is incorporated herein by reference in its entirety.
[0995] Examples include upper GI targeting technologies such as the Accordion Pill (Intec Pharma), floating capsules and materials that can adhere to the mucosal wall.
[0996] Other examples include lower GI targeting technologies. To target various areas of the intestine, several enteric / pH responsive coatings and excipients are available. These materials are typically polymers designed to dissolve or erode within a specific pH range, selected based on the GI region where drug release is desired. In cases where the active ingredient may irritate the upper GI, these materials also serve to protect acid-labile drugs from gastric fluid or limit exposure (e.g., hydroxypropyl methylcellulose phthalate series, Coateric (polyvinyl acetate phthalate), cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate, Eudragit series (methacrylic acid-methyl methacrylate copolymers), and Marcoat. Other technologies include dosage forms that respond to the local flora of the GI tract, pressure-controlled colonic delivery capsules, and Pulsincap.
[0997] Ophthalmic compositions may include, but are not limited to, any one or more of the following: viscogens (e.g., carboxymethylcellulose, glycerol, polyvinylpyrrolidone, polyethylene glycol); stabilizers (e.g., Pluronic (triblock copolymer), cyclodextrin); preservatives (e.g., benzalkonium chloride, ETDA, SofZia (boric acid, propylene glycol, sorbitol, and zinc chloride; Alcon Laboratories Inc.), Purite (stabilized chlorine oxide complex; Allergan, Inc.).
[0998] Topical compositions can include ointments and creams. Ointments are semisolid preparations, typically based on petrolatum or other petroleum derivatives. Creams containing the selected active agent are typically viscous liquids or semisolid emulsions, typically oil-in-water or water-in-oil. The cream base is typically washable and comprises an oil phase, an emulsifier, and an aqueous phase. The oil phase, sometimes also referred to as the "internal phase," is typically composed of petrolatum and a fatty alcohol (such as cetyl alcohol or stearyl alcohol); although not necessarily, the aqueous phase typically exceeds the volume of the oil phase and typically contains a wetting agent. The emulsifier in a cream formulation is typically a nonionic, anionic, cationic, or amphoteric surfactant. Like other carriers or vehicles, the ointment base should be inert, stable, non-irritating, and non-sensitizing.
[0999] In any of the foregoing embodiments, the pharmaceutical compositions described herein may comprise one or more of the following: lipids, multilamellar vesicles with cross-links between bilayers, biodegradable poly (D, L-lactic-co-glycolic acid) [PLGA]-based or polyanhydride-based nanoparticles or microparticles, and nanoporous particle-loaded lipid bilayers.
[1000] dose
[1001] The dosage may vary depending on the patient's needs, the severity of the disease being treated, and the specific compound being used. The determination of the appropriate dosage for a particular situation can be determined by one skilled in the art of medicine. The total daily dose may be divided and administered in divided doses throughout the day or by providing continuous delivery.
[1002] In some embodiments, the compounds described herein are administered at a dose of about 0.001 mg / Kg to about 500 mg / Kg (e.g., about 0.001 mg / Kg to about 200 mg / Kg; about 0.01 mg / Kg to about 200 mg / Kg; about 0.01 mg / Kg to about 150 mg / Kg; about 0.01 mg / Kg to about 100 mg / Kg; about 0.01 mg / Kg to about 50 mg / Kg; about 0.01 mg / Kg to about 10 mg / Kg; about 0.01 mg / Kg to about 5 mg / Kg; about 0.01 mg / Kg to about 1 mg / Kg; about 0.01 mg / Kg to about 0.5 mg / Kg; about 0.01 mg / Kg to about 0.1 mg / Kg; about 0.1 mg / Kg to about 200 mg / Kg; about 0.1 mg / Kg to about 150 mg / Kg; about 0.1 mg / Kg to about 100 mg / Kg; about 0.1 mg / Kg to about 50 mg / Kg; about 0.1 mg / Kg to about 10 mg / Kg; about 0.1 mg / Kg to about 5 mg / Kg; about 0.1 mg / Kg to about 1 mg / Kg; about 0.1 mg / Kg to about 0.5 mg / Kg).
[1003] Dosage regimen
[1004] The foregoing doses can be administered daily (e.g., as a single dose or as two or more divided doses) or non-daily (e.g., every other day, every two days, every three days, once a week, twice a week, once every two weeks, once a month).
[1005] In some embodiments, the compounds described herein are administered for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months or more. In another embodiment, the administration is stopped for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months or more. In one embodiment, the individual therapeutic compound is administered for a period of time, followed by a separate time period. In another embodiment, the therapeutic compound is administered in the first period of time, the administration is stopped in the second period of time after the first period of time, the therapeutic compound is then restarted in the third period of time, and then the administration is stopped in the fourth period of time after the third period of time. In one aspect of this embodiment, the administration period of the therapeutic compound and the subsequent time period of stopping administration are repeated in a determined or undetermined time period. In another embodiment, the administration period is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months or longer. In another embodiment, the period of time during which dosing is stopped is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months or longer.
[1006] Treatment
[1007] In some embodiments, methods are provided for treating a subject having a condition, disease, or disorder in which increased (e.g., excessive) STING activity (e.g., STING signaling) contributes to the pathology and / or symptoms and / or progression of the condition, disease, or disorder (e.g., immune disorder, cancer).
[1008] Indications
[1009] In some embodiments, the condition, disease or disorder is cancer. Non-limiting examples of cancer include: melanoma, carcinoma, lymphoma, blastoma, sarcoma and leukemia or lymphoid malignancies. More specific examples of such cancers include: breast cancer, colon cancer, rectal cancer, colorectal cancer, kidney cancer, clear cell carcinoma lung cancer, including small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma and lung squamous cell carcinoma, squamous cell carcinoma (e.g., epithelial squamous cell carcinoma), cervical cancer, ovarian cancer, prostate cancer, prostate tumors, liver cancer, bladder cancer, peritoneal cancer, hepatocellular carcinoma, gastric cancer, including gastrointestinal cancer, gastrointestinal stromal tumors, pancreatic cancer, head and neck cancer, glioblastoma, retinoblastoma, astrocytoma, theca Thecomas, Wilms' tumor, hepatocellular carcinoma (hepatoma), hematologic malignancies including non-Hodgkin's lymphoma (NHL), multiple myeloma, myelodysplasia, myeloid proliferative disorders, chronic myeloid leukemia, and acute hematologic malignancies, endometrial or uterine cancer, endometriosis, endometrial stromal sarcoma, fibrosarcoma, choriocarcinoma, salivary gland cancer, vulvar cancer, thyroid cancer, esophageal cancer, hepatic cancer (hepatic In some cases, the cancer is melanoma.
[1010] In some embodiments, the condition, disease, or disorder is a neurological disorder, which includes disorders involving the central nervous system (brain, brainstem, and cerebellum), the peripheral nervous system (including the cranial nerves), and the autonomic nervous system (parts of which are located in both the central and peripheral nervous systems). Non-limiting examples of cancer include: acquired epileptiform aphasia; acute disseminated encephalomyelitis; adrenoleukodystrophy; age-related macular degeneration; agenesis of the corpus callosum; agnosia; Aicardi syndrome; Alexander disease; Alpers' disease; alternating hemiplegia; Alzheimer's disease; vascular dementia; amyotrophic lateral sclerosis; anencephaly; Angelman syndrome; angiomatosis; hypoxia; aphasia; apraxia; arachnoid cyst; arachnoiditis; Anronl-Chiari malformation; arteriovenous malformation; Asperger syndrome; ataxia; attention deficit hyperactivity disorder; autism; dysautonomia; back pain; Batten disease; Behcet's disease; Bell's palsy palsy; benign essential blepharospasm; benign focal dyskinesia; amyotrophy; benign intracranial hypertension; Binswanger disease; blepharospasm; Bloch-Sulzberger syndrome; brachial plexus injury; brain abscess; brain injury; brain tumors (including glioblastomas); spinal tumors; Brown-Sequard syndrome; Canavan disease; carpal tunnel syndrome; causalgia; central pain syndrome; central pontine myelinolysis; headache; cerebral aneurysm; cerebral arteriosclerosis; brain atrophy; cerebral gigantism; cerebral palsy; Charcot-Marie-Tooth disease; chemotherapy-induced neuropathy and neuropathic pain; Chiari malformation; chorea; chronic inflammatory demyelinating polyneuropathy; chronic pain; chronic regional pain syndrome; Coffin-Lowry syndrome; coma, including persistent vegetative state; congenital facial palsy; corticobasal degeneration; cranial arteritis; craniosynostosis; Creutzfeldt-Jakob disease disease; cumulative trauma disorder; Cushing's syndrome; cytomegalovirus inclusion disease; cytomegalovirus infection; dancing eyes and feet syndrome; Dandy-Walker syndrome; Dawson disease; De Morsier's syndrome; Dejerine-Klumke palsy; dementia; dermatomyositis; diabetic neuropathy; diffuse sclerosis; dysautonomia; dysgraphia;Dyslexia; dystonia; early infantile epileptic encephalopathy; empty sella syndrome; encephalitis; encephalocele; encephalotrigeminal angiomatosis; epilepsy; Erb's palsy; essential tremor; Fabry's disease; Fahr's syndrome; syncope; familial spastic paralysis; febrile seizures; Fisher syndrome; Friedreich's ataxia; frontotemporal dementia and other "tauopathies"; Gaucher's disease; Gerstmann's syndrome; giant cell arteritis; giant cell inclusion disease; globular cell leukodystrophy; Guillain-Barré syndrome syndrome; HTLV-1-associated myelopathy; Hallervorden-Spatz disease; head injury; headache; hemifacial spasm; hereditary spastic paraplegia; heredopathia atactica polyneuritiformis; herpes zoster oticus; herpes zoster; Hirayama syndrome; HIV-associated dementia and neuropathy (also a neurologic manifestation of AIDS); holoprosencephaly; Huntington's disease and other glutamine repeat disorders; hydrocephalus; hydrocephalus; hypercortisolism; hypoxia; immune-mediated encephalomyelitis; inclusion body myositis; incontinentia pigmenti; infantile phytic acid storage disease; infantile nasal discharge; infantile spasms; inflammatory myopathy; intracranial cysts; intracranial hypertension; Jobart syndrome; Kearns-Sayre syndrome; Kennedy disease; Kinsbourne syndrome; Klippel-Feil syndrome; Krabbe disease disease; Kugelberg-Welander disease; kuru; Lafora disease; Lambert-Eaton myasthenic syndrome; Landau-Kleffner syndrome; Wallenberg syndrome; learning disabilities; Leigh's disease; Lennox-Gustaut syndrome; Lesch-Nyhan syndrome; leukodystrophy; dementia with Lewy bodies; Lissencephaly; locked-in syndrome;Lou Gehrig's disease (also known as motor neuron disease or amyotrophic lateral sclerosis); lumbar disc disease; Lyme disease-neurological sequelae; Machado-Joseph disease; hydrocephalus; megalencephaly; Melkersson-Rosenthal syndrome; Menieres disease; meningitis; Menkes disease; metachromatic leukodystrophy; microcephaly; migraine; Miller Fisher syndrome; mini-stroke; mitochondrial myopathy; Mobius syndrome syndrome; monosomy; motor neuron disease; Moyamoya disease; mucopolysaccharidosis; multi-infarct dementia; multifocal motor neuropathy; multiple sclerosis and other demyelinating diseases; multiple system atrophy with postural hypotension; muscular dystrophy; myasthenia gravis; diffuse myelofibrotic sclerosis; infantile myoclonic encephalopathy; myoclonus; myopathy; myotonia congenita; narcolepsy; neurofibromatosis; neuroleptic malignant syndrome; neurologic manifestations of AIDS; neurologic sequelae of lupus; neuromyotonia; neuronal lipofuscinosis; neuronal migration disorders; Niemann-Pick disease; O'Sullivan-McLeod syndrome; occipital neuralgia; recessive spondylodysplasia sequence; Ohtahara syndrome syndrome; oligopontine cerebellar atrophy; myoclonus; optic neuritis; orthostatic hypotension; overuse syndrome; paresthesia; Parkinson's disease; myotonia congenita; paraneoplastic disorders; paroxysmal seizures; Parry Romberg syndrome; Pelizaeus-Merzbacher disease; periodic paralysis; peripheral neuropathy; painful neuropathy and neuropathic pain; persistent vegetative state; pervasive developmental disorder; sneeze reflex; phytic acid storage disease; Pick's disease; pinched nerve; pituitary tumor; polymyositis; foraminal disease; post-polio syndrome; postherpetic neuralgia; postinfectious encephalomyelitis; orthostatic hypotension; Prader-Willi syndrome syndrome); primary lateral sclerosis; prions; progressive hemifacial atrophy; progressive multifocal leukoencephalopathy; progressive sclerosing poliomyelitis; progressive supranuclear palsy; pseudoencephalitis; Ramsay-Hunt syndrome (types I and II); Rasmussen's encephalitis; reflex sympathetic dystrophy syndrome;Refsum disease; repetitive motion disorder; repetitive stress injury; restless legs syndrome; retroviral myelopathy; Rett syndrome; Reye's syndrome; Saint Vitus dance; Sandhoff disease; Schilder's disease; schizophrenia; photopic dysplasia; shaken baby syndrome; shingles; Shy-Drager syndrome; Sjögren's syndrome syndrome; sleep apnea; Soto's syndrome; spasticity; spina bifida; spinal cord injury; spinal cord tumor; spinal muscular atrophy; Stiff-Person syndrome; stroke; Sturge-Weber syndrome; subacute sclerosing panencephalitis; subcortical arteriosclerotic encephalopathy; Sydenham chorea; syncope; syringomyelia; tardive dyskinesia; Tay-Sachs disease; temporal arteritis; tethered cord syndrome; Thomsen disease; thoracic outlet syndrome; Tic Douloureux; Todd's paralysis; Tourette syndrome syndrome; transient ischemic attack; transmissible spongiform encephalopathy; transverse myelitis; traumatic brain injury; tremor; trigeminal neuralgia; tropical spastic paresis; tuberous sclerosis; vascular dementia (multi-infarct dementia); vasculitis including temporal arteritis; Von Hippel-Lindau disease; Wallenberg's syndrome; Werdnig-Hoffman disease; West syndrome; whiplash; Williams syndrome; Wildon's disease; amyotrophic lateral sclerosis; and Zelweger syndrome.
[1011] In some embodiments, the condition, disease or disorder is a condition associated with STING, for example, type I interferon disease (e.g., STING-associated vasculopathy of infancy (SAVI)), Aicardi-Goutières Syndrome (AGS), inherited forms of lupus and inflammation-related diseases, such as systemic lupus erythematosus and rheumatoid arthritis. In certain embodiments, the condition, disease or disorder is an autoimmune disease (e.g., an autoinflammatory disease triggered by cytoplasmic DNA). Non-limiting examples include: rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease (IBD) including Crohn's disease (CD) and ulcerative colitis (UC), which are chronic inflammatory diseases with polygenic susceptibility. In certain embodiments, the disorder is inflammatory bowel disease. In certain embodiments, the condition is Crohn's disease, autoimmune colitis, iatrogenic autoimmune colitis, ulcerative colitis, colitis induced by one or more chemotherapeutic agents, colitis induced by adoptive cell therapy, colitis associated with one or more alloimmune diseases (e.g., graft versus host disease, such as acute graft versus host disease and chronic graft versus host disease), radiation enteritis, collagenous colitis, lymphocytic colitis, microscopic colitis, and radiation enteritis. In some of these embodiments, the condition is an alloimmune disease (e.g., graft versus host disease, such as acute graft versus host disease and chronic graft versus host disease), celiac disease, irritable bowel syndrome, rheumatoid arthritis, lupus, scleroderma, psoriasis, cutaneous T-cell lymphoma, uveitis, and mucositis (e.g., oral mucositis, esophageal mucositis, or intestinal mucositis).
[1012] In some embodiments, regulating the immune system by STING provides treatment for diseases, including diseases caused by exogenous agents. Exemplary infections of exogenous agents that can be treated and / or prevented by the methods of the present invention include: bacterial (e.g., Gram-positive or Gram-negative) infections, fungal infections, parasitic infections, and viral infections. In one embodiment of the present invention, the infection is a bacterial infection (e.g., Escherichia coli, Klebsiella pneumonia, Pseudomonas aeruginosa, Salmonella spp., Staphylococcus aureus, Streptococcus or vancomycin-resistant enterococci) or sepsis. In another embodiment, the infection is a fungal infection (e.g., mold, yeast or higher fungal infection). In another embodiment, the infection is a parasitic infection (e.g., an infection caused by a unicellular or multicellular parasite, including Giardia duodenalis, Cryptosporidium parvum, Cyclospora cayetanensis, and Toxoplasma gondiz). In yet another embodiment, the infection is a viral infection (e.g., a viral infection associated with AIDS, avian influenza, chickenpox, cold sores, the common cold, gastroenteritis, glandular fever, influenza, measles, mumps, pharyngitis, pneumonia, rubella, SARS, and lower or upper respiratory tract infections (e.g., respiratory syncytial virus).
[1013] In some embodiments, the condition, disease, or disorder is hepatitis B (see, e.g., WO 2015 / 061294).
[1014] In some embodiments, the condition, disease, or disorder is selected from cardiovascular disease (including, for example, myocardial infarction).
[1015] In certain embodiments, the condition, disease, or disorder is age-related macular degeneration.
[1016] In some embodiments, the condition, disease, or disorder is mucositis, also known as stomatitis, which can occur as a result of chemotherapy or radiation therapy, used alone or in combination, as well as damage caused by exposure to radiation outside the context of radiation therapy.
[1017] In some embodiments, the condition, disease, or disorder is uveitis, which is an inflammation of the uvea (e.g., anterior uveitis, such as iridocyclitis or iritis; intermediate uveitis (also known as parsplanitis); posterior uveitis; or chorioretinitis, such as pan-uveitis).
[1018] In some embodiments, the condition, disease, or disorder is selected from the group consisting of: cancer, a neurological disease, an autoimmune disease, hepatitis B, uveitis, cardiovascular disease, age-related macular degeneration, and mucositis.
[1019] Other examples may include those indications discussed herein and below in the context of contemplated combination therapy regimens.
[1020] Combination therapy
[1021] The present disclosure encompasses monotherapy regimens as well as combination therapy regimens.
[1022] In some embodiments, the methods described herein can further comprise administering one or more additional therapies (eg, one or more additional therapeutic agents and / or one or more treatment regimens) in combination with the compounds described herein.
[1023] In some embodiments, the methods described herein can further comprise administering one or more additional cancer therapies.
[1024] The one or more additional cancer therapies may include, but are not limited to, surgery, radiation therapy, chemotherapy, toxin therapy, immunotherapy, cryotherapy, cancer vaccines (e.g., HPV vaccine, hepatitis B vaccine, Oncophage, Provenge), and gene therapy, and combinations thereof. Immunotherapy, including but not limited to adoptive cell therapy, stem cell and / or dendritic cell derivation, transfusion, lavage, and / or other therapies, including but not limited to freezing of tumors.
[1025] In some embodiments, the one or more additional cancer therapies is chemotherapy, which may include administering one or more additional chemotherapeutic agents.
[1026] In certain embodiments, the additional chemotherapeutic agent is an immunomodulatory molecule, such as an immune checkpoint inhibitor. In some of these embodiments, the immune checkpoint inhibitor targets an immune checkpoint receptor selected from the group consisting of CTLA-4, PD-1, PD-L1, PD-1–PD-L1, PD-1–PD-L2, interleukin-2 (IL-2), indoleamine 2,3-dioxygenase (IDO), IL-10, transforming growth factor-β (TGFβ), T cell immunoglobulin and mucin 3 (TIM3 or HAVCR2), galectin 9–TIM3, phosphatidylserine–TIM3, lymphocyte activation gene 3 protein (LAG3), MHC Class II–LAG3, 4-1BB–4-1BB ligand, OX40–OX40 ligand, GITR, GITR ligand–GITR, CD27, CD70-CD27, TNFRSF25, TNFRSF25–TL1A, CD40L, CD40–CD40 ligand, HVEM–LIGHT–LTA, HVEM, HVEM–BTLA, HVEM–CD160, HVEM–LIGHT, HVEM–BTLA–CD160, CD80, CD80–PDL-1, PDL2–CD80, CD244, CD48–CD244, CD244, ICOS, ICOS–ICOS ligand, B7-H3, B7-H4, VISTA, TMIGD2, HHLA 2–TMIGD2, Butyrophilins, including BTNL2, Siglec family, TIGIT and PVR family members, KIRs, ILTs and LIRs, NKG2D and NKG2A, MICA and MICB, CD244, CD28, CD86–CD28, CD86–CTLA, CD80–CD28, CD39, CD73 adenosine–CD39–CD73, CXCR4–CXCL12, phosphatidylserine, TIM3, phosphatidylserine–TIM3, SIRPA–CD47, VEGF, neuropilin, CD160, CD30, and CD155; e.g., CTLA-4 or PD1 or PD-L1). See, e.g., Postow, MJ Clin. Oncol. 2015, 33, 1.
[1027] In certain of these embodiments, the immune checkpoint inhibitor is selected from the group consisting of: Urelumab, PF-05082566, MEDI6469, TRX518, Varlilumab, CP-870893, Pembrolizumab (PD1), Nivolumab (PD1), Atezolizumab (formerly MPDL3280A) (PDL1), MEDI4736 (PD-L1), Avelumab ( mab) (PD-L1), PDR001 (PD1), BMS-986016, MGA271, Lirilumab, IPH2201, Emactuzumab, INCB024360, Galunisertib, Ulocuplumab, BKT140, Bavituximab, CC-90002, Bevacizumab, MNRP1685A, and MGA271.
[1028] In certain embodiments, the additional chemotherapeutic agent is an alkylating agent. Alkylating agents are so named because they are able to alkylate a variety of nucleophilic functional groups under conditions present in cells, including but not limited to cancer cells. In another embodiment, alkylating agents include but are not limited to cisplatin, carboplatin, methylethylamine, cyclophosphamide, chlorambucil, ifosfamide, and / or oxaliplatin. In one embodiment, alkylating agents may act by disrupting cellular function by forming covalent bonds with amino, carboxyl, sulfhydryl, and phosphate groups in biologically important molecules, or they may act by modifying the DNA of the cell. In another embodiment, the alkylating agent is synthetic, semisynthetic, or a derivative.
[1029] In some embodiments, the additional chemotherapeutic agent is an antimetabolite. Antimetabolites disguise themselves as purines or pyrimidines (which are the basic building blocks of DNA), typically preventing these substances from incorporating into DNA during the "S" phase (of the cell cycle), thereby preventing normal development and division. Antimetabolites can also affect RNA synthesis. In one embodiment, antimetabolites include but are not limited to: azathioprine and / or mercaptopurine. In another embodiment, the antimetabolite is synthetic, semisynthetic, or a derivative.
[1030] In certain embodiments, the additional chemotherapeutic agent is a plant alkaloid and / or terpenoid. These alkaloids are typically derived from plants and inhibit cell division by preventing microtubule function. In one embodiment, the plant alkaloid and / or terpenoid is a vinca alkaloid, a podophyllotoxin, and / or a taxane. Typically, vinca alkaloids bind to specific sites on tubulin, typically during the M phase of the cell cycle, inhibiting tubulin assembly into microtubules. In one embodiment, vinca alkaloids are not limited to: Madagascar periwinkle, Catharanthus roseus (formerly known as Vinca rosea). In one embodiment, vinca alkaloids include but are not limited to: vincristine, vinblastine, vinorelbine, and / or vindesine. In one embodiment, taxanes include but are not limited to: Taxol, paclitaxel, and / or docetaxel. In another embodiment, the plant alkaloid or terpenoid is synthetic, semisynthetic, or a derivative. In another embodiment, the podophyllotoxin is, but is not limited to, etoposide and / or teniposide. In one embodiment, taxane is but not limited to docetaxel and / or octataxel.
[021] In one embodiment, the cancer therapeutic agent is a topoisomerase. Topoisomerase is an essential enzyme that maintains the topological structure of DNA. The inhibition of type I or type II topoisomerase interferes with the transcription and replication of DNA by destroying the proper DNA supercoiling. In another embodiment, topoisomerase is but not limited to a type I topoisomerase inhibitor or a type II topoisomerase inhibitor. In one embodiment, a type I topoisomerase inhibitor is but not limited to camptothecin. In another embodiment, camptothecin is but not limited to exatecan, irinotecan, rutotecan, topotecan, BNP 1350, CKD 602, DB 67 (AR67) and / or ST1481. In one embodiment, a type II topoisomerase inhibitor is but not limited to epipodophyllotoxin. In another embodiment, an epipodophyllotoxin is but not limited to amsacrine, etoposide, etoposide phosphate and / or teniposide. In another embodiment, the topoisomerase is synthetic, semisynthetic or a derivative, including those found in nature, such as, but not limited to, epipodophyllotoxin, which is a substance naturally present in the roots of the American Mayapple (Podophyllum peltatum).
[1031] In certain embodiments, the additional chemotherapeutic agent is a stilbenoid. In further embodiments, stilbenoids include, but are not limited to, resveratrol, piceatannol, pinosylvin, pterostilbene, alpha-viniferin, ampelopsin A, ampelopsin E, diptoindonesin C, diptoindonesin F, epsilon-vinferin, flexuosol A, geninins D, hopeaphenol, trans-diindonesin B, astringin, piceid, and diptoindonesin A. In another embodiment, the stilbenoid is synthetic, semisynthetic, or a derivative.
[1032] In certain embodiments, additional chemotherapeutic agents are cytotoxic antibiotics. In one embodiment, cytotoxic antibiotics are but are not limited to: actinomycin, anthracenedione, anthracycline, thalidomide, dichloroacetic acid, nicotinic acid, 2-deoxyglucose and / or chlorfluazimine. In one embodiment, actinomycin is but is not limited to: actinomycin D, bacitracin, colistin (colistin) (polymyxin E) and / or polymyxin B. In another embodiment, anthraquinones are but are not limited to mitoxantrone and / or pixantrone. In another embodiment, anthracycline drugs are but are not limited to bleomycin, doxorubicin (adriamycin (Adriamycin)), daunorubicin (daunomycin), epirubicin, idarubicin, mitomycin, puromycin and / or valfloxacin. In another embodiment, cytotoxic antibiotics are synthetic, semisynthetic or derivatives.
[1033] In certain embodiments, the additional chemotherapeutic agent is selected from the group consisting of: endostatin, angiopoietin, angiostatin, chemokine, angioarrestin, angiostatin (plasminogen fragment), basement membrane collagen-derived anti-angiogenic factors (tumstatin, canstatin or arrestin), anti-angiogenic antithrombin III, signal transduction inhibitors, cartilage-derived inhibitor (CDI), CD59 complement fragment, fibronectin fragment, gro-β, heparinase, heparin hexasaccharide fragment, human chorionic gonadotropin (hCG), interferon α / β / γ, interferon-induced protein (IP-10), interleukin 12, kringle 5 (plasminogen fragment), metalloproteinase inhibitor (TIMP), 2-methoxyestradiol, placental ribonuclease inhibitor, plasminogen activator inhibitor, platelet factor-4 (PF4), prolactin 16kD fragment, proliferation protein-related protein (PRP), various retinoids, tetrahydrocortisol-S, thrombospondin 1 (TSP-1), transforming growth factor-β (TGF-β), vasculostatin, vasostatin (calreticulin fragment), etc.
[1034] In certain embodiments, the additional chemotherapeutic agent is selected from the group consisting of abiraterone acetate, altretamine, anhydrovinblastine, auristatin, bexarotene, bicalutamide, BMS184476, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzenesulfonamide, bleomycin, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-1-L proline-tert-butyramide, cachectin, cemadotin, chlorambucil, cyclophosphamide, vinorelbine tartrate (3′,4′-didehydro-4′-deoxy-8′-norv in-caleukoblastine, docetaxel, doxetaxel, cyclophosphamide, carboplatin, carmustine, cisplatin, cryptophycin, cyclophosphamide, cytarabine, dacarbazine (DTIC), dactinomycin, daunorubicin, decitabine, dolastatin, doxorubicin (adriamycin), etoposide, 5-fluorouracil, finasteride, flutamide, hydroxyurea and hydroxyureaamine taxanes, ifosfamide, liprazole, lonidamine, lomustine (CCNU), MDV3100, alachlor (nitrogen mustard), melphalan, mivobulin (hydroxytryptamine isethionate), isethionate, rhizoxin, sertenef, streptozocin, mitomycin, methotrexate, taxanes, nilutamide, onapristone, paclitaxel, prednimustine, procarbazine, RPR109881, estramustine phosphate, tamoxifen, tasonermin, paclitaxel, tretinoin, vinblastine, vincristine, vindesine sulfate, and vinflunine.
[1035] In certain embodiments, the additional chemotherapeutic agent is platinum, cisplatin, carboplatin, oxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil, azathioprine, mercaptopurine, vincristine, vinblastine, vinorelbine, vindesine, etoposide and teniposide, paclitaxel, docetaxel, irinotecan, topotecan, amsacrine, etoposide, etoposide phosphate, teniposide, 5-fluorouracil, folinate, methotrexate, gemcitabine, taxanes, folinic acid, mitomycin C, tegafur-uracil, idarubicin, fludarabine, mitoxantrone, ifosfamide, and doxorubicin. Other agents include mTOR (mammalian target of rapamycin) inhibitors, including but not limited to rapamycin, everolimus, temsirolimus, and deforolimus.
[1036] In other embodiments, the additional chemotherapeutic agent may be selected from those described in US Patent 7,927,613, which is incorporated herein by reference in its entirety.
[1037] In some embodiments, the additional therapeutic agent and / or treatment regimen can be used to treat other STING-associated disorders, such as type I interferonopathies, e.g., STING-associated vasculopathy of infancy (SAVI), Aicardi-Gutiérrez syndrome (AGS), hereditary forms of lupus, inflammation-related disorders, such as systemic lupus erythematosus, and rheumatoid arthritis, among others.
[1038] Non-limiting examples of additional therapeutic agents and / or treatment regimens for the treatment of rheumatoid arthritis include: nonsteroidal anti-inflammatory drugs (NSAIDs; e.g., ibuprofen and naproxen), corticosteroids (e.g., prednisone), disease-modifying antirheumatic drugs (DMARDs; e.g., methotrexate), Leflunomide Hydroxychloroquine (Plaquenil), PF-06650833, iguratimod, tofacitinib ABBV-599, evobrutinib and sulfasalazine and biologics (eg, abatacept Adalimumab Anakinra Certolizumab Etanercept Golimumab infliximab Rituximab tocilizumab vobarilizumab, sarilumab secukinumab, ABP 501, CHS-0214, ABC-3373, and tocilizumab ).
[1039] Non-limiting examples of additional therapeutic agents and / or treatment regimens for the treatment of lupus include: steroids, topical immunomodulators (e.g., tacrolimus ointment, and pimecrolimus cream ), thalidomide Nonsteroidal anti-inflammatory drugs (NSAIDs; for example, ibuprofen and naproxen), antimalarial drugs (for example, hydroxychloroquine (Plaquenil)), corticosteroids (for example, prednisone), and immunomodulators (for example, evobrutinib, iberdomide, voclosporin, cenerimod, azathioprine) Cyclophosphamide and cyclosporine (Neoral, ), and mycophenolate mofetil), baricitinib, iguratimod, filogotinib, GS-9876, rapamycin, and PF-06650833), and biologics (e.g., belimumab anifrolumab, prezalumab, MEDI0700, obinutuzumab, vobarilizumab, lulizumab, atacicept, PF-06823859, and lupizor, rituximab, BT063, BI655064, BIIB059, aldesleukin Dapirolizumab, edratide, IFN-α-kinoid, OMS721, RC18, RSLV-132, theralizumab, XmAb5871, and ustekinumab For example, non-limiting treatments for systemic lupus erythematosus include: nonsteroidal anti-inflammatory drugs (NSAIDs; e.g., ibuprofen and naproxen), antimalarials (e.g., hydroxychloroquine (Plaquenil)), corticosteroids (e.g., prednisone), and immunomodulators (e.g., iberdomide, voclosporin, azathioprine). Cyclophosphamide and cyclosporine (Neoral, ), and mycophenolate mofetil, baricitinib, filogotinib, and PF-06650833), as well as biologics (eg, belimumab anifrolumab, prezalumab, MEDI0700, vobarilizumab, lulizumab, atacicept, PF-06823859, lupiizor, rituximab, BT063, BI655064, BIIB059, aldesleukin Dapirolizumab, edratide, IFN-α-kinoid, RC18, RSLV-132, theralizumab, XmAb5871, and ustekinumab As another example, non-limiting examples of treatments for cutaneous lupus include: steroids, immunomodulators (e.g., tacrolimus ointment and pimecrolimus cream ), GS-9876, filogotinib, and thalidomide Agents and regimens used to treat drug-induced and / or neonatal lupus may also be administered.
[1040] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating STING-associated vasculopathy of infancy (SAVI) include JAK inhibitors (e.g., tofacitinib, ruxolitinib, filgotinib, and baricitinib).
[1041] Non-limiting examples of additional therapeutic agents and / or treatment regimens for the treatment of AGS include: physical therapy, treatment of respiratory complications, anticonvulsant therapy for seizures, tube feeding, nucleoside reverse transcriptase inhibitors (e.g., emtricitabine (e.g., ), tenofovir (e.g. ), emtricitabine / tenofovir (e.g. ), zidovudine, lamivudine, and abacavir), and JAK inhibitors (e.g., tofacitinib, ruxolitinib, filgotinib, and baricitinib).
[1042] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating IBD include: 6-mercaptopurine, AbGn-168H, ABX464, ABT-494, adalimumab, AJM300, alicaforsen, AMG139, anrukinzumab, apremilast, ATR-107 (PF0530900), autologous CD34-selected peripheral blood stem cell transplantation, azathioprine, bertilimumab, BI 655066, BMS-936557, certolizumab pegol cobitolimod, corticosteroids (e.g., prednisone, methylprednisolone, prednisone), CP-690,550, CT-P13, cyclosporine, DIMS0150, E6007, E6011, etrasimod, etrolizumab, fecal microbiota transplant, figlotinib, fingolimod, firategrast (SB-683699) (formerly known as T-0047), GED0301, GLPG0634, GLPG0974, guselkumab, golimumab, GSK1399686, HMPL-004 (Andrographis paniculata), paniculata extract), IMU-838, infliximab, interleukin-2 (IL-2), Janus kinase (JAK) inhibitors, laquinimod, masitinib (AB1010), matrix metalloproteinase 9 (MMP 9) inhibitors (e.g., GS-5745), MEDI2070, mesalamine, methotrexate, mirikizumab (LY3074828), natalizumab, NNC 0142-0000-0002, NNC0114-0006, ozanimod, peficitinib (JNJ-54781532), PF-00547659, PF-04236921, PF-06687234, QAX576, RHB-104, rifaximin, risankizumab, RPC1063, SB012, SHP647, sulfasalazine, TD-1473, thalidomide, tildrakizumab (MK 3222), TJ301, tofacitinib, tralokinumab, TRK-170, upadacitinib, ustekinumab, UTTR1147A, V565, vatelizumab, VB-201, vedolizumab, and vidofludimus.
[1043] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating irritable bowel syndrome include: alosetron, bile acid sequestrants (e.g., cholestyramine, colestipol, colesevelam), chloride channel activators (e.g., lubiprostone), coated peppermint oil capsules, desipramine, dicyclomine, ebastine, eluxadoline, farnesoid X receptor agonists (e.g., obeticholic acid), fecal microbiota transplantation, fluoxetine, gabapentin, ), guanylate cyclase C agonists (e.g., linaclotide, plecanatide, ibodutant, imipramine, JCM-16021, loperamide, lubiprostone, nortriptyline, ondansetron), opioids, paroxetine, pinaverium, polyethylene glycol, pregabalin, probiotics, ramosetron, rifaximin, and tanpanor.
[1044] Non-limiting examples of additional therapeutic agents and / or treatment regimens for the treatment of scleroderma include: nonsteroidal anti-inflammatory drugs (NSAIDs; e.g., ibuprofen and naproxen), corticosteroids (e.g., prednisone), immunomodulators (e.g., azathioprine, methotrexate), Cyclophosphamide and cyclosporine Antithymocyte globulin, mycophenolate mofetil, intravenous immune globulin, rituximab, sirolimus, and alefacept), calcium channel blockers (such as nifedipine), alpha blockers, serotonin receptor antagonists, angiotensin II receptor inhibitors, statins, topical nitrates, iloprost, phosphodiesterase 5 inhibitors (such as sildenafil), bosentan, tetracycline antibiotics, endothelin receptor antagonists, prostaglandins, and tyrosine kinase inhibitors (such as imatinib, nilotinib, and dasatinib).
[1045] Non-limiting examples of additional therapeutic agents and / or treatment regimens for the treatment of Crohn's disease (CD) include: adalimumab, autologous CD34-selected peripheral blood stem cell transplantation, 6-mercaptopurine, azathioprine, certolizumab pegol Corticosteroids (e.g., prednisone), etrolizumab, E6011, fecal microbiota transplant, figlotinib, guselkumab, infliximab, IL-2, JAK inhibitors, matrix metalloproteinase 9 (MMP 9) inhibitors (e.g., GS-5745), MEDI2070, mesalamine, methotrexate, natalizumab, ozanimod, RHB-104, rifaximin, risankizumab, SHP647, sulfasalazine, thalidomide, upadacitinib, V565, and vedolizumab.
[1046] Non-limiting examples of additional therapeutic agents and / or treatment regimens for the treatment of UC include: AbGn-168H, ABT-494, ABX464, apremilast, PF-00547659, PF-06687234, 6-mercaptopurine, adalimumab, azathioprine, belimumab, brazikumab (MEDI2070), cobitolimod, certolizumab pegol CP-690,550, corticosteroids (e.g., multimax budesonide, methylprednisolone), cyclosporine, E6007, eltrosimod, etrolizumab, fecal microbiota transplant, filotinib, guselkumab, golimumab, IL-2, IMU-838, infliximab, matrix metalloproteinase 9 (MMP9) inhibitors (e.g., GS-5745), mesalamine, mirikizumab (LY3074828), RPC1063, risankizumab (BI 6555066), SHP647, sulfasalazine, TD-1473, TJ301, tildrakizumab (MK 3222), tofacitinib, tofacitinib, ustekinumab, UTTR1147A, and vedolizumab.
[1047] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating autoimmune colitis include corticosteroids (e.g., budesonide, prednisone, prednisolone, beclomethasone dipropionate), trihexyphenidyl / atropine, infliximab, loperamide, mesalamine, TIP60 inhibitors (see, e.g., U.S. Patent Application Publication No. 2012 / 0202848), and vedolizumab.
[1048] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating nosocomial autoimmune colitis include: corticosteroids (e.g., budesonide, prednisone, prednisolone, beclomethasone dipropionate), trihexyphenidyl / atropine, infliximab, loperamide, TIP60 inhibitors (see, e.g., U.S. Patent Application Publication No. 2012 / 0202848), and vedolizumab.
[1049] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating colitis caused by one or more chemotherapeutic agents include: corticosteroids (e.g., budesonide, prednisone, prednisolone, beclomethasone dipropionate), benzylpek / atropine, infliximab, loperamide, mesalamine, TIP60 inhibitors (see, e.g., U.S. Patent Application Publication No. 2012 / 0202848), and vedolizumab.
[1050] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating colitis caused by adoptive cell therapy include: corticosteroids (e.g., budesonide, prednisone, prednisolone, beclomethasone dipropionate), benzylpek / atropine, infliximab, loperamide, TIP60 inhibitors (see, e.g., U.S. Patent Application Publication No. 2012 / 0202848), and vedolizumab.
[1051] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating colitis associated with one or more alloimmune diseases include: corticosteroids (eg, budesonide, prednisone, prednisolone, beclomethasone dipropionate), sulfasalazine, and eicosapentaenoic acid.
[1052] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating radiation enteritis include: teduglutide, amifostine, angiotensin-converting enzyme (ACE) inhibitors (e.g., benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, and trandolapril), probiotics, selenium supplementation, statins (e.g., atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, and pitavastatin), sucralfate, and vitamin E.
[1053] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating collagenous colitis include: 6-mercaptopurine, azathaioprine, bismuth subsalicate, Boswellia serrata extract, cholestyramine, colestipol, corticosteroids (e.g., budesonide, prednisone, prednisolone, beclomethasone dipropionate), loperamide, mesalamine, methotrexate, probiotics, and sulfasalazine.
[1054] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating lymphocytic colitis include: 6-mercaptopurine, azathioprine, bismuth subsalicylate, cholestyramine, colestipol, corticosteroids (e.g., budesonide, prednisone, prednisolone, beclomethasone dipropionate), loperamide, mesalamine, methotrexate, and sulfasalazine.
[1055] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating microbial colitis include: 6-mercaptopurine, azathioprine, bismuth subsalicate, Boswellia serrata extract, cholestyramine, colestipol, corticosteroids (e.g., budesonide, prednisone, prednisolone, beclomethasone dipropionate), fecal microbiota transplantation, loperamide, mesalamine, methotrexate, probiotics, and sulfasalazine.
[1056] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating alloimmune diseases include: intrauterine platelet transfusion, intravenous immunoglobulin, maternal steroids, abatacept, alemtuzumab, alpha 1-antitrypsin, AMG592, antithymocyte globulin, barcitinib, basiliximab, bortezomib, brentuximab, cannabidiol, corticosteroids (e.g., methylprednisone, prednisone), cyclosporine, dacilzumab, defribrotide, denileukin-toxin conjugates, and sirolimus. diftitox, glasdegib, ibrutinib, IL-2, infliximab, itacitinib, LBH589, maraviroc, mycophenolate mofetil, natalizumab, neihulizumab, pentostatin, pevonedistat, photobiomodulation, photohemolysis, ruxolitinib, sirolimus, sonidegib, tacrolimus, tocilizumab, and vismodegib.
[1057] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating multiple sclerosis (MS) include: alemtuzumab ALKS 8700, amiloride, ATX-MS-1467, azathioprine, baclofen Interferon beta (eg, IFN-beta-1a, IFN-beta-1b), cladribine, corticosteroids (eg, methylprednisolone), daclizumab, dimethyl fumarate fingolimod Fluoxetine, glatiramer acetate Hydroxychloroquine, ibudilast, idebenone, laquinimod, lipoic acid, losartan, masitinib, MD1003 (biotin), mitoxantrone, montelukast, natalizumab NeuroVax TM , ocrelizumab, ofatumumab, pioglitazone, and RPC1063.
[1058] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating graft-versus-host disease include: abatacept, alemtuzumab, alpha 1-antitrypsin, AMG592, antithymocyte globulin, barcitinib, basiliximab, bortezomib, brentuximab, cannabidiol, corticosteroids (e.g., methylprednisone, prednisone), cyclosporine, dacilzumab, defribrotide, denileukin-toxin conjugates, and / or sirolimus. diftitox, glasdegib, ibrutinib, IL-2, imatinib, infliximab, itacitinib, LBH589, maraviroc, mycophenolate mofetil, natalizumab, neihulizumab, pentostatin, pevonedistat, photobiomodulation, photohemolysis, ruxolitinib, sirolimus, sonidegib, tacrolimus, tocilizumab, and vismodegib.
[1059] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating acute graft-versus-host disease include: alemtuzumab, alpha 1-antitrypsin, antithymocyte globulin, basiliximab, brentuximab, corticosteroids (e.g., methylprednisone, prednisone), cyclosporine, dacilzumab, defribrotide, denileukin diftitox, ibrutinib, infliximab, itacitinib, LBH589, mycophenolate mofetil, natalizumab, neihulizumab, pentostatin, photohemolysis, ruxolitinib, sirolimus, tacrolimus, and tocilizumab.
[1060] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating chronic graft-versus-host disease include: abatacept, alemtuzumab, AMG592, antithymocyte globulin, basiliximab, bortezomib, corticosteroids (e.g., methylprednisone, prednisone), cyclosporine, dacilzumab, denileukin-toxin conjugates, and sirolimus. diftitox, glasdegib, ibrutinib, IL-2, imatinib, infliximab, mycophenolate mofetil, pentostatin, photobiomodulation, photohemolysis, ruxolitinib, sirolimus, sonidegib, tacrolimus, tocilizumab, and vismodegib.
[1061] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating celiac disease include: AMG 714, AMY01, Aspergillus niger prolyl endoproteinase, BL-7010, CALY-002, GBR 830, Hu-Mik-Beta-1, IMGX003, KumaMax, Larazotide Acetate, Pancreatic lipase, TIMP-GLIA, vedolizumab, and ZED1227.
[1062] Non-limiting examples of additional therapeutic agents and / or regimens for treating psoriasis include: topical corticosteroids, topical crisaborole / AN2728, topical SNA-120, topical SAN021, topical tapinarof, topical tocafinib, topical IDP-118, topical M518101, topical calcipotriene, and betamethasone dipropionate (e.g., MC2-01 cream and ), local P-3073, local LEO 90100 Topical betamethasone dipropionate Betasol propionate Vitamin D analogs (eg, calcipotriene and calcitriol ), anthralin (e.g., and ), topical retinoids (e.g., tazarotene (e.g., and ), calcineurin inhibitors (eg, tacrolimus and pimecrolimus ), salicylic acid, coal tar, moisturizers, light therapy (eg, sun exposure, UVB light therapy, narrow-band UVB light therapy, Goeckerman therapy, psoralen plus ultraviolet A (PUVA) therapy, and excimer laser), retinoids (eg, acitretin methotrexate Apo805K1, baricitinib, FP187, KD025, prurisol, VTP-43742, XP23829, ZPL-389, CF101 (piclidenoson), LAS41008, VPD-737 (servopitant), upadacitinib (ABT-494), aprmilast, tofacitinib, cyclosporine Biologics (eg, etanercept Etanercept-szzs Infliximab Adalimumab Adalimumab-adbm ustekinumab Golimumab Apremilast secukinumab Pegylated cetuximab, secukinumab, tildrakizumab-ASMN, infliximab-dyyb, abatacept, ixekizumab ABP 710, BCD-057, BI695501, bimekizumab (UCB4940), CHS-1420, GP2017, guselkumab (CNTO 1959), HD203, M923, MSB11022, mirikizumab (LY3074828), PF-06410293, PF-06438179, risankizumab (BI655066), SB2, SB4, SB5, siliq (brodalumab), namilumab (MT203, tildrakizumab (MK-3222), and ixekizumab ), thioguanine, and hydroxyurea (e.g., and ).
[1063] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating cutaneous T-cell lymphoma include: phototherapy (e.g., exposure to sunlight, UVB phototherapy, narrow-band UVB phototherapy, Gokman therapy, psoralen plus ultraviolet A (PUVA) therapy, and excimer laser), extracorporeal photopheresis, radiation therapy (e.g., spot radiation and whole-body electron beam therapy), stem cell transplantation, corticosteroids, imiquimod, bexarotene gel, topical bischloroethyl-nitrosourea, methoxazole gel, vorinostat, Romidepsin Pralatrexate Biologics (eg, alemtuzumab) brentuximab vedotin (SGN-35), mogamulizumab and IPH4102).
[1064] Non-limiting examples of additional therapeutic agents and / or regimens for the treatment of uveitis include: corticosteroids (e.g., intravitreal triamcinolone acetonide injection), antibiotics, antivirals (e.g., acyclovir), dexamethasone, immunomodulators (e.g., tacrolimus, leflunomide, cyclophosphamide, and cyclosporine chlorambucil, azathioprine, methotrexate, and mycophenolate mofetil), biologics (eg, infliximab Adalimumab Etanercept Golimumab Certolizumab Rituximab Abatacept Basiliximab Anakinra Canakinumab Gevokixumab (XOMA052), tocilizumab Alemtuzumab Efalizumab LFG316, sirolimus Abatacept, sarilumab and daclizumab ), cytotoxic drugs, surgical implants (eg, fluocinolone acetonide inserts), and vitrectomy.
[1065] Non-limiting examples of additional therapeutic agents and / or treatment regimens for treating mucositis include: AG013, SGX942 (dusquetide), amifostine Cryotherapy, cepacol lonzenges, capsaicin lozenges, mucosal adhesives (e.g., ), oral diphenhydramine (e.g., elixirs), oral bioadhesives (eg, polyvinylpyrrolidone-sodium hyaluronate gel ), oral lubricants (eg, Oral ), caphosol, chamomillarecutita mouthwash, edible grape plant exosomes, antiseptic mouthwashes (e.g., chlorhexidine gluconate (e.g., or ), topical analgesics (e.g., lidocaine, benzocaine, dyclonine hydrochloride, xylocaine (e.g., viscous xylocaine 2%), and (0.6% phenol), corticosteroids (e.g., prednisone), analgesics (e.g., ibuprofen, naproxen, acetaminophen, and opioids), GC4419, palifermin (keratinocyte growth factor; ), ATL-104, clonidine lauriad, IZN-6N4, SGX942, rebamipide, nepidermin, soluble beta-1,3 / 1,6 glucan, P276, LP-0004-09, CR-3294, ALD-518, IZN-6N4, quercetin, granules containing vaccinium myrtillus extract, macleaya cordata alkaloids, and echinacea angustifolia extract (e.g., ), and a gastrointestinal mixture (an acid reducing agent such as aluminum hydroxide and magnesium hydroxide (e.g., Maalox), an antifungal (e.g., nystatin), and an analgesic (e.g., hurricane liquid). Non-limiting examples of additional therapeutic agents and / or treatment regimens for the treatment of oral mucositis include: AG013, amifostine Cryotherapy, cepacol lozenges (lonzenges), mucosal adhesives (e.g., ), oral diphenhydramine (e.g., elixirs), oral bioadhesives (eg, polyvinylpyrrolidone-sodium hyaluronate gel ), oral lubricants (eg, Oral ), caphosol, chamomilla recutita mouthwash, edible grape plant exosomes, antiseptic mouthwashes (e.g., chlorhexidine gluconate (e.g., or ), topical analgesics (e.g., lidocaine, benzocaine, dyclonine hydrochloride, xylocaine (e.g., viscous xylocaine 2%), and (0.6% phenol), corticosteroids (e.g., prednisone), analgesics (e.g., ibuprofen, naproxen, acetaminophen, and opioids), GC4419, palifermin (keratinocyte growth factor; ), ATL-104, clonidine lauriad, IZN-6N4, SGX942, rebamipide, nepidermin, soluble beta-1,3 / 1,6 glucan, P276, LP-0004-09, CR-3294, ALD-518, IZN-6N4, quercetin, and a gastrointestinal mixture (an acid reducing agent such as aluminum hydroxide and magnesium hydroxide (e.g., Maalox), an antifungal (e.g., nystatin), and an analgesic (e.g., hurricane liquid As another example, non-limiting examples of treatments for esophageal mucositis include: xylenecaine (e.g., gel viscous xylenecaine 2%). As another example, treatments for intestinal mucositis that alter the effects of intestinal mucositis, and treatments for the signs and symptoms of intestinal mucositis include: a gastrointestinal mixture (an acid reducing agent, such as aluminum hydroxide and magnesium hydroxide (e.g., Maalox), an antifungal (e.g., nystatin), and an analgesic (e.g., Hurricane liquid).
[1066] In certain embodiments, the subject is administered the second therapeutic agent or regimen prior to contact with or administration of the chemical entity (e.g., about an hour before, or about 6 hours before, or about 12 hours before, or about 24 hours before, or about 48 hours before, about a week before, or about a month before).
[1067] In other embodiments, the second therapeutic agent or regimen is administered to the subject at about the same time as the chemical entity is contacted or administered. For example, the second therapeutic agent or regimen and the chemical entity are provided to the subject simultaneously in the same dosage form. As another example, the second therapeutic agent or regimen and the chemical entity are provided to the subject simultaneously in separate dosage forms.
[1068] In other embodiments, the subject is administered a second therapeutic agent or regimen after contact with or administration of the chemical entity (e.g., after about one hour, or about 6 hours, or about 12 hours, or about 24 hours, or about 48 hours, about 1 week, or about 1 month).
[1069] Patient selection
[1070] In some embodiments, the methods described herein further include the step of identifying a subject (e.g., a patient) in need of such treatment (e.g., by biopsy, endoscopy, or other conventional methods known in the art). In certain embodiments, the STING protein can be used as a biomarker for certain types of cancer, such as colon cancer and prostate cancer. In other embodiments, identifying a subject can include analyzing whether T cells are absent and / or whether exhausted T cells are present in the tumor microenvironment of a patient (e.g., a patient with one or more cold tumors). Such patients can include patients who are resistant to treatment with checkpoint inhibitors. In certain embodiments, such patients can be treated with the chemical entities herein, for example, to recruit T cells to the tumor, and in some cases, for example, once the T cells are exhausted, further treated with one or more checkpoint inhibitors.
[1071] In some embodiments, the chemical entities, methods, and compositions described herein can be administered to certain patient populations that are resistant to treatment (e.g., patients who are resistant to checkpoint inhibitors; e.g., patients with one or more cold tumors (e.g., tumors that lack T cells or are T cell-depleted)).
[1072] Compound preparation
[1073] As will be appreciated by those skilled in the art, the method for synthesizing the compound of the formula described herein will be apparent to those of ordinary skill in the art. For example, the compounds described herein can be synthesized, for example, using one or more methods described herein and / or using the method described in US2015 / 0056224, the contents of which are incorporated herein by reference in their entirety. Synthetic chemical conversions and protecting group methods (protection and deprotection) that can be used to synthesize compounds described herein are known in the art, and include, for example, R.Larock, " Comprehensive Organic Transformations " (Comprehensive Organic Transformations), VCH Press (1989);TWGreene and RGM.Wuts, " Protective Groups in Organic Synthesis ", 2nd Edition, John Wiley and Sons (John Wiley and Sons) (1991);L.Fieser and M.Fieser, " Fieser and Fieser's Organic Synthesis Reagents ", John Wiley and Sons (1994);L.Paquette, ed., " Encyclopedia of Organic Synthesis Reagents ", John Wiley and Sons (1995), and those described in its subsequent versions. The raw materials for preparing the compounds of this invention are known and can be prepared by known methods, or can be commercially available. It will also be appreciated by those skilled in the art that the conditions and reagents described herein can be interchanged with alternative art-recognized equivalents. For example, in many reactions, triethylamine can be interchanged with other bases, such as non-nucleophilic bases (e.g., diisopropylamine, 1,8-diazabicycloundec-7-ene, 2,6-di-tert-butylpyridine, or tetrabutylphosphazene).
[1074] The skilled artisan will recognize a variety of analytical methods that can be used to characterize the compounds described herein, including, e.g. 1 HNMR, heteronuclear NMR, mass spectroscopy, liquid chromatography and infrared spectroscopy. The foregoing list is a subset of the characterization methods available to one skilled in the art and is not intended to be limiting.
[1075] To further illustrate the foregoing, the following non-limiting exemplary synthetic schemes are included. Variations of these embodiments within the scope of the claims are within the purview of those skilled in the art and should be considered to fall within the scope of the invention as described and claimed. The reader will recognize that those skilled in the art will be able to prepare and use the present invention based on this disclosure without the need for detailed illustrations.
[1076] Example
[1077] Synthesis of compound 100
[1078]
[1079] 4-Butylaniline (1 mmol) and TEA (1 mmol) were dissolved in DCM and the solution was cooled to 0°C. 3-Isocyanato-4,5,6,7-tetrahydro-1H-indole (1 mmol) was added dropwise over 10 minutes and the mixture was stirred at room temperature overnight. Water was added and the organic layer was separated. The organic layer was dried over anhydrous MgSO4 and the solvent was removed under reduced pressure. The crude product was purified by flash chromatography on silica gel using hexane.
[1080] / EtOAc was used as eluent.
[1081] The following examples were synthesized from the corresponding isocyanates and amines by the above method.
[1082]
[1083]
[1084]
[1085]
[1086]
[1087] Compounds 132-183b were synthesized using the above method.
[1088]
[1089]
[1090]
[1091]
[1092]
[1093]
[1094]
[1095]
[1096]
[1097]
[1098]
[1099] Compound 29 was synthesized by thiolation of compound 9. Compound 30 was synthesized by compound 29. Compound 31 was obtained by deprotection of compound 30 (e.g., under acidic conditions, such as TFA).
[1100]
[1101] Abbreviations for chemical terms
[1102] ACN = acetonitrile
[1103] AcOH = acetic acid
[1104] BTC = trichloromethyl chloroformate
[1105] DBU=1,8-diazabicycloundec-7-ene
[1106] DCM = dichloromethane
[1107] Dess-Martin=(1,1,1-triacetoxy)-1,1-dihydro-1,2-benzidoxyl-3(1H)-one
[1108] DMEDA=N,N'-dimethylethylenediamine
[1109] DMF=N,N-dimethylformamide
[1110] DMSO = dimethyl sulfoxide
[1111] Et = Ethyl
[1112] EtOH = ethanol
[1113] LC-MS = Liquid Chromatography-Mass Spectrometry
[1114] LDA = lithium diisopropylamide
[1115] Me = methyl
[1116] MeOH = methanol
[1117] n-Bu=n-butyl
[1118] NBS = N-bromosuccinimide
[1119] NCS = N-chlorosuccinimide
[1120] NIS = N-iodosuccinimide
[1121] NMR = Nuclear Magnetic Resonance
[1122] Pd(dppf)Cl2=Dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium
[1123] Pd(PPh3)4=tetrakis(triphenylphosphine)palladium(0)
[1124] Ph = phenyl
[1125] PE = Petroleum Ether
[1126] HPLC = High Performance Liquid Chromatography
[1127] PTSA = p-toluenesulfonic acid
[1128] Py = pyridine
[1129] RT = Room temperature
[1130] TBAF = Tetrabutylammonium fluoride
[1131] TBDPSCl = tert-butyldiphenylsilyl chloride
[1132] t-Bu = tert-butyl
[1133] TEA = triethylamine
[1134] TFA = trifluoroacetic acid
[1135] THF = Tetrahydrofuran
[1136] Ti(i-PrO)4=tetraisopropyl titanate
[1137] TLC = Thin Layer Chromatography
[1138] SEM-Cl = (2-(chloromethoxy)ethyl)trimethylsilane
[1139] CDI=N,N'-carbonyldiimidazole
[1140] Materials and methods
[1141] Reaction progress is typically monitored by TLC or LC-MS. Product identity is typically confirmed by LC-MS. LC-MS is recorded using one of the following methods.
[1142] Method A: Shim-pack XR-ODS, C18, 3x50mm, 2.5um column, 1.0uL injection, 1.5mL / min flow rate, 90-900amu scan range, 190-400nm UV range, 5-100% (1.1 minutes), 100% (0.6 minutes), ACN (0.05% TFA) and water (0.05% TFA) gradient elution, total run time 2 minutes.
[1143] Method B: Kinetex EVO, C18, 3x50mm, 2.2um column, 1.0uL injection, 1.5mL / min flow rate, 90-900amu scan range, 190-400nm UV range, 10-95% (1.1 minutes), 95% (0.6 minutes), ACN and water (0.5% NH4HCO3) gradient elution, total run time 2 minutes.
[1144] Method C: Shim-pack XR-ODS, C18, 3x50mm, 2.5um column, 1.0uL injection, 1.5mL / min flow rate, 90-900amu scan range, 190-400nm UV range, 5-100% (2.1 minutes), 100% (0.6 minutes), ACN (0.05% TFA) and water (0.05% TFA) gradient elution, total run time 3 minutes.
[1145] Method D: Kinetex EVO, C18, 3x50mm, 2.2um column, 1.0uL injection, 1.5mL / min flow rate, 90-900amu scan range, 190-400nm UV range, 10-95% (2.1 minutes), 95% (0.6 minutes), ACN and water (0.5% NH4HCO3) gradient elution, total run time 3 minutes.
[1146] Method E: YMC Triart-C18, 50 x 3.0 mm, 1.0 μL injection, 1.0 mL / min flow rate, 90-900 amu scan range, UV detection at 254 nm. Mobile phase A: water (5 mmol / L NH₄HCO₃), mobile phase B: MeCN. 10% MPB to 95.0% over 1.1 minutes, 95% MPB held for 0.5 minutes, 95% MPB to 10% over 0.1 minutes, then equilibrated to 10% MPB held for 0.1 minutes, total run time 1.8 minutes.
[1147] Method F: Poroshell HPH-C18, 50 x 3.0 mm, 2.7 μm, 0.3 μL injection, 1.5 mL / min flow rate, 90-900 amu scan range, UV detection at 254 nm. Mobile phase A: water (5 mmol / L NH₄HCO₃), mobile phase B: MeCN. 10% MPB to 95.0% over 2.0 minutes, 95% MPB held for 0.6 minutes, 95% MPB to 10% over 0.15 minutes, then equilibrated to 10% MPB held for 0.15 minutes.
[1148] Method G: Kinetex EVO, C18, 3x50mm, 2.2µm column, 0.3µL injection, 1.5mL / min flow rate, 90-900amu scan range, 190-400nm UV range, mobile phase A: water (5mmoL / L NH4HCO3), mobile phase B: MeCN. 10% MPB to 95.0% in 1.1 minutes, 95% MPB held for 0.5 minutes, 95% MPB to 10% in 0.1 minutes, then equilibrated to 10% MPB held for 0.1 minutes, total run time 1.8 minutes.
[1149] Method H: XBridge C18, 50 x 3.0 mm, 0.5 µL injection, 1.2 mL / min flow rate, 90-900 amu scan range, UV detection at 254 nm. Mobile phase A: water / 5 mM NH₄HCO₃, mobile phase B: MeCN. 10% MPB to 95.0% over 1.99 minutes, 95% MPB held for 0.60 minutes, 95% MPB to 10% over 0.20 minutes, then equilibrated to 10% MPB held for 0.20 minutes.
[1150] Method I: XBridge BEH C18, 50 x 3.0 mm, 2.5 μm injection, 1.2 mL / min flow rate, 90-900 amu scan range, UV detection at 254 nm. Mobile phase A: water (5 mmol / L NH₄HCO₃), mobile phase B: MeCN. 10% MPB to 95.0% over 2.0 minutes, 95% MPB held for 0.6 minutes, 95% MPB to 10% over 0.15 minutes, then equilibrated to 10% MPB held for 0.15 minutes.
[1151] Method J: Poroshell HPH-C18, 50 x 3.0 mm, 2.7 μm, 1.0 mL / min flow rate, 90-900 amu scan range, UV detection at 254 nm. Mobile phase A: water / 5 mM NH₄HCO₃; mobile phase B: ACN; 30% water / 5 mM NH₄HCO₃ to 95% over 3.1 minutes, 95% ACN held for 0.6 minutes, 100% MPB to 10% over 0.1 minutes, then equilibrated to 10% ACN held for 0.2 minutes.
[1152] Method K: Shim-pack XR-ODS, 50 x 3.0 mm, 2.2 µL injection, 1.2 mL / min flow rate, 90-900 amu scan range, UV detection at 254 nm. Mobile phase A: Water (0.05% TFA), Mobile phase B: MeCN. 5% MPB to 80.0% over 3 minutes, 80% MPB to 95% over 0.2 minutes, 95% MPB held for 0.5 minutes, 95% MPB to 5% over 0.1 minutes, then equilibrated to 5% MPB held for 0.2 minutes.
[1153] Method L: Titank C18, 50 x 3.0 mm, 0.5 µL injection, 1.0 mL / min flow rate, 90-900 amu scan range, UV detection at 210 nm. Mobile phase A: water / 5 mM NH₄HCO₃, mobile phase B: ACN. 50% MPB to 95% in 2.89 minutes, 95% MPB held for 0.80 minutes, 95% MPB to 10% in 0.10 minutes, then equilibrated to 10% MPB held for 0.20 minutes.
[1154] Method M: Column: XSelect HSS T3, 100 x 4.5 mm, 3.5 μm injection, flow rate: 1.5 mL / min, scan range: 90-900 amu, UV detection: 254 nm. Mobile phase A: water / 0.05% TFA, mobile phase B: ACN / 0.05% TFA. Fluidization: 5% MPB to 100% over 2.0 minutes, 100% MPB held for 0.7 minutes, 100% MPB to 5% over 0.05 minutes, then equilibrated to 5% MPB held for 0.25 minutes.
[1155] Method N: Kinetex XB-C18 100A, 2.7x50mm, 1.7um column, 2.0uL injection, 1.0mL / min flow rate, 90-900amu scan range, 190-400nm UV range, 5-100% (1.1 minutes), 100% (0.6 minutes), ACN (0.05% TFA) and water (0.05% TFA) gradient elution, total run time 2 minutes.
[1156] Method O: HALO column, 3 x 30 mm, 0.5 μL injection, 1.5 mL / min flow rate, 90-900 amu scan range, UV detection at 254 nm. Mobile phase A: water / 0.1% FA; mobile phase B: ACN / 0.05% FA; gradient: 10% B to 100% B over 1.29 minutes, hold for 0.5 minutes, then equilibrate to 10% MPB for 0.03 minutes.
[1157] Method P: Pre-HPLC, chromatographic column, XBridge Shield RP18OBD (19x250mm, 10um); mobile phase, water (10mmol / L NH4HCO3) and ACN, UV detection 254 / 210nm.
[1158] Method Q: Pre-HPLC, chromatographic column, Xselect CSH OBD column 30*150mm5um; mobile phase, water (0.05% FA) and ACN, UV detection 254 / 210nm.
[1159] Method R: Pre-HPLC, chromatographic column, XBridge Shield RP18OBD column, 30*150 mm, 5 μm; mobile phase, water (10 mmol / L NH4HCO3+0.1% NH3.H2O) and CAN, UV detection 254 / 210 nm.
[1160] NMR spectra were recorded on a BRUKER NMR 300.03 Mz, DUL-CH, ULTRASHIELD™ 300, AVANCE II 300 B-ACS™ 120 or a BRUKER NMR 400.13 Mz, BBFO, ULTRASHIELD™ 400, AVANCE III 400, B-ACS™ 120.
[1161] Preparation Example
[1162] Preparation Schemes of Key Intermediates: The following schemes illustrate the preparation of key intermediates.
[1163] Scheme 1: Synthesis of Intermediate 1 (N-(1H-pyrrolo[3,2-b]pyridin-3-yl)-1H-imidazole-1-carboxamide)
[1164]
[1165]
[1166] 1. Synthesis of 3-nitro-1H-pyrrolo[3,2-b]pyridine
[1167]
[1168] 1H-Pyrrolo[3,2-b]pyridine (10 g, 4.7 mmol, 1.0 equiv) was dissolved in concentrated H2SO4 (40 mL). KNO3 (10.3 g, 101.6 mmol, 1.2 equiv) was added portionwise at 0°C and stirred at 0°C for 4 hours. After the reaction was completed, the pH of the resulting solution was adjusted to 8.0 by dropwise addition of NaOH (1 mol / L) solution. The solid was collected by filtration and washed with water (200 mL x 5). 3-Nitro-1H-pyrrolo[3,2-b]pyridine (11 g, 80%) was obtained as a dark solid. LCMS: Method A, MS-ESI, 164.1 [M+H + ].
[1169] 2. Synthesis of 1H-pyrido[3,2-b]pyridine-3-amine dihydrochloride
[1170]
[1171] 3-Nitro-1H-pyrrolo[3,2-b]pyridine (10 g, 61.3 mmol, 1.0 equiv) was dissolved in MeOH (40 mL). Pd / C (10% wt., 1 g) was added to the flask under nitrogen atmosphere and stirred at 0°C for 16 hours under H2. The solid was filtered. HCl / dioxane (4 M, 40 mL) solution was added to the filtrate and stirred at 0°C for 0.5 hours. The product precipitated and was collected by filtration. 1H-pyrrolo[3,2-b]pyridine-3-amine dihydrochloride (4.8 g, 38.1%) was isolated as a dark yellow solid. LCMS: Method A, MS-ESI 207.1
[1172] [M+H + ].
[1173] 3. Synthesis of N-(1H-pyrrolo[3,2-b]pyridin-3-yl)-1H-imidazole-1-carboxamide
[1174]
[1175] 1H-Pyrrolo[3,2-b]pyridin-3-amine (100.0 mg, 0.8 mmol, 1.0 equiv) was dissolved in THF (10.0 mL). KCO (207.6 mg, 1.5 mmol, 2.0 equiv) and CDI (121.8 mg, 0.8 mmol, 1.0 equiv) were added at room temperature and stirred under a nitrogen atmosphere at room temperature for 1 hour. The resulting mixture was used directly in the next step without further purification.
[1176] Scheme 2: Synthesis of Intermediate 2 (5-fluoro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl azide)
[1177]
[1178]
[1179] 1. Synthesis of 5-fluoro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl azide
[1180] 5-Fluoro-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid (10.0 g, 55.6 mmol, 1.0 equiv) was dissolved in THF (100 mL). DPPA (22.9 g, 83.3 mmol, 1.5 equiv) and TEA (11.2 g, 111.1 mmol, 2.0 equiv) were added and stirred at room temperature for 18 hours (h). After evaporation of most of the solvent in vacuo, the crude product precipitated and was collected by filtration and then washed with EtOAc (200 mL x 3). 5-Fluoro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl azide (6.3 g, 55.3%) was isolated as a light yellow solid. LCMS: Method L, MS-ESI, 206.2 [M+H + ].
[1181] The following intermediates were synthesized from the corresponding acids by the above method
[1182] Intermediate 2a: 1H-pyrrolo[2,3-c]pyridine-3-carbonyl azide
[1183]
[1184] LCMS: Method L, MS-ESI, 188.2 [M+H + ].
[1185] Intermediate 3a: (1H-pyrrolo[2,3-b]pyridine-3-carbonyl azide)
[1186]
[1187] LCMS: Method L, MS-ESI, 188.2 [M+H + ].
[1188] Intermediate 3b: (5-methyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl azide)
[1189]
[1190] LCMS: Method A, MS-ESI, 202.2 [M+H + ].
[1191] Intermediate 3c: (5-methyl-1H-pyrrolo[3,2-b]pyridine-3-carbonyl azide)
[1192]
[1193] LCMS: Method A, MS-ESI, 202.1 [M+H + ].
[1194] Intermediate 3d: (1H-pyrrolo[3,2-b]pyridine-3-carbonyl azide)
[1195]
[1196] LCMS: Method L, MS-ESI, 188.0 [M+H + ].
[1197] Intermediate 3e: (5-Butylpicolinoyl azide)
[1198]
[1199] LCMS: Method A, MS-ESI, 205.1 [M+H + ].
[1200] Intermediate 3f (1H-pyrrolo[3,2-c]pyridine-3-carbonyl azide)
[1201]
[1202] LCMS: Method L, MS-ESI, 188.2 [M+H + ].
[1203] Intermediate 3g (6-fluoro-1H-pyrrolo[3,2-b]pyridine-3-carbonyl azide)
[1204]
[1205] LCMS: Method L, MS-ESI, 206.0 [M+H + ].
[1206] Scheme 3: Synthesis of Intermediate 4 (1-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea) (Compound 147)
[1207]
[1208] 1. Synthesis of 5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonyl azide
[1209]
[1210] Synthesized using the method described in Scheme 2. LCMS: Method L, MS-ESI 266.0 [M+H + ].
[1211] 2. Synthesis of 1-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea
[1212]
[1213] 5-Bromo-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid (9.0 g, 33.8 mmol, 1.0 equiv) was dissolved in toluene (300.0 mL). 4-(Trifluoromethyl)aniline (16.4 g, 101 mmol, 3.0 equiv) was added and stirred at 80 °C for 16 hours. The resulting mixture was cooled to room temperature. The solid was then collected by filtration and washed with MeOH (100 mL x 3). 1-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea (5.3 g, 39.3%) was isolated as an off-white solid. LCMS: Method L, MS-ESI, 399.0 [M+H + ].
[1214] The following intermediates were synthesized by the above method.
[1215] Intermediate 4a (1-(5-bromo-1H-pyrrolo[3,2-b]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea)
[1216]
[1217] LCMS: Method A, MS-ESI, 399.0 [M+H + ].
[1218] Intermediate 4b (1-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(4-(trifluoromethyl)cyclohexyl)urea)
[1219]
[1220] LCMS: Method A, MS-ESI, 405.0 [M+H + ].
[1221] Scheme 4: Synthesis of intermediate 6 (7-fluoro-1H-pyrrolo[3,2-c]pyridin-3-amine hydrochloride)
[1222]
[1223] 1. Synthesis of 7-fluoro-1H-pyrrolo[3,2-c]pyridine-3-carbonyl azide
[1224]
[1225] The same synthesis method as Scheme 2. LCMS: Method L, MS-ESI, 206.2 [M+H + ].
[1226] 2. Synthesis of tert-butyl (7-fluoro-1H-pyrrolo[3,2-c]pyridin-3-yl)carbamate
[1227]
[1228] 7-Fluoro-1H-pyrrolo[3,2-c]pyridin-3-carbonyl azide (1.0 g, 4.9 mmol, 1.0 equiv) was dissolved in t-BuOH (50 mL) and stirred at 80 °C for 12 h. The resulting mixture was concentrated under vacuum and purified on a silica gel column using EtOAc / PE (1:8) as eluent. Tert-butyl (7-fluoro-1H-pyrrolo[3,2-c]pyridin-3-yl)carbamate (430.0 mg, 17.6%) was isolated as a brown solid. LCMS: Method L, MS-ESI, 252.3 [M+H + ].
[1229] 3. Synthesis of 7-fluoro-1H-pyrrolo[3,2-c]pyridin-3-amine hydrochloride
[1230]
[1231] Tert-butyl (7-fluoro-1H-pyrrolo[3,2-c]pyridin-3-yl)carbamate (430.0 mg, 1.7 mmol, 1.0 equiv) was dissolved in 1,4-dioxane (10.0 mL). A solution of HCl (4 M, 10 mL) in 1,4-dioxane was then added dropwise. The resulting mixture was stirred at room temperature for 3 hours and concentrated under vacuum. 7-fluoro-1H-pyrrolo[3,2-c]pyridin-3-amine hydrochloride (400 mg, crude) was obtained as a yellow solid. LCMS: Method L, MS-ESI, 188.6 [M+H + ].
[1232] The following intermediates were synthesized by the above method.
[1233] Intermediate 6a: 3-amino-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile
[1234]
[1235] LCMS: Method A, MS-ESI, 195.6 [M+H + ].
[1236] Intermediate 6b: (5-chloro-1H-pyrrolo[2,3-b]pyridin-3-amine)
[1237]
[1238] Method L, MS-ESI, 168.6 [M+H + ].
[1239] Intermediate 6c: (4-bromo-1H-pyrrolo[2,3-b]pyridin-3-amine)
[1240]
[1241] LCMS: Method A, MS-ESI, 212.0 [M+H + ].
[1242] Intermediate 6d: (4-Fluoro-1H-pyrrolo[2,3-c]pyridin-3-amine)
[1243]
[1244] LCMS: Method A, MS-ESI, 152.1 [M+H + ].
[1245] Intermediate 6e (1H-pyrrolo[2,3-b]pyridin-3-amine dihydrochloride)
[1246]
[1247] LCMS: Method A, MS-ESI, 206.0 [M+H + ].
[1248] Intermediate 6f: (1H-pyrrolo[3,2-b]pyridin-3-amine dihydrochloride)
[1249]
[1250] LCMS: Method A, MS-ESI, 206.0 [M+H + ].
[1251] Intermediate 6g (6-fluoro-1H-pyrrolo[3,2-b]pyridin-3-amine)
[1252]
[1253] 1. Synthesis of 6-fluoro-3-nitro-1H-pyrrolo[3,2-b]pyridine
[1254]
[1255] Synthesized using the method described in Scheme 1. LCMS: Method A, MS-ESI, 182.0 [M+H + ].
[1256] 2. Synthesis of 6-fluoro-1H-pyrrolo[3,2-b]pyridin-3-amine
[1257]
[1258] Synthesized using the method described in Scheme 1. LCMS: Method A, MS-ESI, 152.1 [M+H + ].
[1259] Scheme 10: Synthesis of Intermediate 13: (4-Methoxy-1H-pyrrolo[3,2-c]pyridine-3-carboxylic acid)
[1260]
[1261] 1. Synthesis of 4-methoxy-1H-pyrrolo[3,2-c]pyridine-3-carboxylic acid
[1262] To a stirred solution of 4-methoxy-1H-pyrrolo[3,2-c]pyridine (300.0 mg, 2.0 mmol, 1.0 equiv) in THF (10 mL) under nitrogen was added n-BuLi (2.5 M, 4.1 mL, 10.3 mmol, 5.1 equiv) in hexanes dropwise while stirring at -20°C for 2 minutes. The resulting solution was stirred at -20°C for 30 minutes. Dry ice (10.0 g, 227.2 mmol, 112.0 equiv) was added portionwise at -20°C and stirred at room temperature for 2 hours. The reaction was then quenched with MeOH (10 mL). The solid was filtered off and the resulting mixture was concentrated under vacuum. The crude product was purified by Method P. This afforded 100 mg (25.7%) of 4-methoxy-1H-pyrrolo[3,2-c]pyridine-3-carboxylic acid as a white solid. LCMS: Method A, MS-ESI, 193.1 [M+H + ].
[1263] Scheme 11: Synthesis of intermediate 14 (5-phenyl-1H-pyrrolo[2,3-c]pyridin-3-amine)
[1264]
[1265] 1. Synthesis of 5-bromo-3-nitro-1H-pyrrolo[2,3-c]pyridine
[1266]
[1267] Synthesized using the method described in Scheme 1. LCMS: Method L, MS-ESI, 241.9 [M+H + ].
[1268] 2. Synthesis of 3-nitro-5-phenyl-1H-pyrrolo[2,3-c]pyridine
[1269]
[1270] 5-Bromo-3-nitro-1H-pyrrolo[2,3-c]pyridine (100.0 mg, 0.4 mmol, 1.0 equiv) was dissolved in dioxane (3.0 mL) and H₂O (0.3 mL). Phenylboronic acid (50.4 mg, 0.4 mmol, 1.0 equiv), Cs₂CO₃ (269.2 mg, 0.8 mmol, 2.0 equiv), Pd(dppf)Cl₂ (30.2 mg, 0.04 mmol, 0.1 equiv), and XPhos (19.7 mg, 0.04 mmol, 0.1 equiv) were added and stirred at 90°C under nitrogen for 12 hours. The resulting mixture was concentrated under vacuum. The crude product was purified by column chromatography using EtOAc / PE (1 / 1) as the eluent. 300 mg (75.9%) of 3-nitro-5-phenyl-1H-pyrrolo[2,3-c]pyridine were obtained as a yellow solid. LCMS: Method L, MS-ESI, 240.1 [M+H + ].
[1271] 3. Synthesis of 5-phenyl-1H-pyrrolo[2,3-c]pyridin-3-amine hydrochloride
[1272]
[1273] Synthesized using the method described in Scheme 1. LCMS: Method L, MS-ESI, 246.1 [M+H + ].
[1274] Scheme 13: Synthesis of Intermediate 17 (3-isocyanato-1H-pyrrolo[3,2-b]pyridine)
[1275]
[1276] 1H-Pyrrolo[3,2-b]pyridin-3-amine (100.0 mg, 0.8 mmol, 1.0 equiv) was dissolved in THF (10.0 mL). KCO (207.6 mg, 1.5 mmol, 2.0 equiv) and BTC (77.2 mg, 0.3 mmol, 0.3 equiv) were added at room temperature and stirred under a nitrogen atmosphere at room temperature for 1 hour. The resulting mixture was used directly in the next step without further purification.
[1277] Scheme 15: Synthesis of Intermediate 20 (1-(5-bromo-1H-pyrrolo[3,2-b]pyridin-3-yl)-3-(4-(trifluoromethyl)cyclohexyl)urea)
[1278]
[1279] Synthesized using the method described in Scheme 3. LCMS: Method L, MS-ESI, 405.0 [M+H + Scheme 16: Synthesis of Intermediate 21 (3-isocyanato-5-phenyl-1H-pyrrolo[2,3-c]pyridine)
[1280]
[1281] Synthesized using the method described in Scheme 3.
[1282] Scheme 17: Synthesis of intermediate 23 (5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-amine hydrochloride)
[1283]
[1284]
[1285] 1. Synthesis of tert-butyl (5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbamate
[1286]
[1287] Synthesized using the method described in Scheme 4. LCMS: Method L, MS-ESI, 252.1 [M+H + ].
[1288] 2. Synthesis of 5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-amine hydrochloride
[1289]
[1290] Synthesized using the method described in Scheme 4. LCMS: Method A, MS-ESI, 188.0 [M+H + ].
[1291] Scheme 18: Synthesis of Intermediate 24 (N-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-imidazole-1-carboxamide)
[1292]
[1293]
[1294] Synthesized using the method described in Scheme 1. The resulting mixture was used directly in the next step without further purification.
[1295] Scheme 28: Synthesis of Intermediate 28 (6-cyclohexylpyridin-3-amine)
[1296]
[1297]
[1298] 1. Synthesis of 6-(cyclohex-1-en-1-yl)pyridin-3-amine
[1299]
[1300] 6-Iodopyridin-3-amine (2.0 g, 9.1 mmol, 1.0 equiv) was dissolved in 1,4-dioxane (20.0 mL). Cyclohex-1-en-1-ylboronic acid (1.7 g, 13.7 mmol, 1.5 equiv), Pd(dppf)Cl2 (971.9 mg, 1.4 mmol, 0.15 equiv), K2CO3 (2.5 g, 18.2 mmol, 2.0 equiv), and H2O (4.0 mL) were added and stirred at 100°C under a nitrogen atmosphere for 16 hours. The resulting mixture was cooled to room temperature and concentrated under vacuum. The remaining residue was then purified on a silica gel column using EtOAc / PE (1:2) as the eluent. 6-(cyclohex-1-en-1-yl)pyridin-3-amine (800.0 mg, 50.0%) was isolated as a yellow solid.
[1301] LCMS: Method L, MS-ESI, 175.1 [M+H + ].
[1302] 2. Synthesis of 6-cyclohexylpyridin-3-amine
[1303]
[1304] 6-(Cyclohex-1-en-1-yl)pyridin-3-amine (295.8 mg, 1.7 mmol, 1.0 equiv) was dissolved in MeOH (20.0 mL). Pd / C (27.48 mg, 0.258 mmol, 0.15 equiv) was added under a nitrogen atmosphere and stirred at room temperature under a hydrogen atmosphere for 16 hours. The solid was filtered off, and the resulting mixture was concentrated under vacuum and applied to a silica gel column with EtOAc / PE (2:1) as the eluent. 6-Cyclohexylpyridin-3-amine (120.1 mg, 40.1%) was obtained as a yellow solid.
[1305] LCMS: Method L, MS-ESI, 177.1 [M+H + ].
[1306] Scheme 29: Synthesis of Intermediate 29 (2-amino-N-methyl-3-phenylpropionamide)
[1307]
[1308]
[1309] 1. Synthesis of tert-butyl (1-(methylamino)-1-oxo-3-phenylpropan-2-yl)carbamate
[1310]
[1311] 2-[(tert-Butoxycarbonyl)amino]-3-phenylpropanoic acid (500.0 mg, 1.9 mmol, 1.0 equiv) was dissolved in THF (20.0 mL). TEA (381.4 mg, 3.8 mmol, 2.0 equiv), T3P (1199.3 mg, 3.8 mmol, 2.0 equiv) and methylamine (117.1 mg, 3.8 mmol, 2.0 equiv) were added and stirred for 8 hours. The solution was concentrated under vacuum and applied to a silica gel column with EtOAc / PE (2:1) as eluent. tert-Butyl N-[1-(methylcarbamoyl)-2-phenylethyl]carbamate (520 mg, 99.1%) was obtained as a brown solid. LCMS: Method F, MS-ESI, 279.2 [M+H + ].
[1312] 2. Synthesis of 2-amino-N-methyl-3-phenylpropionamide
[1313]
[1314] Synthesized using the method described in Scheme 4. LCMS: Method L, MS-ESI, 179.1 [M+H + ].
[1315] Scheme 30: Synthesis of Intermediate 30 (5-cyclohexylpyridin-2-amine)
[1316]
[1317]
[1318] 1. Synthesis of 5-(cyclohex-1-en-1-yl)pyridin-2-amine
[1319]
[1320] Synthesized using the method described in Scheme 28. LCMS: Method L, MS-ESI, 175.1 [M+H + ].
[1321] 2. Synthesis of 5-cyclohexylpyridin-2-amine
[1322]
[1323] Synthesized using the method described in Scheme 28. LCMS: Method L, MS-ESI, 177.1 [M+H + ].
[1324] Scheme 31: Synthesis of Intermediate 31 (Spiro[2.5]octan-6-amine hydrochloride)
[1325]
[1326]
[1327] 1. Synthesis of spiro[2.5]octane-6-carbonyl azide
[1328]
[1329] Synthesized using the method described in Scheme 2. LCMS: Method A, MS-ESI, 180.1 [M+H + ].
[1330] 2. Synthesis of tert-butyl spiro[2.5]octan-6-ylcarbamate
[1331]
[1332] Synthesized using the method described in Scheme 4. LCMS: Method A, MS-ESI, 226.2 [M+H + ].
[1333] 3. Synthesis of Spiro[2.5]octan-6-amine Hydrochloride
[1334]
[1335] Synthesized using the method described in Scheme 4. LCMS: Method A, MS-ESI, 162.1 [M+H + Scheme 34: Synthesis of Intermediate 34 (6-cyclohexylpyridin-2-amine)
[1336]
[1337]
[1338] 1. Synthesis of 6-(cyclohex-1-en-1-yl)pyridin-2-amine
[1339]
[1340] Synthesized using the method described in Scheme 28. LCMS: Method A, MS-ESI, 175.1 [M+H + ].
[1341] 2. Synthesis of 6-cyclohexylpyridin-2-amine
[1342]
[1343] Synthesized using the method described in Scheme 28. LCMS: Method A, MS-ESI, 177.1 [M+H + ].
[1344] Scheme 35: Synthesis of Intermediate 35 (6-bromo-1H-pyrrolo[2,3-b]pyridin-3-amine)
[1345]
[1346]
[1347] 1. Synthesis of 6-bromo-3-nitro-1H-pyrrolo[2,3-b]pyridine
[1348]
[1349] Synthesized using the method described in Scheme 1. LCMS: Method A, MS-ESI, 241.9 [M+H + ].
[1350] 2. Synthesis of 6-bromo-1H-pyrrolo[2,3-b]pyridin-3-amine
[1351]
[1352] Synthesized using the conditions shown in the above scheme. LCMS: Method L, MS-ESI, 212.0 [M+H + ].
[1353] Scheme 36: Synthesis of Intermediate 36 (6-butyl-5-fluoropyridin-3-amine)
[1354]
[1355]
[1356] 6-Bromo-5-fluoropyridin-3-amine (1.0 g, 5.2 mmol, 1.0 equiv) and 1-butaneboronic acid were dissolved in toluene (8.00 mL). CataCXium A Pd G2 (350.1 mg, 0.5 mmol, 0.1 equiv), CataCXium A (187.7 mg, 0.5 mmol, 0.1) and K3PO4 (2.2 g, 10.5 mmol, 2.0 equiv) were added at room temperature. The reaction system was evacuated and purged with nitrogen three times and stirred at 60 ° C for 16 hours under a nitrogen atmosphere. The mixture was cooled to room temperature and filtered through celite. The filtrate was concentrated, diluted with EtOAc (10 mL), washed with water (4 mL) and brine (4 mL), then dried over anhydrous Na2SO4 and concentrated under vacuum. The residue was applied to a silica gel column with EtOAc / PE (1:5) as eluent. 6-Butyl-5-fluoropyridin-3-amine (468 mg, 53.2%) was isolated as a brown oil. LCMS: Method L, MS-ESI, 169.1 [M+H + ].
[1357] Scheme 37: Synthesis of Intermediate 37 (5-butyl-3-fluoropyridin-2-amine)
[1358]
[1359]
[1360] Synthesized using the method described in Scheme 36. LCMS: Method A, MS-ESI, 169.1 [M+H + ].
[1361] Scheme 38: Synthesis of Intermediate 38 (1-(5-Bromo-1-((2-(trimethyl-silyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea)
[1362]
[1363]
[1364] 1-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea (1.0 g, 2.5 mmol, 1.0 equiv) was dissolved in THF (15.0 mL). TEA (505.0 mg, 5.0 mmol, 2.0 equiv) and SEM-Cl (2.1 g, 12.5 mmol, 5.0 equiv) were added at room temperature and stirred for 16 hours. The mixture was concentrated and applied to a silica gel column using EtOAc / PE (1:3) as the eluent. 1-(5-Bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea (800.0 mg, 60.6%) was isolated as a yellow solid. LCMS: Method A, MS-ESI, 529.1 [M+H + ].
[1365] Example Preparation Scheme
[1366] Example 1: Synthesis of 1-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea (Compound 173)
[1367]
[1368] N-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-imidazole-1-carboxamide (80.0 mg, 0.5 mmol, 1.0 equiv) was dissolved in THF (10.0 mL). 4-(Trifluoromethyl)aniline (90.1 mg, 0.5 mmol, 1.0 equiv) and KCO (138.8 mg, 1.0 mmol, 2.0 equiv) were added and stirred at room temperature for 1 hour. The solid was filtered off, the filtrate was concentrated in vacuo, and the residue was purified via Method P. 1-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea (9.9 mg, 5.8%) was isolated as a white solid.
[1369] LCMS: Method K, MS-ESI, 339.1 [M+H + ].
[1370] 1 H NMR (400MHz, DMSO-d6) δ11.58–11.53(m,1H),9.07(s,1H),8.70–8.65(m,1H),8.22(dd,J=2.8,1.7Hz,1H),7.80–7.69(m,2H),7.71–7.59(m,5H).
[1371] 19 F NMR(400MHz,DMSO-d6)δ–59.99,-139.94
[1372] Analogs prepared by this method:
[1373]
[1374]
[1375]
[1376]
[1377]
[1378]
[1379]
[1380]
[1381]
[1382]
[1383]
[1384]
[1385]
[1386]
[1387]
[1388]
[1389]
[1390]
[1391]
[1392]
[1393]
[1394]
[1395]
[1396]
[1397]
[1398]
[1399]
[1400]
[1401]
[1402]
[1403]
[1404]
[1405]
[1406]
[1407]
[1408]
[1409]
[1410]
[1411]
[1412]
[1413]
[1414]
[1415]
[1416]
[1417]
[1418]
[1419]
[1420]
[1421]
[1422]
[1423]
[1424]
[1425]
[1426]
[1427]
[1428]
[1429]
[1430]
[1431]
[1432]
[1433]
[1434]
[1435]
[1436]
[1437]
[1438]
[1439]
[1440]
[1441]
[1442]
[1443]
[1444]
[1445]
[1446]
[1447]
[1448]
[1449]
[1450]
[1451]
[1452]
[1453]
[1454]
[1455]
[1456]
[1457]
[1458]
[1459] Example 95: Synthesis of Compound 159
[1460]
[1461]
[1462] 3-Isocyanato-1H-pyrrolo[3,2-b]pyridine (100.0 mg, 0.6 mmol, 1.0 equiv) was dissolved in THF (10 mL). TEA (127.2 mg, 1.3 mmol, 2.0 equiv) and azaspirodecane (87.5 mg, 0.6 mmol, 1.0 equiv) were added and stirred at room temperature for 30 minutes. The reaction was then quenched by the addition of water. The resulting solution was extracted with 3 x 30 mL of DCM. The organic layers were combined and concentrated under vacuum. The crude product was purified by Method P. N-(1H-pyrrolo[3,2-b]pyridin-3-yl)-8-azaspiro[4.5]decane-8-carboxamide (25.0 mg, 13.3%) was isolated as a white solid.
[1463] LCMS: Method A, MS-ESI, 299.2 [M+H + ].
[1464] 1HNMR: (400MHz, DMSO-d6)δ10.89(s,1H),8.29(dd,J=4.6,1.4Hz,1H),8.02(s,1H),7.75–7.67 (m,2H),7.11(dd,J=8.2,4.5Hz,1H),3.48–3.41(m,4H),1.67–1.55(m,4H),1.48–1.38(m,8H).
[1465] Analogs prepared by this method:
[1466]
[1467]
[1468]
[1469]
[1470]
[1471] Example 158: Synthesis of Compound 328
[1472]
[1473]
[1474] Synthesized using the method described in Scheme 11. The crude product was purified by Method P. Yielded 26 mg (26.2%) of 1-(5-phenyl-1H-pyrrolo[3,2-b]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea as an off-white solid.
[1475] LCMS: Method L, MS-ESI, 397.1 [M+H + ].
[1476] 1 HNMR: (300MHz, DMSO-d6) δ10.98(s,1H),9.63(s,1H),8.72(s,1H),8.22–8.14(m,2H) ,7.91–7.78(m,2H),7.78–7.59(m,5H),7.50(t,J=7.6Hz,2H),7.39(t,J=7.2Hz,1H).
[1477] Analogs prepared by this method:
[1478]
[1479]
[1480] Example 161: Synthesis of Compound 320
[1481]
[1482]
[1483] To a stirred solution of 4-methoxy-1H-pyrrolo[3,2-c]pyridine-3-carboxylic acid (80.0 mg, 0.4 mmol, 1.0 equiv) in toluene (5.0 mL) in a sealed tube under nitrogen was added TEA (126.0 mg, 1.2 mmol, 3.0 equiv) and 4-(trifluoromethyl)aniline (80.0 mg, 0.5 mmol, 1.2 equiv). DPPA (149.0 mg, 0.5 mmol, 1.3 equiv) was added dropwise to the mixture at room temperature. The resulting solution was stirred at 95 ° C for 4 hours. The reaction was quenched with water (20.0 mL). The resulting solution was extracted with 3×20 mL of EtOAc, and the organic layers were combined and dried over anhydrous sodium sulfate. The resulting mixture was concentrated under vacuum. The crude product was purified by Procedure R to afford 42.1 mg (28.9%) of 1-(4-methoxy-1H-pyrrolo[3,2-c]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea as an off-white solid.
[1484] LCMS: Method L, MS-ESI, 351.1 [M+H + ].
[1485] 1 HNMR: (400MHz, DMSO-d6) δ11.4(s,1H),9.36(s,2H),9.32(s,1H),7.71(d,J=8.8Hz,2H),7. 67(d,J=8.8Hz,2H),7.64(d,J=7.2Hz,1H),7.01(d,J=5.6Hz,1H),6.08(s,1H),3.94(s,3H).
[1486] Example 162: Synthesis of Compound 276
[1487]
[1488]
[1489] 3-[5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl]-1-[4-(trifluoromethyl)phenyl]urea (300.0 mg, 0.8 mmol, 1.0 equiv) was dissolved in dioxane (50.0 mL). HO (10.0 mL), 2-vinyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (173.7 mg, 1.1 mmol, 1.5 equiv), XPhos Pd G3 (30.0 mg, 0.04 mmol, 0.05 equiv), XPhos (30.0 mg, 0.06 mmol, 0.08 equiv), and K3PO4 (319.1 mg, 1.5 mmol, 2.0 equiv) were added under nitrogen, and the mixture was stirred at 80°C for 2 hours. The resulting solution was concentrated under vacuum and applied to a silica gel column with EtOAc as eluent. The crude product was purified by Method Q. This afforded 10 mg (3.9%) of 3-[5-vinyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-1-[4-(trifluoromethyl)phenyl]urea as a white solid.
[1490] LCMS: Method G, MS-ESI, 347.1 [M+H + ].
[1491] 1 HNMR: (400MHz, DMSO-d6) δ11.40(s,1H),9.25(s,1H),8.93(s,1H),8.37(d,J=2.1Hz,1H),8.08(d,J=2.1Hz,1H),7.71(d,J=8.5Hz,2H), 7.63(d,J=8.5Hz,2H), 7.57(d,J=2.5Hz,1H), 6.87(dd,J=17.7,11.1Hz,1H), 5.82(dd,J=17.7,1.0Hz,1H), 5.24(dd,J=11.0,1.0Hz,1H).
[1492] Example 163: Synthesis of Compound 268
[1493]
[1494]
[1495] Synthesized using the method described in Scheme 28. The crude product was purified by Method Q. This afforded 10 mg (6.6%) of 3-[5-ethyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-1-[4-(trifluoromethyl)phenyl]urea as a white solid.
[1496] LCMS: Method D, MS-ESI, 349.1 [M+H + ].
[1497] 1 HNMR: (400MHz, DMSO-d6) δ11.22(d,J=2.4Hz,1H),9.02(s,1H),8.67(s,1H),8.12(d,J=2.0Hz,1H),7.75(d,J=2.0Hz, 1H), 7.70 (d, J = 8.6Hz, 2H), 7.63 (d, J = 8.7Hz, 2H), 7.53 (d, J = 2.5Hz, 1H), 2.73 (q, J = 7.6Hz, 2H), 1.26 (t, J = 7.6Hz, 3H).
[1498] Example 164: Synthesis of Compound 277
[1499]
[1500]
[1501] Synthesized using the method described in Example 162. Obtained 460 mg (76.5%) of 3-[5-(cyclohex-1-en-1-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-1-[4-(trifluoromethyl)phenyl]urea as an off-white crude solid.
[1502] LCMS: Method G, MS-ESI, 401.2 [M+H + ].
[1503] 1 HNMR: (400MHz, DMSO-d6) δ11.26(s,1H),9.35(s,1H),9.05(s,1H),8.33(d,J=2.2Hz,1H),7.97(d,J=2.2Hz,1H),7.71(d,J=8.6Hz,2H),7. 62(d,J=8.6Hz,2H),7.55(d,J=2.5Hz,1H),6.18–6.11(m,1H),2.48–2.42(m,2H),2.25–2.18(m,2H),1.83–1.73(m,2H),1.70–1.61(m,2H).
[1504] Example 165: Synthesis of Compound 267
[1505]
[1506]
[1507] Synthesized using the method described in Example 163. The crude product was purified by Method P. This afforded 62 mg (30.9%) of 3-[5-cyclohexyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-1-[4-(trifluoromethyl)phenyl]urea as an off-white solid. LCMS: Method D, MS-ESI, 403.2 [M+H + ]. 1 HNMR: (400MHz, DMSO-d6) δ11.21(d,J=2.6Hz,1H),9.02(s,1H),8.70(s,1H),8.13(d,J=2.1Hz,1H),7.77(d,J=2.1Hz,1H),7 .70(d,J=8.6Hz,2H),7.64(d,J=8.6Hz,2H),7.53(d,J=2.5Hz,1H),2.69–2.59(m,1H),1.91–1.69(m,5H),1.55–1.21(m,5H). 19 FNMR: (400MHz, DMSO-d6)δ–59.95.
[1508] Example 166: Synthesis of Compound 143
[1509]
[1510]
[1511] Synthesized using the method described in Scheme 11. The crude product was purified by Method P. 1-(5-Phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea (30 mg, 21%) was isolated as an off-white solid.
[1512] LCMS: Method G, MS-ESI, 397.1 [M+H + ].
[1513] 1 HNMR: (400MHz, DMSO-d6) δ11.47(d,J=2.4Hz,1H),9.07(s,1H),8.84(s,1H),8.55(d,J=2.1Hz,1H),8.1 9(d,J=2.1Hz,1H),7.75–7.68(m,4H),7.67–7.60(m,3H),7.52(t,J=7.6Hz,2H),7.39(t,J=7.6Hz,1H).
[1514] 19 FNMR: (400MHz, DMSO-d6)δ–59.93,-59.97
[1515] Example 167: Synthesis of Compound 258
[1516]
[1517]
[1518] 1. Synthesis of 1-(4-(trifluoromethyl)phenyl)-3-(5-((trimethylsilyl)ethynyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)urea
[1519]
[1520] 3-[5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl]-1-[4-(trifluoromethyl)phenyl]urea (200.0 mg, 0.5 mmol, 1.0 equiv) was dissolved in 1,4-dioxane (10.0 mL). Trimethylsilylacetylene (59.1 mg, 0.6 mmol, 1.2 equiv), BrettPhos (26.9 mg, 0.05 mmol, 0.1 equiv), BrettPhos Pd G3 (45.4 mg, 0.05 mmol, 0.1 equiv), and TEA (101.4 mg, 1.0 mmol, 2.0 equiv) were added, and the reaction mixture was stirred at 90°C for 16 hours. The solid was filtered and applied to a silica gel column with EtOAc / PE (1:1) as the eluent. 110 mg (52.7%) of 1-[4-(trifluoromethyl)phenyl]-3-[5-[2-(trimethylsilyl)ethynyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]urea were obtained as a yellow solid.
[1521] LCMS: Method A, MS-ESI, 417.1 [M+H + ].
[1522] 2. Synthesis of 1-(5-ethynyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea
[1523]
[1524] 1-[4-(Trifluoromethyl)phenyl]-3-[5-[2-(trimethylsilyl)ethynyl]-1H-pyrrolo[2,3-b]pyridin-3-yl]urea (150.0 mg, 0.4 mmol, 1.0 equiv) was dissolved in THF (5 mL). KCO (149.3 mg, 1.2 mmol, 3.0 equiv) was added and stirred at room temperature for 4 hours. The resulting mixture was cooled to room temperature and concentrated under vacuum, then applied to a silica gel column with EtOAc / PE (1:1) as eluent. The crude product was purified via Method P. 22 mg (17.8%) of 3-[5-ethynyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-1-[4-(trifluoromethyl)phenyl]urea was obtained as an off-white solid.
[1525] LCMS: Method A, MS-ESI, 345.1 [M+H + ].
[1526] 1 HNMR: (400MHz, DMSO-d6) δ11.67(s,1H),9.04(s,1H),8.81(s,1H),8.34(d,J=2.0Hz ,1H),8.09(d,J=2.0Hz,1H),7.71(d,J=8.6Hz,2H),7.67–7.61(m,3H),4.19(s,1H). 19 FNMR: (400MHz, DMSO-d6)δ–59.98
[1527] Example 168: Synthesis of Compound 256
[1528]
[1529]
[1530] 1. Synthesis of tert-butyl 2-(3-(3-(4-(trifluoromethyl)phenyl)ureido)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)acetate
[1531]
[1532] 1-(5-Bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea (800.0 mg, 1.5 mmol, 1.0 equiv) was dissolved in THF (10.0 mL). Pd2(dba)3CH3Cl (145.0 mg, 0.15 mmol, 0.1 equiv), XPhos (71.6 mg, 0.15 mmol, 0.1 equiv), and (2-(tert-butoxy)-2-oxoethyl)zinc(II) bromide (1.9 g, 7.5 mmol, 5.0 equiv) were added and stirred at 65°C under a nitrogen atmosphere for 16 hours. The reaction was then quenched by the addition of 20 mL of water and extracted with EtOAc (3 x 50 mL). The combined layers were dried over anhydrous sodium sulfate, concentrated under vacuum, and applied to a silica gel column with EtOAc / PE (1:4) as the eluent to afford 500.0 mg (59.1%) of tert-butyl 2-(3-(3-(4-(trifluoromethyl)phenyl)ureido)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)acetate as a yellow solid.
[1533] LCMS: Method C, MS-ESI, 565.2 [M+H + ].
[1534] 2. Synthesis of 2-(3-(3-(4-(trifluoromethyl)phenyl)ureido)-1H-pyrrolo[2,3-b]pyridin-5-yl)acetic acid
[1535]
[1536] Tert-Butyl 2-[3-([[4-(Trifluoromethyl)Ph]carbamoyl]amino)-1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrolo[2,3-b]pyridin-5-yl]acetate (50.0 mg, 0.1 mmol, 1.0 equiv) was dissolved in DCM (4.00 mL). Boron trifluoride etherate (25.1 mg, 0.2 mmol, 2.0 equiv) was added dropwise at 0°C and stirred at room temperature for 90 minutes. The mixture was quenched with two drops of ice water and concentrated under vacuum. The resulting residue was purified via Method Q. [3-([[4-(Trifluoromethyl)phenyl]carbamoyl]amino)-1H-pyrrolo[2,3-b]pyridin-5-yl]acetic acid (7.0 mg, 20.9%) was isolated as a white solid.
[1537] LCMS: Method O, MS-ESI, 379.1 [M+H + ].
[1538] 1HNMR: (400MHz, DMSO-d6) δ11.04(s,1H),8.32(brs,1H),8.10(s,1H),7.82–7.69(m,2H),7.64–7.54(m,3H),3.57(s,2H). 19 FNMR: (400MHz, DMSO-d6)δ–59.72
[1539] Example 171: Synthesis of Compound 162
[1540]
[1541]
[1542] Synthesized using the method described in Scheme 28. The crude product was further purified by Method Q. This afforded 6.5 mg (6.6%) of 3-[5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-1-[4-(trifluoromethyl)cyclohexyl]urea as a yellow solid.
[1543] LCMS: Method L, MS-ESI, 403.2 [M+H + ].
[1544] 1 HNMR: (400MHz, DMSO-d6) δ11.24(s,1H),8.51(s,1H),8.34(s,1H),8.10(s,1H),7.74–7.67(m,2H),7.55–7.46(m,3 H),7.40–7.36(m,1H),6.34(d,J=7.6Hz,1H),3.92(s,1H),2.64–2.56(m,1H),1.85–1.71(m,4H),1.66–1.45(m,4H).
[1545] Example 172: Synthesis of Compound 324
[1546]
[1547]
[1548] 1. Synthesis of 1-(4-(trifluoromethyl)phenyl)-3-(5-((trimethylsilyl)ethynyl)-1H-pyrrolo[3,2-b]pyridin-3-yl)urea
[1549]
[1550] Under nitrogen, 3-[5-bromo-1H-pyrrolo[3,2-b]pyridin-3-yl]-1-[4-(trifluoromethyl)phenyl]urea (200.0 mg, 0.5 mmol, 1.0 equiv) was dissolved in DMF (5.0 mL). Trimethylsilylacetylene (49.2 mg, 0.5 mmol, 1.0 equiv), TEA (101.4 mg, 1.0 mmol, 2.0 equiv), CuI (47.7 mg, 0.3 mmol, 0.5 equiv), Pd(dba)2 (28.8 mg, 0.05 mmol, 0.1 equiv) and PPh3 (13.2 mg, 0.05 mmol, 0.1 equiv) were added under nitrogen and stirred at 90 ° C for 12 hours. The solid was filtered off and the resulting mixture was concentrated under vacuum. The crude product was purified by flash column using EA / PE (1 / 3). 100 mg (47.9%) of 1-[4-(trifluoromethyl)phenyl]-3-[5-[2-(trimethylsilyl)ethynyl]-1H-pyrrolo[3,2-b]pyridin-3-yl]urea were obtained as a light yellow solid.
[1551] LCMS: Method C, MS-ESI, 417.1 [M+H + ].
[1552] 2. Synthesis of 1-(5-ethynyl-1H-pyrrolo[3,2-b]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea
[1553]
[1554] The synthesis was carried out using the method of Example 167. The crude product was purified by Method P. This afforded 5.5 mg (7.6%) of 3-[5-ethynyl-1H-pyrrolo[3,2-b]pyridin-3-yl]-1-[4-(trifluoromethyl)phenyl]urea as an off-white solid.
[1555] LCMS: Method C, MS-ESI, 345.1 [M+H + ].
[1556] 1 HNMR: (300MHz, DMSO-d6) δ11.14(s,1H),9.41(s,1H),8.91(s,1H),8.40(d,J=1.7Hz ,1H),7.94(d,J=2.7Hz,1H),7.87(d,J=1.7Hz,1H),7.71–7.58(m,4H),4.26(s,1H).
[1557] Example 173: Synthesis of Compound 240
[1558]
[1559] Procedure 1: 1-(4-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea (80 mg, 200 μmol, 1.0 equiv) and (4-(methylsulfonyl)phenyl)boronic acid (300 μmol, 1.5 equiv) were mixed in dioxane (2 mL). Then, Cs2CO3 aqueous solution (2.0 M, 2.0 equiv, 200 μl) and Pd(dppf)Cl2 (0.05 equiv) were added under a nitrogen atmosphere. The mixture was stirred at 100 ° C for 4 hours, and then water (2 mL) was added. The resulting mixture was extracted with EtOAc (5 mL×3). The organic layer was collected and the solvent was removed using Speedvac. The residue was purified by preparative HPLC to give the final compound.
[1560] Instruments: GILSON 281 and Shimadzu LCMS2010A; chromatographic column name: Xtimate C18150*25mm*5um; mobile phase: MeOH-water (0.225% FA); start (%) 42, end (%) 67; gradient time (min) 12.5; flow rate (mL / min) 30; detector: MS trigger.
[1561] Agilent 1200 HPLC / 6100 Series MSD or equivalent API-ES; Gradient: 90% A (0.04% TFA in water) and 10% B (0.02% TFA in acetonitrile) to 0% A and 100% B in 3.4 minutes, flow rate 0.8 ml / min; Column: XBridge C18, 2.1*50 mm, 5 μm or equivalent; Temperature: 40°C; Detector: DAD, 220 nm.
[1562] MS-ESI, 475.1[M+H + ].
[1563] 1 H NMR(400MHz,DMSO-d6)δppm 11.89(br s,1H)8.78(br s,1H)8.32(d,J=5.02Hz,1H)7.81-7.90(m,2H)7.76(d,J=8.28Hz,2H)7.45-7.61(m,4H)7.34(d,J=8.53Hz,2H)7.08(d,J=4.77Hz,1H)2.86(br s,3H).
[1564] Example 174: Synthesis of Compound 234
[1565]
[1566] Procedure 2: 1-(4-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl)urea (80 mg, 200 umol, 1.0 eq) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(trifluoromethyl)-1H-pyrazole (300 umol, 1.5 eq) were mixed in dioxane (2 mL). To the mixture was then added aqueous K3PO4 (2.0 M, 2.0 eq, 200 μL) and XPhos Pd G3 (0.05 eq) under a nitrogen atmosphere. The mixture was stirred at 120°C for 16 hours, and then water (2 mL) was added. The resulting mixture was extracted with EtOAc (5 mL x 3). The organic layer was collected, and the solvent was removed by Speedvac. The residue was purified by preparative HPLC to afford the final compound.
[1567] Instruments: GILSON 281 and Shimadzu LCMS2010A; chromatographic column name: Xtimate C18150*25mm*5um; mobile phase: MeOH-water (0.225% FA); start (%) 51, end (%) 72; gradient time (min) 12.5; flow rate (mL / min) 30; detector: MS trigger.
[1568] Agilent 1200 HPLC / 6100 Series MSD or equivalent API-ES; Gradient: 90% A (0.04% TFA in water) and 10% B (0.02% TFA in acetonitrile) to 0% A and 100% B in 3.4 minutes, flow rate 0.8 ml / min; Column: XBridge C18, 2.1*50 mm, 5 μm or equivalent; Temperature: 40°C; Detector: DAD, 220 nm.
[1569] MS-ESI,469.1[M+H + ].
[1570] 1 H NMR (400MHz, DMSO-d6) δppm 11.76 (br s, 1H) 8.99 (br s, 1H) 8.24 (d, J = 4.77Hz, 1H) 7.97 (s, 1H) 7.47-7.59 (m, 5H) 7.34 (br s,1H)6.90(d,J=4.77Hz,1H)3.76(s,3H).
[1571] The following compounds were synthesized by the above method through coupling of the following intermediates with the corresponding boronate esters:
[1572]
[1573]
[1574]
[1575] For the following boronate esters, the following compounds were synthesized by the above method:
[1576]
[1577]
[1578]
[1579]
[1580] For the following boronate esters, the following compounds were synthesized by the above method:
[1581]
[1582]
[1583]
[1584]
[1585] The following compounds were synthesized using methods similar to those described elsewhere herein.
[1586]
[1587]
[1588]
[1589]
[1590]
[1591] Biological tests
[1592] Using the THP1-Dual TM The activation of the STING pathway by the compounds described herein was measured in vitro in vitro (KO-IFNAR2) cells.
[1593] THP1-Dual TMKO-IFNAR2 cells (obtained from Invivogen) were maintained in RPMI, 10% FCS, 5 ml P / S, 2 mM L-glutamic acid, 10 mM Hepes, and 1 mM sodium pyruvate. Compounds were spotted using Echo in empty 384-well tissue culture plates (Greiner 781182) at final concentrations of 0.0017–100 μM. Cells were seeded into TC plates at a concentration of 2 × 10 cells / mL in 40 μL per well. For activation with STING ligands, 2'3' cGAMP (MW 718.38, obtained from Invivogen) was prepared in Optimem medium.
[1594] Prepare the following solutions for each 1 x 384 plate:
[1595] Solution A: 2 mL Optimem with one of the following irritants:
[1596] 60uL of 10mM 2'3'cGAMP->150μM stock solution
[1597] Solution B: 2 mL Optimem and 60 μL Lipofectamine 2000 -> incubate at room temperature for 5 minutes
[1598] 2 mL of solution A and 2 ml of solution B were mixed and incubated at room temperature (RT) for 20 minutes. 20 uL of transfection solution (A+B) was added on top of the plated cells for a final 2'3' cGAMP concentration of 15 μM. The plate was then immediately centrifuged at 340 g for 1 minute and then incubated at 37°C, 5% CO2, >98% humidity for 24 hours. Luciferase reporter activity was then measured. EC was calculated using standard methods known in the art. 50 value.
[1599] Luciferase reporter gene assay: Transfer 10 μL of supernatant from the assay to a white 384-well plate with a flat bottom and square wells. TM Plus is dissolved in 25 mL of water. TM Add 100 μL of QLC Stabilizer to each well. Then, add 50 μL of QUANTI-Luc to each well. TM Plus / QLC solution. Luminescence is measured on a plate reader (eg, Spectramax I3X (Molecular Devices GF3637001)).
[1600] Luciferase reporter activity was then measured. EC was calculated using standard methods known in the art. 50value.
[1601] Table A shows the activity of compounds in the STING reporter gene assay: <0.008 μM = "++++++"; ≥0.008 and <0.04 μM = "+++++"; ≥0.04 and <0.2 μM = "++++"; ≥0.2 and <1 μM = "+++"; ≥1 and <5 μM = "++"; ≥5 and <100 μM = "+" μM.
[1602] Table A
[1603]
[1604]
[1605]
[1606]
[1607]
[1608]
Claims
1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising the compound of claim 1 and one or more pharmaceutically acceptable excipients.
3. Use of the compound according to claim 1 in the preparation of a medicament for inhibiting STING activity.
4. The use according to claim 3, wherein: The inhibition comprises antagonizing STING.
5. The use according to claim 3, wherein the use is performed in vitro.
6. The use according to claim 5, wherein: The use comprises contacting a sample comprising one or more cells comprising STING with the compound.
7. The use according to claim 6, wherein: The one or more STING-containing cells are one or more cancer cells.
8. The use according to claim 6, wherein: The sample also comprises one or more cancer cells, wherein the cancer is selected from the group consisting of: melanoma, cervical cancer, breast cancer, ovarian cancer, prostate cancer, testicular cancer, urothelial carcinoma, bladder cancer, non-small cell lung cancer, small cell lung cancer, sarcoma, colorectal adenocarcinoma, gastrointestinal stromal tumor, gastroesophageal cancer, colorectal cancer, pancreatic cancer, renal cancer, hepatocellular carcinoma, malignant mesothelioma, leukemia, lymphoma, myelodysplastic syndrome, multiple myeloma, transitional cell carcinoma, neuroblastoma, plasmacytoma, Wilms' tumor or hepatocellular malignancy.
9. Use of a compound as claimed in claim 1 in the preparation of a medicament for treating a disease in which increased STING signaling leads to the pathology and / or symptoms and / or progression of the disease.
10. Use of the compound of claim 1 in the preparation of a medicament for treating a disease, disorder or condition associated with STING.
11. The use according to claim 10, wherein: The disease, disorder or condition is selected from the group consisting of: type I interferonopathy, Acardi-Gutiérrez syndrome (AGS), hereditary forms of lupus, inflammation-related disorders and rheumatoid arthritis.
12. The use according to claim 11, wherein: The disease, disorder or condition is a type I interferonopathy.
13. The use according to claim 12, wherein: The type I interferonopathy is STING-associated vasculopathy of infancy (SAVI).
14. The use according to claim 11, wherein: The disease, disorder or condition is Aicardi-Gutiérrez syndrome (AGS).
15. The use according to claim 11, wherein: The disease, disorder or condition is a genetic form of lupus.
16. The use according to claim 11, wherein: The disease, disorder or condition is an inflammation-related disorder.
17. The use according to claim 16, wherein: The inflammation-related disorder is systemic lupus erythematosus.
18. The application according to any one of claims 3 to 17, wherein the application further comprises an authentication object.
